Adverse events/mode of action relationship of monoclonal antibodies-based therapies : overview of marketed produts in the European Union by Lemos, Francisca Mendes
  
UNIVERSIDADE DE LISBOA 
FACULDADE DE FARMÁCIA 
 
 
ADVERSE EVENTS/MODE OF ACTION RELATIONSHIP 
OF MONOCLONAL ANTIBODIES-BASED THERAPIES: 
OVERVIEW OF MARKETED PRODUCTS 
IN THE EUROPEAN UNION 
 
 
Francisca Mendes Lemos 
 
Dissertation 
Master’s degree in Biopharmaceutical Sciences 
 
 
 
 
Lisbon, 2014 
   
  
UNIVERSIDADE DE LISBOA 
FACULDADE DE FARMÁCIA 
 
 
ADVERSE EVENTS/MODE OF ACTION RELATIONSHIP 
OF MONOCLONAL ANTIBODIES-BASED THERAPIES: 
OVERVIEW OF MARKETED PRODUCTS 
IN THE EUROPEAN UNION 
 
 
Francisca Mendes Lemos 
 
Dissertation oriented by Beatriz Lima, PhD  
and co-oriented by Rosário Lobato, PhD 
 
 
Master in Biopharmaceutical Sciences 
Lisbon, 2014 
 
Lisbon, 2013 
 
  
Master’s degree in Biopharmaceutical Sciences: Adverse Events/Mode of Action Relationship 
of Monoclonal Antibodies-Based Therapies: Overview of Marketed Products in the European Union 
Francisca Mendes Lemos i 
 
ACKNOWLEDGEMENTS 
When thinking back, it becomes very clear to me that the work here presented would not have 
been possible without all the ones who, in some way or shape, contributed, supported and 
encouraged this journey. To all those, I would like to express my sincere gratitude: 
To Prof. Beatriz Lima, who accepted me as her master's student and oriented me through all 
this process. Your support, availability and brilliant ideas were the basis for this work and 
words will never be able to express how I admire you. It was a privilege and a huge pride to 
count with your orientation. 
To Prof. Rosário Lobato, who introduced me to the world of biosimilars and 
biopharmaceuticals and who accompanied ever since. Your support, ideas and persistency 
were a key factor since the beginning and I cannot thank you enough for all the availability and 
support. I could not have hoped for a better co-orientation. 
To the company and all my colleagues and friends from Eurotrials, Scientific Consultants, who 
always gave me the time and encouragement when needed, thank you so much. Your patient 
and support were crucial for the execution of this work. 
To all “my persons” from Aveiro, Coimbra and Lisbon, whose friendship and support was 
always immeasurable and tireless. Your patience, kind words and magic ways to turn the 
impossible in just difficult will always mean more than what I can put on words. I owe you 
some of the days I got through. 
To my parents, sister and remaining family, who encouraged this journey since the beginning 
and helped me through with all possible means and forms. Your persistency, serenity and care 
were fundamental for the whole process. Thank you for making this possible and for your 
unconditional love and support through all the steps. 
 
 
Master’s degree in Biopharmaceutical Sciences: Adverse Events/Mode of Action Relationship 
of Monoclonal Antibodies-Based Therapies: Overview of Marketed Products in the European Union 
Francisca Mendes Lemos iii 
 
ABSTRACT 
In the past few years, great discoveries and improvements have been done in drug 
development field and a market that was previously populated just by chemical drugs is now 
growing to include the so called biopharmaceuticals. 
As biotechnologically-derived drugs rely on the fundamental understanding of the related 
disease, it can be predicted that they will play a major – if not dominant – role in the drug 
development arena of the next decades. 
Following the success of recombinant proteins, therapeutic Monoclonal Antibodies (mAbs) 
represent the second wave of innovation created by the biotechnology industry. Overcoming 
the problems initially raised by these biopharmaceuticals, the recent generations of mAbs 
have managed to reduce some of the immunogenicity problems observed with murine mAbs. 
Other concerns remain, however, and the adverse events arising during the long-life 
experience will continue to be an important factor to monitor. 
The target specificity of mAbs associated to the fact that they are large protein molecules 
make the emergence of off-target or metabolite–related toxicities less probable, being 
immunogenicity and target-mediated effects the most relevant determinants of toxicity.  
This project focus was in the correlation and comparison of mAbs’ adverse events with their 
specific mechanism of action. The data here analysed comprises mainly European data (EMA) 
but also some United States data [1]. Due to the large diversity of mechanisms for the 
marketed mAbs, the analysis has been restricted to three pharmacological classes of mAbs: 
anti-TNFα, anti-VGEF and anti-CD20 mAbs. 
Adverse events were compared within each mAb class and then compared through all mAbs 
classes. There were antibody-related adverse events reported transversally for all mAbs but 
there were also some class-related adverse events which were only reported in specific 
classes, with specific mechanisms of action. 
For class-related adverse events it was observed that additional key factors – like 
administration routes, mAbs structural configurations and profile of patients receiving those 
mAbs – may also impact the adverse events and cannot be excluded in safety profile 
characterisation. 
It was confirmed that the adverse events reported for all mAbs analysed were strictly related 
to mAbs’ mechanism of action. Hence, characterisation of each mAb specifities together with a 
precise understanding of the mAbs mechanism of action is crucial for mAbs safety profile 
characterisation. 
 
 
Key Words: Biopharmaceuticals; Monoclonal Antibodies; mAbs Adverse Events; mAbs 
Mechanism of Action; anti-TNF alpha mAbs; anti-VEGF mAbs; anti-CD20 mAbs. 
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INTRODUCTION 
From a pharmacological point of view, the ideal drug would be the one with a specific 
pathology-related target, a precise and effective mechanism of action, no systemic side effects 
and efficient elimination. Although very wanted, no drug currently available has such high 
specificity and low toxicity. In the beginning of the 20th century, the German immunologist and 
Nobel Prize winner Paul Ehrlich figured that «if a compound could be made to selectively target 
a disease causing organism, then a toxin for that organism could be delivered along with the 
agent of selectivity» and introduced, this way, the idea of “magic bullet” against disease. 
Nevertheless, once again, he also said that magic substances like antibodies which affect 
exclusively the harmful agent would not be easy to find [2, 3]. Due to their ability to selectively 
hit a specific target, monoclonal antibodies (mAbs) may be the closest fit to the concept of 
"ideal drugs" or “magic bullets”, first proposed by Paul Ehrilich [2-5]. 
 
I. Biopharmaceuticals 
1. Historic Note – From small molecules to biopharmaceuticals 
In the past few years, great discoveries and improvements have been done in drug 
development filed and a market that was previously populated just by chemical drugs is now 
growing to include the so called biopharmaceuticals [6-9]. Also referred in literature as 
“biologicals”, “biological medicinal products”, “biotechnologically-derived drugs” or just 
“biologics”, these drugs are revolutionizing treatment for many diseases [5, 7, 10, 11]. 
According to FDA, therapeutic biologic products or biologics can be defined as “a virus, 
therapeutic serum, toxin, antitoxin, vaccine, antibody, blood, blood component or derivative, 
allergenic product, or analogous product, or arsphenamine or derivative of arsphenamine (or 
any other trivalent organic arsenic compound), applicable to the prevention, treatment, or cure 
of a disease or condition of human beings” [1]. Biopharmaceuticals are a subset of drug 
products distinguished by their manufacturing process. While classic drugs (chemicals) are 
synthesized via a chemical process, biopharmaceuticals are manufactured utilizing biological 
process (e.g. living cells) and are typically derived from living material – as human, animal, or 
microorganism. Biotech drugs can be considered as those biopharmaceuticals that are 
manufactured using biotechnology-based production process [5]. Apart from obvious 
differences in manufacturing process, some other great differences can be found between 
these two sets of therapeutic molecules (biopharmaceuticals vs. traditional chemicals) and 
those include, but are not limited to, size, complexity and efficacy, which cannot be compared 
to chemical’s, mainly due to high specificity of biopharmaceuticals [7-9, 12-16]. 
In recent years, biotechnologically-derived drugs including proteins, peptides, monoclonal 
antibodies and antibody fragments, have been a major focus of research and development 
(R&D) efforts in the pharmaceutical industry and these biopharmaceuticals constitute already 
a sizable fraction of the medications used in clinical practice [5]. It has been estimated that 
more than 250 million patients have benefited from a biopharmaceuticals to treat or prevent 
heart attacks, stoke, multiple sclerosis, leukaemia, hepatitis, rheumatoid arthritis, breast 
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cancer, diabetes, congestive heart failure, kidney cancer, cystic fibrosis and other diseases [5]. 
Since the development of biotechnologically-derived drugs generally rests on a fundamental 
understanding of the related disease, clinical development of biopharmaceuticals has potential 
to be more successful than conventional chemically derived drugs. It is predictable that 
biotechnologically-derived drugs will play a major – if not dominant – role in the drug 
development arena of the next decades [5, 17]. Interferons to treat multiple sclerosis, anti 
tumour necrosis factor to treat cancer or epoetin alpha to stimulate red blood cell production, 
are examples of biopharmaceuticals [16]. 
  
 
Figure 1 – Advances in biotech drug development. In Tricia Nagle et al., 2003. 
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2. Biotechnology – at first, all were replacing therapies 
Biotechnology, founded on the principles of recombinant DNA (rDNA) protein production is an 
R&D-intensive sector. Beginning in the early 1970s, advances in molecular biology and genetic 
engineering have led to enormous progress in the ability to understand the biomolecular roots 
of human disease. 
Stanford University’s Paul Berg, the 1980 Nobel Prize winner in chemistry, first produced rDNA 
in 1972. His lead was followed by a team coordinated by Herbert Boyer (University of 
California, San Francisco) who, in 1973, transformed Escherichia coli cells with recombinant 
plasmid and later founded Genetic Engineering Technology (Genentech, S. San Francisco, CA, 
U.S.). 
In 1978, the Genentech joined City of Hope National Medical Center to produce human insulin 
in the laboratory using recombinant DNA (rDNA) technology. City of Hope National Medical 
Center’ scientists had synthesized the genes for the protein's two chains before inserting them 
into Escherichia coli, which would, in turn, be stimulated to synthesize insulin. 
With its expertise in purifying and handling insulin and the desire to remain a leader in the 
field, Eli Lilly (Indianapolis, IN, U.S.), immediately licensed recombinant insulin from Genentech 
and set about developing it. Because rDNA guidelines at the time allowed the expression of 
only inactive protein products, Eli Lilly had to use the two-chain method. Clinical studies began 
in 1980 and in 1982, Eli Lilly's recombinant human insulin (Humulin), became the first 
genetically engineered drug approved in the United States and the United Kingdom [18-20]. 
FDA Endocrine Division Director Dr. Sol Sobel signed the FDA’s HUMULIN approval letter. He 
was not unaware of the historical significance of this letter, «Except for my marriage license» 
he recalls, «that [approval letter] was the most important document I ever signed» [19]. 
The US approval came just one month after British regulatory authorities allowed its 
introduction in the UK. Although the development of HUMULIN took just four years, it was a 
major undertaking for both the developers and regulators, breaking new ground. The reason 
for the speedy action in the United States, despite the newness of the product, was attributed 
to “the vast amount of prior experience with the animal insulins, which are very closely related 
to HUMULIN”, said Dr. Miller (medical officer in charge of HUMULIN at the FDA) [21]. Animal 
and laboratory studies have shown that the potency of the genetically engineered human 
insulin appeared to be virtually indistinguishable from that of the purified pork insulin. 
Despite initial reservations about the technology, rDNA derived proteins actually had an 
enhanced safety profile and HUMULIN had proved to be safe and effective in clinical trials 
involving more than 400 patients [18, 19]. 
After more than two decades of continuous global expansion, business formation, 
technological diversification as well as subsequent approvals of crucial rDNA products – such 
as the rDNA form of an enzyme to treat Gaucher's disease, thyroid stimulating hormone (TSH) 
for diagnostic use in thyroid cancer, as well as many products for the production of 
monoclonal antibodies for the treatment of cancer – the sector of rDNA therapeutics is now 
the core of the human medical biotechnology industry [18, 19, 22]. «At the present time» 
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concludes FDA's Dr. Sol Sobel, «I can't imagine producing a new therapeutic protein by any 
other means» [19]. 
 
3. Regulatory Approval Process 
EUROPE: In the European Union (EU), medicines can be authorised by the centralised 
authorisation procedure or national authorisation procedures. Biopharmaceuticals are all 
approved by centralised authorisations [23]. 
As per Regulation (EC) No 726/2004, centralised procedure in Europe is compulsory for 
medicinal products developed by means of biotechnological processes like: recombinant DNA 
technology; controlled expression of genes coding for biologically active proteins in 
prokaryotes and eukaryotes including transformed mammalian cells; and hybridoma and 
monoclonal antibody methods [24]. 
Applications through the centralised procedure are submitted directly to the Agency and once 
a marketing authorisation has been granted, the marketing-authorisation holder can legally 
begin to market the medicine in all EU countries, as well as in the European Economic Area 
(EEA) countries Iceland, Liechtenstein and Norway [23]. 
 
UNITED STATES: Similarities in the drug development and evaluation process for biotech drugs 
and conventional, chemical synthesized drugs have recently been acknowledged in the FDA’s 
2003 decision to transfer certain product oversight responsibilities from the Center for 
Biologics Evaluation and Research (CBER) to the Center for Drug Evaluation and Research 
(CDER). The biologics whose oversight was transferred include monoclonal antibodies for in 
vivo use, proteins intended for therapeutic use, including cytokines (e.g. Interferons), enzymes 
(e.g. thrombolytic), growth factors, and other novel proteins that are derived from plants, 
animals, or microorganisms, as well as recombinant versions of these products, and other non-
vaccine and non-allergenic therapeutic immunotherapy. Classical biologics such as blood, 
blood components and vaccines remain under the regulatory authority of the CBER. 
Although under this new structure, the biologic products transferred to CDER will continue to 
be regulated as licensed biologics – meaning a Biologic License Application (BLA) must be 
submitted to obtain market-authorization, in opposition to a New Drug Application (NDA) 
which is used for traditionally, chemically manufactured drug products [5]. 
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4. Biosimilars 
With the biopharmaceutical’s market quote growing, together with the fact that a substantial 
number of biopharmaceutical’s patents are starting to expire, the so-called copycat 
pharmaceuticals aroused interest in developing generics of the biopharmaceuticals [6-8, 25]. 
These new medicines seek to copy the effect and activity of innovator biological medicines and 
with the advantage of less associated costs [6, 7]. However, the aim to copy the effect, cannot 
be pursued using a conventional generic manufacture process [12, 25, 26]. 
As proteins, biologicals present many changes in activity and compound interactions within the 
body when compared to traditional medicines [25]. For this reason, and bearing in mind that 
some of those interactions are not even well explained yet, the assessment and approval 
cannot be strictly based on pharmacokinetic assessments of bioequivalence. Even the tiniest 
change in the manufacture process can lead to changes in the structure of the medicine which, 
ultimately, may lead to differences in its biological activity, elimination, distribution and 
metabolism, leading to consequent alterations of efficacy, toxicology and ability to trigger 
patient immune response [7, 12-14, 16]. 
 
Biosimilars are a new class of biological medicines [15] and, according to EMA, defined as: 
BIOSIMILAR: “biological medicinal product that contains a version of the active substance of an 
already authorised original biological medicinal product (reference medicinal product) in the 
EEA. Similarity to the reference medicinal product in terms of quality characteristics, biological 
activity, safety and efficacy based on a comprehensive comparability exercise needs to be 
established. 
In principle, the concept of biosimilarity is applicable to any biological medicinal product. 
However, in practice, the success of developing a biosimilar will depend on the ability to 
produce a medicinal product which is similar to the reference medicinal product, and to 
convincingly demonstrate the similar nature of the concerned products. This includes 
comprehensive physicochemical and biological characterisation and comparison and requires 
knowledge on how to interpret any differences between a biosimilar and its reference 
medicinal product.” [27] 
 
A special risk factor of biosimilars – as with all biotechnologically produced pharmaceuticals – 
is their potential immunogenicity with the generation of neutralizing antibodies against the 
active substance. Pharmaceutical tests can detect only part of the properties of proteins so 
that safe predictions about immunogenicity are not possible by means of pharmaceutical 
analyses. Therefore biosimilars are approved under the prerequisite that circumstantial 
pharmacovigilance studies have to be conducted after their commercial launch to evaluate 
their safety (including immunogenicity) and efficacy also after a prolonged period of 
application. (Pharmacovigilance). Post-marketing pharmacovigilance and risk management 
plans are of extreme importance and those must be strictly followed so that clinical safety of 
biosimilars can be closely monitored even after their approval [25].  
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II. Immune System 
In order to recognize and protect the human body against foreign substances or invading 
microorganisms (pathogens), the immune system has developed several defence mechanisms, 
being the ultimate goal to eliminate these potentially harmful interferences from the body [5]. 
The Immune system, a very complex system comprising a high amount of cells involved, can be 
divided in two types of immunity systems: Innate Immunity and Adaptive Immunity (specific 
immune system). 
 
1. Innate Immune System 
Upon exposure to a new pathogen, the body relies on the first line of defence which consists in 
the innate immunity, a subset of the immune system which is able to recognize and respond 
immediately in a generic way to the pathogens (non pathogen-specific response). Innate 
immune responses are dependent on a group of proteins and phagocytic cells that recognize 
conserved features of pathogens and become quickly activated to help destroying invaders. 
The downside is: innate immune system does not confer a long-lasting immunity; that is more 
commonly obtained by the adaptive immune system [28, 29]. However, as adaptive immune 
response usually takes 4-7 days to start, the innate immune response has a critical role in 
controlling infections during this period [29]. 
Microorganisms do occasionally breach the epithelial barricades. It is then up to the innate and 
adaptive immune systems to recognize and destroy them, without harming the host. 
Consequently, the immune systems must be able to distinguish self from non-self. 
The innate immune system relies on the recognition of particular types of molecules that are 
common to many pathogens but are absent in the host. These include many types of 
molecules on microbial surfaces and the double-stranded RNA of some viruses. Pathogen-
associated molecules (called PAMPs – pathogen-associated molecular patterns) stimulate two 
types of innate immune responses – Inflammatory responses and phagocytosis by cells such as 
neutrophils, macrophages, dendritic cells (DC) and natural killer (NK) cells. Both of these 
responses can occur quickly, even if the host has never been previously exposed to a particular 
pathogen [28]. 
The main cell types seen in the initial phase of an inflammatory response are neutrophils, 
which are recruited into the inflamed, infected tissue in large numbers. Like macrophages, 
they have surface receptors for common PAMPs and complement, and they are the main cells 
which engulf and destroy the invading pathogens. The influx of neutrophils is followed shortly 
by monocytes that rapidly differentiate into macrophages. Thus, Macrophages and neutrophils 
are also known as inflammatory cells. Later in an infection, the inflammatory responses also 
involve lymphocytes, which have meanwhile been activated by antigen that has drained from 
the site of infection via the afferent lymphatics [29]. 
Upon contact with pathogens, macrophages and NK cells may kill pathogens directly or, in 
cooperation with dendritic cells, may activate a series of events that both slow the infection 
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and recruit the more recently evolved intervenient of the human immune system – the 
adaptive immune system [28-30]. 
The inflammatory response increases the flow of lymph containing antigen and antigen-
bearing cells into lymphoid tissue, while complement fragments on microbial surfaces provide 
signals that synergize in activating lymphocytes whose receptors bind to specific antigens. 
Macrophages that have phagocytised pathogens and become activated can also activate T 
lymphocytes; still, the cells that specialize in presenting antigen to T lymphocytes and initiating 
adaptive immunity are usually the dendritic cells [29]. 
 
2. The Adaptive Immune System 
Adaptive immunity is characterized by antigen-specific responses to a foreign antigen or 
pathogen. A key feature of adaptive immunity is that following the initial contact with antigen, 
the subsequent antigen exposure leads to more rapid and vigorous immune responses 
(immunologic memory) [28, 30]. 
Some cells of the innate immune system directly present microbial antigens to T cells to 
initiate an adaptive immune response. The cells that do this most efficiently are called 
dendritic cells, which are present in most vertebrate tissues. They recognize and phagocytise 
pathogens at an infection site and then engulf pathogens and degrade them intracellularly. 
Dendritic cells main role however is not to destroy pathogens, but to carry pathogen antigens 
to peripheral lymphoid organs and then present them to T lymphocytes. As such, they act as 
antigen-presenting cells (APCs), which directly activate T cells to respond to the pathogen 
antigens [28, 29]. 
The adaptive immune system comprises both cellular and humoral immunity, whose principal 
effectors are, respectively, T cells and B cells.  
Adaptive immunity is found only in vertebrates and is based on the generation on T and B 
lymphocytes of antigen receptors by gene rearrangements, such that individual T or B cells 
express unique antigen receptors on their surface capable of specifically recognizing diverse 
antigens of the innumerable infectious agents in the environment. Coupled with fine-tuned 
specific recognition mechanisms that maintain tolerance (non-reactivity) to self-antigens, T 
and B lymphocytes bring both specificity and immune memory to vertebrate host defences [5, 
28, 30].  
Once activated, some of the T cells migrate to the site of infection, where they promote the 
synthesis and release of soluble factors or mediators (like cytokines) to either kill infected host 
cells or help other phagocytic cells (mainly macrophages) to destroy the pathogens (cellular 
immune response). Other activated T cells remain in the lymphoid organ and act as T helper-
cells that have an important role in enhancing B cells response to pathogens (humoral immune 
response). In opposition to cell-mediated immune response, humoral immune response does 
not have to be developed at the site of infection and, once activated, B cells are able to secrete 
antibodies that circulate in the body and coat the microbes, targeting them for efficient 
phagocytosis [5, 28, 30]. 
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Both B and T cells circulate continuously between the blood and lymph. Only if they encounter 
their specific foreign antigen in a peripheral lymphoid organ they stop migrating, proliferate, 
and differentiate into effector cells or memory cells [28]. 
 
3. Complement System 
The complement system consists of more than 15 individual glycoprotein compounds in the 
plasma that react with each other in a predetermined manner. The result includes the 
attraction and stimulation of immune cells (e.g. macrophages), the initiation of phagocytosis, 
or the lysis of cells that are targeted by the complement system [5, 28]. 
Although the complement system is usually associated with humoral immune response, by its 
ability to amplify and “complement” the action of antibodies, there are some components of 
complement that can also be characterized as pattern recognition receptors (PRRs) that can be 
activated directly upon recognition of pathogen-associated molecular patterns (PAMPs) [28]. 
Recognition of pathogen PAMPs leads to activation/production of the complement cascade, 
cytokines, and antimicrobial peptides as effector molecules. In addition, pathogen PAMPs as 
host danger signal molecules activate dendritic cells to mature and to express molecules on 
dendritic cell surface that optimize antigen presentation to respond to foreign antigens [30]. 
The early complement components are activated first and they all act locally to activate C3, 
which is the pivotal component of complement. The larger fragment of C3, called C3b, binds 
covalently to the surface of the pathogen and, once in place, not only acts as a protease to 
catalyze the subsequent steps in the complement cascade, but also is recognized by specific 
receptors on phagocytic cells which enhance the ability of these cells to phagocytose the 
pathogen. The smaller fragment of C3 (called C3a), as well as fragments of C4 and C5, act 
independently as diffusible signals to promote an inflammatory response by recruiting 
phagocytes and lymphocytes to the site of infection. 
The phagocytic cells use a combination of degradative enzymes, antimicrobial peptides, and 
reactive oxygen species to kill the invading microorganisms and, in addition, release signalling 
molecules that trigger an inflammatory response and begin to assemble the forces of the 
adaptive immune system [28].  
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III. Antibodies  
Following the success of recombinant proteins, such as insulin, therapeutic Monoclonal 
Antibodies (mAbs) today represent the second wave of innovation created by the 
biotechnology industry in the past 20 years [5]. 
 
1. Main basis  
Upon the presence of foreign molecules in the body, the immune system is capable of 
generating its own physiological antibodies to recognize and eliminate/inactivate invading 
material with antigenic determinants. All antibodies are immunoglobulins [31] and are 
glycoproteins produced by B lymphocytes (plasma cells). As part of the specific humoral 
immune response, they are secreted into the blood or lymph system and neutralize foreign 
invading microorganisms (bacteria, parasites or viruses) or other non-endogenous substances. 
Antibodies are strictly defined products that contain a complementary region towards the 
binding part of the antigen (epitope) [2, 5]. 
 
2. Basic Structure and Functions 
Though differently produced, basic structure of antibodies is most of the times the same.  
Antibodies are ~150kDa immunoglobulins (IgGs), usually represented as Y-shaped, and 
composed by four polypeptide chains, two identical copies of a heavy chain (H) and two 
identical copies of a light chain (L) [32-35]. Each light chain is bound to a heavy chain by a 
disulfide bond and by such noncovalent interactions as salt linkages, hydrogen bonds, and 
hydrophobic bonds, to form a heterodimer (H-L). Similar noncovalent interactions and 
disulfide bonds link the two identical heavy and light (H-L) chain combinations to each other to 
form basic four-chain (H-L)2 antibody structure, a dimer of dimers [35]. 
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Figure 2 – Antibody Basic Structure. 
In Hansel, Kropshofer et al. 2010. 
 
Figure 3 – Schematic diagram of antibody structure. 
In Goldsby, Richard et al. 2003. 
 
The heavy chains contain a variable domain (V H) and three constant domains (C H) whereas the 
light chains contain a variable domain (V L) linked to a single constant domain (C L) [4, 33]. 
Variable regions (V L & V H) are, by excellence, the antigen-binding site and these are located in 
Y’s arms, also called antibody’s Fab (fragment, antigen binding) region.  
Within the variable chains, biding-site is defined by highly variable amino acid sequences – the 
complementarity-determining regions (CDRs) – and these are the major site of interaction with 
an antigen. There are three CDRs (CDR1, CDR2 and CDR3) on each variable chain and 
antibodies diversity is achieved by variations in these CDRs aminoacid sequences [32, 34, 35]. 
Although a highly selective antigen binding is a signature and functionally crucial property of 
antibodies, when considering the role of antibodies in defence against disease, it is important 
to note that antibodies generally to not kill or remove the pathogens just by binding to them. 
Apart from binding to pathogens, antibodies also need to invoke responses that will result in 
the removal of the antigen. These responses are achieved by interactions of the heavy-chain 
constant region (C H) with other proteins or cells. The base of the base of the Y is, thus, the 
region that determines effector functions of antibodies, by modulating immune cell activity. 
This region is called Fc (Fragment, crystallisable) and its role is to ensure that each antibody 
generates an appropriate immune response for a given antigen. This is, most of the times, 
dependent on interaction of the Fc region with other proteins: FcγRs for antibody-dependent 
cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), 
complement components for complement-dependent cytotoxicity (CDC) and FcRn for long 
serum persistence (FcRn is structurally related to MHC class I molecules and protects IgG from 
degradation, resulting in long serum half-life). Different isotypes of immunoglobulins [please 
refer to further section “Immunoglobulins – Antibody Classes and Biological Activities”] are 
defined by the structures of immunoglobulin Fc domains. [32-37]. 
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1. Antibody-Mediated Effector Functions 
Antibodies operate through various mechanisms (Figure 4). These can be divided in Fab-
dependent actions and Fc-dependent effector functions. 
 
Figure 4 – Functions of mAbs. In Hansel, Kropshofer et al. 2010. 
As mechanisms controlled by Fab region, the following can be identified: 
(i) Antagonism: Fab region binds to the antigen and blocks its interaction with the ligand 
(ii) Signalling: Signal transduction inducing by binding of the antibody to a receptor. 
 
Fc portion, on another hand, is responsible for antibody-mediated effector functions and these 
can include: 
(i) Antibody-dependent cell-mediated cytotoxicity (ADCC) 
ADCC occurs when antibodies bind to antigens on target cell (virus infected cell from the host 
or tumour cell) and the antibody Fc domains engage Fc receptors (FcγRs) on the surface of 
immune effector cells such as neutrophils, macrophages and natural killer cells. The resulting 
complex triggers a cytolytic response to induce apoptosis, phagocytosis or lysis, depending on 
the type of mediating effector cell (figure 4). In ADCC, the antibody acts as a newly acquired 
receptor enabling the attaching cell to recognize and kill the target cell [5, 35, 38, 39]. 
 
(ii) Complement-dependent cytotoxicity (CDC) 
Another effector function/ mode of action of antibodies is the so called “complement-
dependent cytotoxicity (CDC)”. Activation of the complement system can lead to lysis of the 
antigen-presenting cell or can induce inflammation reactions aimed to eliminate these cells as 
soon as possible. 
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A prerequisite first step for CDC is the recruitment of the glycoprotein C1q of the complement 
system that will bind to the Fc portion of the antibody. This triggers a proteolytic cascade to 
activate complement. This can lead to the production of the glycoprotein C3b as well as to the 
formation of a membrane attack complex (MAC) that kills the target cell by disrupting its cell 
membrane. Alternatively, tumour-cell-bound C1q can bind to complement receptors, such as 
C1qR, CR1 (CD35) and CR3 (CD11b/CD18), on effector cells, such as neutrophils, macrophages 
and natural killer cells. This can trigger cell-mediated tumour-cell lysis or phagocytosis, 
depending on the type of effector cell (figure 5) [5, 35, 38]. 
 
 
Figure 5 – Antibody effector functions. In Carter, P. 2001. 
 
(iii) Antibody-dependent cellular phagocytosis 
The promotion of phagocytosis of antigens by macrophages and neutrophils is an important 
factor in antibacterial defences. Antibodies’ Fc constant region can bind to Fc Receptors 
present on the surface of macrophages and neutrophils. The binding of Fc receptors with 
several antibody molecules complexed with the same target such as bacterial cell, produces an 
interaction that results in the binding of the pathogen to the phagocyte membrane. Inside the 
phagocyte, the pathogen becomes the target of various destructive processes that include 
enzymatic digestion, oxidative damage and membrane-disrupting effects of antibacterial 
peptides [35]. 
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2. Immunoglobulins – Antibody Classes and Biological Functions 
Antibodies can be classified according to GADME system based on their configuration and 
function. The five different classes (or isotypes) are Immunoglobulins G, A, D, M and E and an 
overview of each one’s specificity is covered in Table 1 [5, 35, 36].  
Table 2 – Immunoglobulins Classes and Biological Functions 
Class Sub-Class Function 
Molecular Mass 
[KDa] 
Rate of 
carbohydrates 
Proportion of 
total Ig [%] 
t1/2 
[days] 
IgG 
IgG 1 
Main Ig in blood and 
extravascular region. 
Binds to antigen and toxins. 
150 2% 75 
21 
IgG 2 21 
IgG 3 7 
IgG 4 21 
IgA 
IgA 1 
Main Ig in secretions. 
IgA is specialized in the 
defence against antigens on 
the surface of mucosal 
membranes, like intestine 
and nose. 
Monomer: 160 
Dimer: 390 
(most abundant 
form) 
Secretory 
dimer: 385 
10% 15 
6 
IgA 2 6 
IgD IgD 
Mainly in humans. 
Found on B lymphocytes 
during some stages of 
maturation and is jointly 
responsible for their 
activation. 
180 11% 0,5 3 
IgM IgM 
First Ig to be produced by 
immune system upon the 
present of an unknown 
antigen. After the primary 
reaction its concentration 
decreases, in opposition to 
the increase of IgG. 
Usually presented in 
pentameric form. 
IgM favours agglutination and 
cytolysis. 
970 10-12% 7 10 
IgE IgE 
Derived from adenoid tissue 
and then transported into the 
blood. 
Although IgE has a low serum 
concentration, it has a main 
role in allergies, being 
responsible for about 90% 
allergic reactions. 
190 12% 0,002 2 
 
Immunoglobulin G (IgG) represents the most important class of immunoglobulins with a serum 
concentration of 12mg/mL, the lowest molecular mass of 150kDa and the longest half-life of 
21 Days (with the exception of the sub-class IgG3 which only has a 7Days half-life). Due to 
differences in chemical structure (differences in Fc portion and disulfide bonds) and biological 
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function, four sub-classes of IgGs can be identified: IgG1, IgG2, IgG3 and IgG4, being the IgG1 
the most abundant [5]. 
Following the first exposure of an individual to an unknown antigen, the first occurrence of 
specific IgG can be detected in average 3 weeks later. Upon the following exposures to the 
same antigen, however, the production of IgG is much quicker and in larger amounts. This is 
characterized as immune memory, which confers the immune system the ability to mount 
rapid recall immune response [5, 30]. 
IgG class is the only class of immunoglobulins capable of crossing the placental barrier and its 
transference from the mother is responsible for the initial immunity of the foetus during the 
first months of pregnancy [5]. 
 In general, immunoglobulins – as proteins with hydrophilic and glycosylated moieties – have a 
high molecular weight of approximately 150-200kDa. The only exception is the tentameric IgM 
which has a molecular weight of 970kDa [5]. 
 
1. Antibodies glycosylation 
Antibodies are glycoproteins and almost all antibodies have the sites of attachment for 
carbohydrates stricted to the constant region. Although it is not completely understood the 
role of glycosylation of antibodies, it is generally observed that the oligosaccharide present in 
glycoproteins contributes to their solubility and stability.  
Changes in glycosylation (or its absence) has an impact in the rate of antibodies clearance from 
the serum as well as in the efficiency of interaction between antibodies and complement 
system and between antibodies and Fc receptors. Antibody glycosylation is a common post-
translational modification and the use of glycoengineering to produce antibodies with specific 
glycoforms may be required to achieve the desired therapeutic efficacy. [31, 35, 40, 41]. 
 
2. Monoclonal Antibodies (mAbs) 
There are two types of antibodies: polyclonal and monoclonal.  
Multiple antibodies produced against the immediate offending antigen, as well as antibodies 
produced against previously encountered antigens owing to the stored memory of past called 
anamnestic reaction, can be considered polyclonal antibodies [2]. 
The use of vaccines for immunization is an excellent example of preventive use of Abs [42].  
The development of new techniques in biotechnology field enabled Abs usage to be extended 
to treatment and, biotechnology-synthesized Abs against a particular antigen [43], become 
known as monoclonal antibodies [2, 3]. 
By definition, mAbs are biological medicines produced using techniques of immunology and 
genetic engineering. Their first appearance was in 1975 when the Nobel Prize winners Köhler 
and Milstein published their seminal manuscript on hybridoma technology enabling the 
production of mouse monoclonal antibodies [4, 11, 32, 34, 44, 45]. Back then, mAbs were 
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produced by injecting laboratory mice with a specific pathogen. This antigenic exposure in the 
mouse would then result in the development of specifically sensitized B cells which were able 
to produce specific antibodies. The genetic machinery of these sensitized B cells would then be 
extracted and inserted into a myeloma B cell thus forming a hybridoma with immortalised B 
cells, capable of producing a higher amount of monospecific and homogeneous antibodies. 
These precise antibodies were called "monoclonal antibodies" since they were derived from a 
single line or clone of specifically sensitized, genetically engineered B cells [2-4, 32, 46]. 
 
2.1. Types of mAbs 
Although mouse-derived mAbs were considered a landmark step in drugs investigation, 
polyclonal as well as monoclonal antibodies when produced in an ordinary animal had very 
limited use in human beings, because those contained some of the unwanted animals antigens 
which would in turn provoke immune reactions in humans [2, 32, 47]. “HAMA response” 
(Human Anti-Mouse Antibodies response) is an example of those human immune reactions 
which can quickly result in the human elimination of the mouse-derived proteins, reducing 
therefore its efficacy [44]. 
The induction of HAMA responses has been postulated to be a major impediment to the 
success of mAb therapy. There are two types of HAMA responses: antiisotypic and anti-
idiotypic. Hence, the development of HAMA has two drawbacks: first, retreatment may result 
in anaphylaxis and allergy; and, second, retreatment may be less effective than previous 
treatments [32]. 
In order to prevent these immune reactions, further research was done and, together with 
some technical advances, it became possible the transition from mouse – via chimeric and 
humanised – to fully human mAbs, with reduced potentially immunogenic mouse components 
[4, 38]. 
 
In summary: 
First Generation Antibodies – Murine, Rat or Rabbit proteins derived by hybridoma 
technology, following immunization of the animal with an antigen preparation [3, 4, 38]. 
Second Generation Antibodies – To overcome the obstacles of first generation antibodies, 
Winter et al. pioneered the techniques to humanize mAbs, by removing the reactions that 
many earlier mAbs caused in some patients [3, 47]. Nowadays, DNA technology or genetic 
engineering is used to construct hybrids composed of human antibody regions linked with a 
murine or primate backbone. These are labelled as second generation mAbs and are referred 
to as chimeric, humanised or human mAbs [3]. 
(i) Chimeric Antibodies – These are composite of antibodies from two different species 
and are obtained by joining the antigen-biding parts (variable domains) of a mouse 
monoclonal antibody with the effector parts (constant domains) of a human antibody 
[3, 4, 38]. 
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(ii) Humanised Antibodies – Human antibody containing the complementarity-
determining regions (CDRs) from a non-human source. These antibodies combine only 
the amino acids responsible for making the antigen-binding site (the hypervariable 
region) of a mouse antibody, remaining the rest of antibody as a human molecule – in 
summary, only the human antibody hypervariable regions are replaced [3, 4, 38]. 
 
(iii) Human Antibodies – can be produced by the following techniques:  
(a) Recombinant DNA technology: By inserting random human genes coding for 
variable Fab portion of human antibodies into the genome of filamentous 
bacteriophages. As the bacteriophage replicate they display antibody Fab portion on 
their surface. The bacteriophages are subsequently mixed with an antigen to select 
those producing complementary Fab portions. Those bacteriophage genomes are then 
converted into plasmids that can subsequently produce specific Fabs in bacteria.  
 
(b) Transgenic mice: Transgenic technology has been exploited to make a transgenic 
mice that have human Ab gene loci inserted into their bodies (using embryo stem cell 
method) and their own genes for making antibodies 'knocked out'. Therefore, mouse 
can be immunized with the desired antigen and produces human Abs. 
 
(c) Phage display: This is another technique human mAbs production. It is used when 
mAbs do not directly recognize antigen or when antigen is undetectable normally and 
expressed only in disease [3].  
These fully humanised mAbs were initiated during the early 1990s by Lonberg and his 
group, who managed to inactivate the key genes which produce antibodies in mice and 
instead transplanted the human antibody genes. 
The advantages of unlimited supplies of all human specific monoclonal antibodies for 
therapeutic – such as improvement of success rate and decrease of immunogenic potential 
– are promising and might fulfil Ehrlich's original notion of “magic bullet” [2-4, 32, 44, 46, 
48]  
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Figure 6 – Differences between differently-produced mAbs. In Paul Carter, 2001. 
 
Curiosity: The United States adopted name (USAN) Council has outlined specific guidelines for 
the nomenclature of mAbs. These guidelines provide a foundation of knowledge about a 
specific mAb just by looking at the generic name.  Below are described some basics of these 
guidelines, as well as some examples of correspondent mAbs [3, 4, 49]: 
1. All mAbs have the suffix “mab” as identifier of the class of medicine. 
2. The infix preceding “mab” usually indicates the source of antibody: 
a. Letter “o” for entirely murine antibodies – e.g. muromonab 
b. Letters “xi” for chimeric antibodies – e.g. rituximab 
c. Letters “zu” for humanised antibodies – e.g. alemtuzumab 
d. Letter “u” for human antibodies – e.g. adalimumab 
3. The infix preceding the source of the antibody refers to medicine target: 
INFIX DEFINITION EXAMPLE 
tu / t tumours trastuzumab 
li / l immunomodulator adalimumab 
ba / b bacterial  
ci / c cardiovascular  
fu / f antifungal  
ki / k  interleukins canakinumab 
ne / n neurons as targets  
so / s bone sulesomab 
vi / v viruses, antiviral indications palivizumab 
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4. The starting prefix is a distinct syllable carrying no special meaning and unique for each 
drug. 
5. If the product is radiolabeled or conjugated to another chemical such as a toxin, a separate 
word is used to identify the conjugate.  
 
2.2. Therapeutic advances 
Since 1975, when Kohler and Milstein developed a procedure to efficiently produce 
monoclonal antibodies (mAbs) it has been widely believed that these molecules would be ideal 
reagents for imaging and therapy, similar to the “magic bullets” idealized by Paul Ehrlich at the 
beginning of the 20th century. 
However, following the first-reaction of excitement, it rapidly became clear that, although 
highly specific and with potential to enable a tailored therapy, these molecules would still 
need improvements in the serious problems they were facing. As the first mAbs were murine 
molecules, they were usually recognized as foreign, leading to their elimination by the 
patient’s immune system. Moreover, as antibodies often needed to interact with certain 
elements of the immune system to be effective, their murine nature would also prevent a 
proper interaction with components of the human immune system, compromising this way 
their biological efficacy. 
Another major improvement came with the development of in vitro selection methods, the 
most successful one being phage display. With the ever increasing power of antibody 
engineering, it became possible to clone entire repertoires of antibody fragment genes, from 
immunized or nonimmunized animals, including humans. 
The creation of chimeric, humanised or fully human antibodies was a major breakthrough and 
led to a wave of new commercialized antibodies. However, mAb-based treatments face several 
other limitations, which limit their widespread use as therapeutics – not only production costs 
are much higher leading, in turn, to higher commercialization costs which limit patients’ 
access; but also mAbs specificities (like molecular size and mode of action) may limit 
penetration of the molecule within the body as well as limit the administration mode to others 
than oral administration. 
Antibody engineering has played a major role in the development of the first generation of 
therapeutic antibodies. It is now being used in several ways to obtain a new generation of 
optimized antibodies with a modified Fc region capable of circumventing some of the 
limitations described before. However, the potential offered by antibody engineering can go 
further than optimization and it is a way to create entirely new Ig domain-based molecules, 
not found in nature, which can be tailored to match desired characteristics.  
Improved delivery; greater selectivity for targets; reduced dosing; enhanced penetration 
within body barriers and possibility of oral administration are some of the challenges and 
future opportunities faced by the therapeutic mAbs field [33, 50]. 
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2.3. Raising concerns following mAbs introduction into the market 
Among the advantages of protein therapeutics, such as mAbs, when compared with low-
molecular-mass drugs, the top ones are their specificities – which facilitate precise action – 
and their long half-lives – which allows infrequent dosing. 
mAbs are having a great success rate in clinic, not only in clinical trials, which have currently 
hundreds of them being tested [4], but also in market approval rate which is greater than for 
chemicals, 20% to 5%, respectively [4, 51]. Taking European case for example, according to 
data published in European Medicines Agency (EMA)l website, in 15 years of investigation 
(1996-2011) 39 marketing authorization applications were submitted to EMA. 35 of those were 
approved and, in the mean time, 7 were withdrawn, which means that, in total, 28 of those 
mAbs are still in European market. 
Despite all known advantages, biopharmaceuticals discovery also brought to scientific 
community and regulatory authorities some challenges until then unknown. Due to 
biopharmaceuticals characteristics in what concerns size, complexity and manufacture, these 
molecules promptly show to require different approaches for efficacy, effectiveness, safety 
and toxicology assessment and approval by scientific community and regulatory agencies [4, 8, 
9, 51, 52]. 
One of the main differences between biopharmaceuticals and chemical molecules is their 
mechanism of action within the body. mAbs have more precise actions since their manufacture 
process is fine-tuned for specific therapeutic actions [4, 32]. If, from one point of view, this is 
clearly an advantage of these medicines, it may also represent a great factor to have in 
account for the evaluation and prediction of mAbs’ side effects. 
Studies had shown that numerous mAbs side effects may be related to their specific targets 
[4], meaning, being related to their mechanism of action.  The goal of this project is to infer the 
actual correlation between mAbs’ reported adverse events and mAbs' specific mechanism of 
action.  
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THESIS OBJECTIVES 
The goal of this project was to correlate mAbs’ adverse events with their specific mechanism of 
action, aiming to prove that one influences the other. By proving that one influences the other, 
it was hypothesised that mAbs mechanism of action may help to predict their adverse events. 
This project had one objective, which was then dived in four tasks, to achieve one milestone: 
 1st Objective – Correlation of mAbs’ mechanism of action with their reported adverse 
events: 
 Task I – Collection of available and relevant information regarding mAbs advances 
since their first appearance in drugs’ market (EMA and FDA data collection). 
 Task II – Collection of available and relevant information regarding mAbs authorised in 
Europe, including withdraws since first approval. 
 Task III – Sorting of mAbs authorised in Europe by classes with similar mechanisms of 
action. 
 Task IV – Comparison of adverse events reported within each class. 
Milestone: mAbs' adverse events are closely related to mechanism of action. 
 
It is important to note that for the purpose of Task IV, the Adverse Events which were 
compared comprised: 
 Adverse Events as per the Initial European Marketing Authorisation Documents 
(Source: mAbs’ first EPARs, available in EMA website [53]) 
 Adverse Events reported in Europe following Marketing Authorisation 
(Source: European database of suspected adverse drug reaction reports [54]) 
 Adverse Events reported in the United States following Marketing Authorisation 
(Source: DrugCite.com website [55]) 
The reason for including the Adverse Events as per the Initial Documents for European 
Marketing Authorisation in addition to the Adverse Events reported post-Marketing 
Authorisations (MA) was for the comparison between the information firstly published on each 
mAb (Initial Documents for EU MA are mainly based on clinical trials data) and the information 
acquired on post-MA period (real life data). It was interesting to see the differences in Adverse 
Event reported pre and post MA. 
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METHODOLOGY 
I. Research sources 
All data collected, reviewed, analysed, summarized and compared has been obtained mainly 
through online research, including not only Pubmed website – for applicable articles, reviews 
and upcoming concerns and discoveries in mAbs mechanism of action field – and EMA website 
– where all European Public Assessment Reports (EPARs) and Summaries of Product 
Characteristics (SmPC) for all mAbs authorised in Europe were available [53] – but also other 
applicable databases, as: 
a) DrugBank Open Data Drug & Drug Target Database [56], for information about mechanism 
of action and drugs’ targets; 
b) ATC/DDD Index 2012 [57], for division of active substances into different groups according 
to the organ or system on which they act and their therapeutic, pharmacological and 
chemical properties; 
c) DrugCite.com website [55], as public access database of adverse events reported through 
the FDA Adverse Events Reporting System (FAERS); 
d) European database of suspected adverse drug reaction reports [54], as public access 
database created in 2012 for information on suspected side effects for approved drugs. 
All efforts were made to keep online search compliant with MeSH Terminology [58] whenever 
applicable. For Adverse Events listing, Medical Dictionary for Regulatory Activities (MedDRA 
17.1) was used. 
Some books, magazines, reports and presentations were also sources for data collection. 
 
II. Data Treatment 
For the comparison of adverse events reported within each class of mAbs the data collected 
and compared has been the European (EU) and United States (U.S.) data, which, in turn, was 
made available through different databases, with different data sources, formats and 
classifications (Table 2). 
Table 3 – Differences in presentation of data pertaining to Adverse Events (AEs) reported in EU and in the U.S. 
Data 
characteristics 
EU database of suspected adverse drug 
reaction reports [54] 
DrugCite.com website [55] 
Source EudraVigilance 
- Comprises submissions by national 
medicines regulatory authorities and 
pharmaceutical companies that hold 
marketing authorisations for the 
medicines 
FDA Adverse Events Reporting System 
(FAERS) 
- Includes adverse events if the drug is 
flagged as a suspect drug causing the 
adverse event.  
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Data 
characteristics 
EU database of suspected adverse drug 
reaction reports [54] 
DrugCite.com website [55] 
Updating frequency cases reported up to the end of the 
previous month (updates are done on the 
15th of the month) 
uncertain (information not available) 
- at the time of data collection, only had 
data from Q1 2004 until Q3 2012 
Data format chart format chart format 
Charts data sorting always the same sorting layout, not 
dependent on values 
descending values, variable sorting layout 
dependent on values 
Charts data labels 
available 
only displayed in the online format 
(for the purpose of this project, those 
were retrieved one by one) 
yes 
Charts data 
classifications 
number of individual cases by reaction 
groups – MedDRA System Organ Classes 
(SOC) 
 
The reaction groups are based on a 
classification of the side effect (also 
known as adverse drug reaction), using 
the MedDRA dictionary of terms. 
top categories of adverse events – 
MedDRA High-Level Group Terms (HLGT) 
% of the AE to all AEs 
reported for the drug 
no yes 
- Percent does not represent a rate 
related to drug utilization 
 
Since the data retrieved from both EU and U.S. databases was significantly different, some 
treatment of data was necessary for enabling the comparison of EU and U.S. data. 
For each mAb, it was firstly analysed the EU and U.S. raw data and only then, a cumulative 
data chart was created. For that cumulative data chart to be created, some treatment of data 
was performed: 
1. U.S. data classification was re-arranged and grouped into a classification similar to EU 
data classification: MedDRA System Organ Class (SOC) system 
2. only MedDRA SOC totals were displayed in the cumulative chart 
3. only absolute values of reported adverse events were displayed in the cumulative 
chart   
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RESULTS AND DISCUSSION 
At an initial stage, no mAbs were excluded from research, as the purpose was the acquisition 
of global knowledge. Only then the search started to be redefined according with this project’s 
focus: in this case, mAbs authorised in Europe. 
Based on dates of mAbs’ marketing authorizations by EMA, it was decided to review data from 
15 years of research, from 1996 to 2011, which corresponds to 35 mAbs. 
1996 year was the first time mAbs were authorised by EMA: Arcitumomab; Igovomab and 
Anti-melanoma mab fragments. Although all those mAbs have already been withdrawn since 
then, they were still an important milestone in the history of biopharmaceuticals in Europe. 
2011 year, on another hand, was also a year for three mAbs authorizations granted by EMA: 
Belimumab; Denosumab and Ipilimumab. Those, in opposition to 1996’s mAbs, are still 
authorised for marketing. 
 
As the main goal of this project is to correlate mAbs with their mechanism of action, it was 
considered important to classify and sort in classes the 35 mAbs approved in Europe from 
1996 to 2011. mAbs’ classification was of extreme importance for the project because all 
subsequent comparisons would be made according with grouping done at this stage. For that 
reason, sorting had to be performed in a consistent way for all mAbs to be analysed and the 
method chosen was to classify mAbs by their targets. 
References used for these classification and sorting process included not only EPARs/ SmPC for 
all 35 mAbs authorised in Europe [53], but also other applicable online databases that also 
classify medicines: i) DrugBank Open Data Drug & Drug Target Database [56] which provides 
information of mechanism of action and drugs’ targets, and ii) ATC/DDD Index 2012 [57], 
which divides active substances into different groups according to the organ or system on 
which they act and their therapeutic, pharmacological and chemical properties. In the ATC 
database, drugs are classified in groups at five different levels: (a) 1st level divides drugs into 
fourteen main groups; (b) 2nd level divides by pharmacological/therapeutic subgroups; (c) 3rd 
and 4th levels dives by chemical, pharmacological and therapeutic subgroups and (d) 5th level 
corresponds to the chemical substance. 
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I. Classification of mAbs 
Classification and sorting of mAbs based on their targets, resulted in Table 2, below presented: 
Table 4 – Classification of European authorised mAbs by target [56, 57] 
Trade name International Non-proprietary Name Target ATC classification 
Removab Catumaxomab CD3 + EpCAM 
Antineoplastic 
Yervoy Ipilimumab CTLA-4 
Zevalin Ibritumomab Tiuxetan 
CD20 Arzerra Ofatumumab 
MabThera Rituximab 
MabCampath Alemtuzumab CD52 
Erbitux Cetuximab 
EGFR 
Vectibix Panitumumab 
Herceptin Trastuzumab HER-2 
Mylotarg Gemtuzumab ozogamicin CD33 
Avastin Bevacizumab 
VEGF 
Lucentis Ranibizumab 
Synagis Palivizumab Fusion glycoprotein 
Anti-infectives 
Mycograb Efungumab Hsp90 
Xolair Omalizumab human IgE Drugs for obstructive airway diseases 
Soliris Eculizumab Complement C5 
Immunosuppressants 
Tysabri Natalizumab Integrin α4β1 
Raptiva Efalizumab Integrin LFA-1 
Simulect Basiliximab Interleukin-2 receptor 
Zenapax Daclizumab Interleukin-2 receptor 
Benlysta Belimumab BLyS 
Ilaris Canakinumab Interleukin-1 beta 
Stelara Ustekinumab IL-12/23p40 
RoActemra Tocilizumab Interleukine-6 
Trudexa Adalimumab 
TNFα 
Remicade Infliximab 
Cimzia Certolizumab pegol 
Simponi Golimumab 
LeukoScan Sulesomab NCA-90 
Diagnostic agents [43, 59] 
Scintimun Besilesomab NCA-95 
CEA-Scan Arcitumomab CEA 
HumaSPECT Votumumab CTAA16.88 
Xgeva Denosumab RANKL Drugs for treatment of bone diseases 
ReoPro Abciximab αIIbβ3 Anti-thrombotic agents 
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It is here to be investigated if similar mechanisms of action result in similar reported adverse 
events and, for that, the classes previously established are the basis for all comparisons to be 
performed. Comparisons will be made first within mAbs of the same class, and secondly across 
different classes are important as well, so that conclusions can be made on which adverse 
events can be expected for a specific mechanism of action. 
If everything goes as expected, European authorised mAbs adverse events will be able to be 
correlated with their mechanism of action and same class mAbs should have similar reported 
adverse events. 
 
1. Selection of 3 Classes of mAbs to be analysed 
Due to the extensive number of mAbs available in Europe, it was decided to study only 3 
classes. The selected classes are the ones below described 
Table 5 – Classification of European authorised mAbs by target– restricted to the 3 classes to be analysed 
Trade name International Non-proprietary Name Target ATC classification 
Zevalin Ibritumomab Tiuxetan 
CD20 
Antineoplastic 
Arzerra Ofatumumab 
MabThera/Rituxan Rituximab 
Avastin Bevacizumab 
VEGF 
Lucentis Ranibizumab 
Trudexa Adalimumab 
TNFα Immunosuppressants 
Remicade Infliximab 
Cimzia Certolizumab Pegol 
Simponi Golimumab 
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I. Anti-TNF mAbs 
TNFα activity was first detected over 100 years ago when physicians noted that some cancer 
patients experienced shrinkage of their tumours if they also had a serious bacterial infection. 
In recent years, however, it has been learned that TNFα has a wide range of biological 
activities in addition to its ability to kill tumour cells. For example, TNFα has been shown to 
induce mitogenesis of fibroblasts, induce expression of adhesion molecules on endothelial 
cells, stimulate interleukin-1 and prostaglandin E2 synthesis in macrophages, trigger a 
respiratory burst and degranulation in neutrophils, increase hepatic synthesis of acute phase 
proteins, suppress collagen synthesis by fibroblasts and act on the hypothalamus to induce 
fever. 
These widely varied activities, some of which play a role in immune reactions, some in 
inflammatory reactions, and some in pathophysiological reactions, attest to the complexity of 
this cytokine. [60-64]. 
 
TNFα is a pluripotent cytokine secreted by macrophages in response to a variety of 
inflammatory agents. 
Gram-negative lipopolysaccharide (LPS) has been extensively studied as a stimuli for 
macrophage activation [61, 65]. Lipopolysaccharide (LPS) is a glycolipid that constitutes the 
major portion of the outermost membrane of Gram-negative bacteria. It is also referred in 
literature as Endotoxin, and this term was introduced in the 19th century to describe the 
component of gram-negative bacteria responsible for the pathophysiological phenomena 
associated with gram-negative infections [61, 65, 66]. 
LPS comprises three parts: O antigen; core oligosaccharide and Lipid A. It is now established 
that the lipid A moiety possesses most of the biological activities of LPS and the interaction of 
the lipid A moiety of LPS with macrophages results in the rapid induction of the syntheses of 
pro-inflammatory molecules, like tumour necrosis factor (TNF), interleukin 1 (IL 1 ), and other 
proteins [65, 66]. 
 
Tumour necrosis factor-alpha (TNFα) is one of several cytokines referred to as pro-
inflammatory and it is a vital component of the inflammatory process [44, 64, 67]  
The precursor form of TNFα, transmembrane TNFα (mTNF), is expressed on the cell surface of 
activated macrophages and lymphocytes as well as other cell types (endothelium). Membrane-
bound mTNF is subsequently cleaved by a metalloproteinase, TNFα converting enzyme (TACE), 
which releases the secreted soluble form of TNFα, a 17kD polypeptide [67, 68]. 
Most cellular responses to TNFα are triggered through its interaction with two structurally 
distinct receptors: type I (TNFR1 – 55kd) and type II (TNFR2 – 75kd) [44, 61, 62, 64, 67]. Both 
receptors are transmembrane glycoproteins with multiple cysteine-rich repeats in the 
extracellular N-terminal domains. Extracellular domains of TNFα receptors are very similar in 
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structure and function, while intracellular domains of TNFα receptors are distinct and 
transduce their signals through both overlapping and distinct pathways [67]. 
While binding of TNFα to TNFR1 seems to induce cytotoxicity, fibroblast proliferation, 
synthesis of prostaglandins, up regulation of adhesion molecules and NF-KB activation; the role 
of TNFR2 is less well defined, but it appears to concentrate soluble TNFα at the cell surface for 
transfer to TNFR1 [69]. 
Secreted TNFα binds to both TNFR1 and TNFR2, while the membrane-bound TNFα binds 
mainly to TNFR2. Like TNFα, these receptors exist both as a membrane-anchored form, where 
they mediate the pleiotropic pathophysiological effects of TNFα, and in a soluble form, where 
they can bind and neutralize bioactive TNFα [67]. 
 
A wide range of biological good outcomes have been associated to TNFα. Nonetheless TNFα 
has also been implicated as a major mediator of septic shock and cachexia associated with 
chronic disease states. A possible reason for the different outcomes associated to TNFα might 
reside in the quantitative rather than qualitative aspects of TNFα physiology: while 
"appropriate" amounts of TNFα are mainly protective to the host, an excess of TNFα has been 
linked to numerous disease states. A qualitative explanation might be that the cell-bound 
rather than secreted version of TNF is advantageous to the host [67, 70]. 
Elevated levels of TNF are found in the synovial fluid of rheumatoid arthritis patients and play 
an important role in both the pathologic inflammation and the joint destruction that are the 
hallmarks of rheumatoid arthritis [63, 71]. 
 
As a key early mediator of the inflammatory process, TNFα has become a major target of 
numerous pharmaceutical investigations, which have yielded several unique proteins that bind 
and neutralize TNFα bioactivity. In theory, specific monoclonal antibodies anti-TNF may 
establish connections with TNF receptors on cellular surface and inhibit, this way, T cells and 
macrophages functions [44, 67]. 
Because of their relative novelty and recent development, little is known about the long-term 
consequences of anti-TNFα biopharmaceuticals or what effects they might have at the cellular 
level [67].  
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1. mAbs targeted for TNF 
Table 6 – anti-TNFα mAbs approved indications for Europe and for the United States 
Anti-TNFα mAbs 
 
ADALIMUMAB INFLIXIMAB GOLIMUMAB 
CERTOLIZUMAB 
PEGOL Indications 
U.S. EU U.S. EU U.S. EU U.S. EU 
X X X X X X X X Rheumatoid Arthritis (RA) 
X X       Polyarticular Juvenile Idiopathic Arthritis 
 X      X Axial spondyloarthritis 
X X X X X X  X Ankylosing Spondylitis 
X X X X X X  X Psoriatic Arthritis 
X X X X     Psoriasis 
X X X X   X  Crohn’s Disease 
X X X X X X   Ulcerative Colitis 
 
1.1. ADALIMUMAB 
The active substance ADALIMUMAB is currently in the market under the trade name HUMIRA 
and it has been approved in Europe and the United States on 2003 and 2002, respectively. 
 
1.1.1. ADALIMUMAB Characterization 
Pharmacotherapeutic group: Immunosuppressants 
ATC code: L04AB04 [57] 
L — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 
L04 — IMMUNOSUPPRESSANTS 
L04A — IMMUNOSUPPRESSANTS 
L04AB — Tumour necrosis factor alpha inhibitors 
 
Adalimumab (HUMIRA) is a recombinant human IgG1 monoclonal antibody specific for human 
tumour necrosis factor (TNF) [63]. 
Adalimumab was created using phage display technology resulting in an antibody with human 
derived heavy and light chain variable regions and human IgG1 constant regions. 
Adalimumab is produced by recombinant DNA technology in a mammalian cell expression 
system and is purified by a process that includes specific viral inactivation and removal steps 
[63]. It consists of 1330 amino acids and has a molecular weight of approximately 148 
kilodaltons  [63, 71] . 
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1.1.2. ADALIMUMAB Mechanism of Action 
Adalimumab binds specifically to soluble TNF-alpha and blocks its interaction with p55 and 
p75, the cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro 
in the presence of complement. Adalimumab does not bind or inactivate lymphotoxin (TNF-
beta) [44, 63]. 
Adalimumab also modulates biological responses that are induced or regulated by TNF, 
including changes in the levels of adhesion molecules responsible for leukocyte migration 
(ELAM-1, VCAM-1, and ICAM-1 with an IC50 of 1-2 X 10-10M) [63]. 
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1.1.3. ADALIMUMAB Treatment 
Table 7 – Adalimumab Treatment: Method of administration and Indications 
ADALIMUMAB  |  Administration: subcutaneous injection 
 
U.S. EU Indications Population Indications Details References 
X X 
Rheumatoid 
Arthritis (RA) Adults 
 in combination with methotrexate, or on its own for 
moderate to severe active RA without adequate 
response to disease-modifying antirheumatic drugs 
(DMARDs)  
 in combination with methotrexate, or on its own for 
severe active rheumatoid arthritis which is getting 
worse and has not been treated with MTX before 
[44, 63, 71, 
72] 
X X 
Polyarticular 
Juvenile 
Idiopathic 
Arthritis 
2 – 17 
years 
 in combination with methotrexate, or on its own for 
polyarticular juvenile idiopathic arthritis which has not 
responded adequately to disease-modifying 
antirheumatic drugs (DMARDs) 
[44, 63, 72] 
 X 
Axial 
spondyloarthritis 
Adults 
 severe axial spondyloarthritis without evidence in the 
X-ray of ankylosing spondylitis but with objective signs 
of inflammation, by elevated C-reactive protein (CRP) 
and /or magnetic resonance imaging (MRI), which has 
not responded adequately or are intolerant to non-
steroidal anti-inflammatory drugs (NSAIDs) 
[44, 63, 72] 
X X 
Ankylosing 
Spondylitis 
Adults 
 severe active ankylosing spondylitis who have not 
responded adequately to other treatments; 
[44, 63, 72] 
X X 
Psoriatic 
Arthritis 
Adults 
 active and progressive psoriatic arthritis who have not 
responded adequately to DMARDs 
[44, 63, 72] 
X X Psoriasis Adults 
 severe chronic plaque psoriasis who failed to respond 
to or who have a contraindication to, or are intolerant 
to other systemic therapy including cyclosporine, 
methotrexate or psoralen ultraviolet-A (PUVA) 
[44, 63, 72] 
X X Crohn’s Disease 
2 – 17 
years 
& Adults 
 severe active Crohn’s disease who have not responded 
adequately or are intolerant to conventional therapy 
including primary nutrition therapy (children), 
corticosteroids, and/or immunomodulator 
[44, 63, 72] 
X X Ulcerative Colitis Adults 
 moderately to severely active ulcerative colitis who 
have not responded adequately or are intolerant to 
conventional therapy including corticosteroids and 6-
mercaptopurine (6-MP) or azathioprine (AZA) 
[44, 63, 72] 
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1.1.1. ADALIMUMAB Adverse Events (as per EU Initial MA documents) 
Table 8 – Adalimumab Adverse Events as per European Initial Marketing-authorisation Documents 
MedDRA 17.1 
System Organ Class (SOC) 
AEs Detailed References 
Blood and lymphatic system 
disorders 
 Agranulocytosis 
 Leukopenia 
 Neutropenia 
 Pancytopenia 
 Thrombocytopenia 
[73] 
Cardiac disorders  
 Congestive heart failure (CHF) – Based on previous experience 
with other TNF-antagonists, Adalimumab is contraindicated in 
moderate to severe heart failure (NYHA class III/IV) and should be 
used with caution in patients with mild heart failure. 
 Tachycardia 
[73] 
Gastrointestinal disorders  Abdominal pain [73] 
General disorders and 
administration site conditions 
 Fatigue 
 Oedema 
 Pain 
 Swelling 
[73] 
Immune system disorders  Anaphylactoid-type reactions [73] 
Infections and Infestations  
 Bronchitis 
 Sepsis 
 Tuberculosis 
 Upper respiratory tract infection 
 Urinary tract infections 
[73] 
Investigations 
 Decreased haemoglobin 
 Increased alt 
  increased bun 
 Increased coagulation time 
[73] 
Metabolism and nutrition 
disorders 
 Hypercholesterolaemia 
 Hyperlipaemia 
[73] 
Musculoskeletal and connective 
tissue disorders 
 Lupus-like syndrome [73] 
Neoplasms benign, malignant and 
unspecified (incl cysts and polyps) 
 Non-Hodgkin’s lymphoma (NHL) [73] 
Nervous system disorders 
 Demyelination 
 Dizziness 
 Headache 
[73] 
Renal and urinary disorders  Haematuria [73] 
Respiratory, thoracic and 
mediastinal disorders 
 Dyspnoea [73] 
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MedDRA 17.1 
System Organ Class (SOC) 
AEs Detailed References 
Skin and subcutaneous tissue 
disorders 
 Cutaneous abdomen rash 
 Erythema 
 Fixed drug eruption rash 
 Itching 
 Rash 
 Urticaria 
[73] 
Vascular disorders 
 Haemorrhage 
 Hypertension 
[73] 
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1.1.1. ADALIMUMAB Adverse Events Charts (following MA) 
 European Data (EU database of suspected adverse drug reactions reports) 
The data here displayed was launched by EMA in the European database of suspected adverse 
drug reactions reports. Reports included in this database correspond to the data submitted 
electronically to EudraVigilance by national medicines regulatory authorities and by 
pharmaceutical companies that hold marketing authorisations (licences) for the medicines. 
 
Chart 1 – Individual cases sorted by reactions groups, submitted for ADLIMUMAB (up to Oct’14) 
in European database of suspected adverse drug reaction reports (www.adrreports.eu) 
(data extracted on 26-Nov-2014) 
The chart above displays the number of cases reported for each reaction group, divided by 
age. The original chart (online format) enabled to pass the mouse through each bar and reveal 
the number of cases for a specific age. Below are the values of the biggest bars. 
EU Top 10 of Individual Cases (by reactions groups): 
1. Infections and Infestations (9399 cases) 
2. General disordes and administration site conditions (7894 cases) 
3. Gastrointestinal disorders (4880 cases) 
4. Neoplasms benign, malignant and unspecified (including cysts and polyps) (4808 cases) 
5. Musculoskeletal and connective tissue disorders (4588 cases) 
6. Nervous system disorders (4092 cases) 
7. Skin and subcutaneous tissue disorders (4049 cases) 
8. Respiratory, thoracic and mediastinal disorders (3725 cases) 
9. Investigations (e.g. Chest X-ray abnormal; Electocardiogram QT prolonged) (3414 cases) 
10. Injury, poisoning and procedural complications (2185 cases)  
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 FDA Adverse Event Reporting System (FAERS) Data (DrugCite.com) 
The data here displayed was made available by DrugCite database. Results included in this 
database correspond to the collection and analysis of reported adverse performed by FDA 
Adverse Events Reporting System (FAERS). These reports are submitted by physicians, 
healthcare consumers, lawyers amongst others. 
 
Chart 2 – Individual cases sorted by reactions groups, submitted for ADALIMUMAB and other drugs with same 
active substance (Q1 2004 – Q3 2012) in DrugCite.com (www.drugcite.com) 
(data extracted on 26-Nov-2014) 
The chart above displays, for each reaction group, the number of cases reported where the 
drug was flagged as a suspect drug causing the adverse event. All percentages (%) are the 
cases reported for a specific reaction group within the sum up of all reported cases in all 
reactions groups (percent does not represent rate related to drug utilization). 
U.S. Top 10 of Individual Cases (by reactions groups): 
1. Infections – Pathogen Unspecified (261 cases) 
2. Epidermal And Dermal Conditions (208 cases) 
3. Therapeutic And Nontherapeutic Effects (e.g. drug ineffective; intorelance) (131 cases) 
4. Respiratory (128 cases) 
5. Joint (e.g. Arthralgia; Joint Stiffness) (120 cases) 
6. Mycobacterial Infections (95 cases) 
7. Bacterial Infections (94 cases) 
8. Gastrointestinal Signs (84 cases) 
9. Hepatic and Hepatobiliary (83 cases) 
10. Body Temperature Conditions (79 cases)  
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 Comparison of Adverse Events reported in EU and in the U.S. 
Following the analysis of the Adverse Events previously presented, it became clear that there 
were some differences between EU data and U.S. data. In order to have a visually enhanced 
perception of such differences, it was decided to create a cumulative chart which would 
aggregate all the data previously presented: 
 Post Marketing EU data (Blue bars in the cumulative chart) 
 Post Marketing U.S. data (Orange bars in the cumulative chart) 
 EU data as per Initial documents for MA (MedDRA SOCs highlighted in yellow in the 
cumulative chart) 
For aggregation purposes, a common classification had to be used and so MedDRA SOC was 
the selected classification for the cumulative chart below presented. 
 
Chart 3 – Individual cases sorted by reactions groups (MedDRA 17.1 SOC), submitted for ADALIMUMAB prior and 
post MA in Europe and post MA the United States 
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Comments to ADALIMUMAB cumulative chart: 
1. SOCs included in EU pre-MA reports vs SOCs included in EU post-MA reports 
Main discrepancies: There are cases of SOCs with a considerable number of AE reports (>1000) 
in post-MA and which were not foreseen by pre-MA clinical trials data. These include: Eye 
Disorders; Psychiatric Disorders; Injury, poisoning and procedural complications & Surgical and 
Medical Procedures. 
 
2. SOCs included in EU post-MA reports vs. SOCs included in U.S. post-MA reports 
Although Adalimumab is approved in EU and in the U.S. almost for the same indications, there 
are some significant discrepancies in the numbers above observed. 
Main discrepancies: Having EU data as reference, there were some U.S. bars which were 
expected to be bigger but are not. These include: Cardiac disorders; General disorders and 
administration site conditions; Neoplasms benign, malignant and unspecified (including cysts 
and polyps) & Psychiatric disorders. 
Another interesting fact observed in the previous chart is that although Adalimumab is in the 
market of EU and U.S. for a similar time, the amount of reports seen in the U.S. data is 
substantially lower than those in EU data. 
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1.2. INFLIXIMAB 
The active substance INFLIXIMAB was firstly introduced as REMICADE (trade name). Marketing 
Authorisation was granted on 13th Aug 1999 and alongside with REMICADE becoming a 
blockbuster in the market, great investment was done in order to pursue biosimilar forms of 
that biologic drug. 
On 10th Sep 2013 Marketing Authorisation was finally granted to 2 biosimilars with the same 
active substance of REMICADE (Infliximab) – REMSIMA and INFLECTRA. 
 
INFLIXIMAB’s Biosimilars (REMSIMA and INFLECTRA) are considered out of the scope of the 
data to be here reviewed since they are Biosimilars rather than reference medicines and their 
approval was granted after the timeframe defined for data review: 15 years of research – 
1996-2011 (please refer to 1st Objective, Task II). 
 
1.2.1. INFLIXIMAB Characterization 
Pharmacotherapeutic group: Immunosuppressants 
ATC code: L04AB02 [57] 
L — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 
L04 — IMMUNOSUPPRESSANTS 
L04A — IMMUNOSUPPRESSANTS 
L04AB — Tumour necrosis factor alpha inhibitors 
 
Infliximab (REMICADE) is a chimeric human-murine IgG1 monoclonal antibody specific for 
human tumour necrosis factor alpha (TNFα) with an approximate molecular weight of 149,100 
Daltons [44, 74-76]. 
 
Infliximab is produced in murine hybridoma cells by recombinant DNA technology and it is 
composed of human constant and murine variable regions [74, 75, 77]. INFLIXIMAB contains 
approximately 30% murine variable region amino acid sequence, which confers antigen-
binding specificity to human TNFα. The remaining 70% correspond to a human IgG1 heavy 
chain constant region and a human kappa light chain constant region [77]. 
Infliximab is supplied as a sterile, white, lyophilized powder for intravenous infusion. Each 
single-use vial contains 100 mg Infliximab, 500 mg sucrose, 0.5 mg polysorbate 80, 2.2 mg 
monobasic sodium phosphate, monohydrate, and 6.1 mg dibasic sodium phosphate, 
dihydrate. Following reconstitution with 10 mL of Sterile Water for Injection, USP, the 
resulting pH is approximately 7.2 [74, 77]. 
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1.2.2. INFLIXIMAB Mechanism of Action 
Infliximab neutralizes the biological activity of TNFα by binding with high affinity to the soluble 
and transmembrane forms of TNFα and inhibits binding of TNFα with its receptors. The 
inhibition of TNFα biological function by the ability of Infliximab to block the interaction of  
TNFα with its cellular receptors, suggests that Infliximab can inhibit TNF-mediated signalling 
through either receptor in vivo [69]. 
When Infliximab is added to preformed TNF/TNF-R p55 or TNF/TNF-R75 complexes, a rapid 
(within 5 minutes) dissociation of TNFα from receptor is observed, with binding of dissociated 
TNFα to Infliximab preventing re-association with receptor [69]. 
Infliximab does not neutralize TNFβ (lymphotoxin α), a related cytokine that utilizes the same 
receptors as TNFα [74, 76]. 
Infliximab clears pro-inflammatory TNF from the circulation and possibly deletes aberrantly 
activated mTNF expressing T cells. This mechanism of action is supported by several pre-
clinical experiments [76]. 
  
Master’s degree in Biopharmaceutical Sciences: Adverse Events/Mode of Action Relationship 
of Monoclonal Antibodies-Based Therapies: Overview of Marketed Products in the European Union 
40 Francisca Mendes Lemos 
 
1.2.3. INFLIXIMAB Treatment 
Table 9 – Infliximab Treatment: Method of administration and Indications 
INFLIXIMAB  |  Administration: intravenous infusion 
 
U.S. EU Indications Population Indications Details References 
X X 
Rheumatoid 
Arthritis (RA) Adults 
 in combination with methotrexate for active RA 
without adequate response to disease-modifying 
antirheumatic drugs (DMARDs)  
 in combination with methotrexate for severe, active 
and progressive RA which is has not been treated with 
MTX before 
[74, 75] 
X X 
Ankylosing 
Spondylitis 
Adults 
 severe active ankylosing spondylitis who have not 
responded adequately to other treatments; 
[74, 75] 
X X 
Psoriatic 
Arthritis 
Adults 
 in combination with methotrexate, or on its own for 
active and progressive psoriatic arthritis who have not 
responded adequately to DMARDs 
[74, 75] 
X X Psoriasis Adults 
 severe plaque psoriasis who failed to respond to or 
who have a contraindication to, or are intolerant to 
other systemic therapy including cyclosporine, 
methotrexate or psoralen ultraviolet-A (PUVA) 
[74, 75] 
X X Crohn’s Disease 
2 – 17 
years 
& Adults 
 moderately to severely active Crohn’s disease which 
has not responded adequately or is intolerant to 
conventional therapy including primary nutrition 
therapy (children), corticosteroids, and/or 
immunomodulator 
 fistulising, active Crohn’s disease which has not 
responded adequately to conventional treatment 
(including antibiotics, drainage and 
immunosuppressive therapy) 
[74, 75] 
X X Ulcerative Colitis 
2 – 17 
years 
& Adults 
 moderately to severely active ulcerative colitis who 
have not responded adequately or are intolerant to 
conventional therapy including corticosteroids and 6-
mercaptopurine (6-MP) or azathioprine (AZA) 
[74, 75] 
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1.1.1. INFLIXIMAB Adverse Events (as per EU Initial MA documents) 
Table 10 – Infliximab Adverse Events as per European Initial Marketing-authorisation Documents 
MedDRA 17.1 
System Organ Class (SOC) 
AEs Detailed References 
Blood and lymphatic system 
disorders 
 Anaemia 
 Pancytopenia 
 Thrombocytopenia 
[77] 
Cardiac disorders  
 Arrhythmia 
 Congestive heart failure (CHF) – Infliximab is contraindicated in 
patients with moderate or severe heart failure (NYHA class III/IV). 
Infliximab should be used with caution in patients with mild heart 
failure (NYHA class I/II) 
 Myocardial ischaemia 
 Pericardial effusion 
[77] 
Gastrointestinal disorders 
 Intestinal perforation 
 Nausea 
 Pancreatitis 
 Stenosis 
[77] 
General disorders and 
administration site conditions 
 Chest pain 
 Chills 
 Deaths – infections are the most common cause of death. Sepsis 
and localised infections (like pneumonia) were also cause of some 
deaths 
 Fever 
[77] 
Hepatobiliary disorders 
 Abnormal hepatic function 
 Cholecystitis 
 Hepatitis 
 Hepatocellular damage 
[77] 
Immune system disorders  Delayed Hypersensitivity (including Serum Sickness-like) Reactions [77] 
Infections and Infestations  
 Aspergillosis, listeriosis 
 Cellulitis 
 Coccidioides 
 Cryptococcus infection 
 Cytomegalovirus (CMV) 
 Histoplasmosis 
 Pneumocystis carinii pneumonia 
 Pneumonia 
 Pyelonephritis 
 Sepsis 
 Sinusitis 
 Systemic candidiasis 
 Tuberculosis 
 Upper respiratory tract infection 
[77] 
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MedDRA 17.1 
System Organ Class (SOC) 
AEs Detailed References 
Investigations 
 Antibodies to Infliximab (various data show an association between 
antibodies to Infliximab and diminished degree of efficacy and 
increased incidence of infusion reactions) 
 Antinuclear antibodies (ANA) increased – Approximately half of 
Infliximab-treated patients in clinical studies who were ANA 
negative at baseline developed a positive ANA during the study. 
There were few cases that newly tested positive for anti-dsDNA 
antibodies. 
 Changes in white blood cells count 
[77] 
Musculoskeletal and connective 
tissue disorders 
 Lupus-like syndrome – mostly for patients who became positive for 
anti-dsDNA 
[77] 
Nervous system disorders 
 Demyelination – suggestive of multiple sclerosis or localized 
demyelination conditions such as optic neuritis 
 Headache 
[77] 
Respiratory, thoracic and 
mediastinal disorders 
 Cough 
 Dyspnoea 
 Interstitial pneumonitis/ fibrosis 
[77] 
Skin and subcutaneous tissue 
disorders 
 Pruritus 
 Rash 
 Urticaria 
[77] 
Vascular disorders 
 Hyper/hypotension 
 Vasculitis 
[77] 
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1.1.1. INFLIXIMAB Adverse Events Charts (following MA) 
 European Data (EU database of suspected adverse drug reactions reports) 
The data here displayed was launched by EMA in the European database of suspected adverse 
drug reactions reports. Reports included in this database correspond to the data submitted 
electronically to EudraVigilance by national medicines regulatory authorities and by 
pharmaceutical companies that hold marketing authorisations (licences) for the medicines. 
 
Chart 4 – Individual cases sorted by reactions groups, submitted for INFLIXIMAB (up to Oct’14) 
in European database of suspected adverse drug reaction reports (www.adrreports.eu) 
(data extracted on 26-Nov-2014) 
The chart above displays the number of cases reported for each reaction group, divided by 
age. The original chart (online format) enabled to pass the mouse through each bar and reveal 
the number of cases for a specific age. Below are the values of the biggest bars. 
EU Top 10 of Individual Cases (by reactions groups): 
1. Infections and Infestations (14171 cases) 
2. General disordes and administration site conditions (11700 cases) 
3. Gastrointestinal disorders (8995 cases) 
4. Injury, poisoning and procedural complications (8826 cases) 
5. Respiratory, thoracic and mediastinal disorders (8673 cases) 
6. Skin and subcutaneous tissue disorders (7821 cases) 
7. Nervous system disorders (7284 cases) 
8. Musculoskeletal and connective tissue disorders (6840 cases) 
9. Neoplasms benign, malignant and unspecified (including cysts and polyps) (6395 cases) 
10. Investigations (e.g. Chest X-ray abnormal; Electocardiogram QT prolonged) (5597 cases)  
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 FDA Adverse Event Reporting System (FAERS) Data (DrugCite.com) 
The data here displayed was made available by DrugCite database. Results included in this 
database correspond to the collection and analysis of reported adverse performed by FDA 
Adverse Events Reporting System (FAERS). These reports are submitted by physicians, 
healthcare consumers, lawyers amongst others. 
 
Chart 5 – Individual cases sorted by reactions groups, submitted for INFLIXIMAB and other drugs with same active 
substance (Q1 2004 – Q3 2012) in DrugCite.com (www.drugcite.com) 
(data extracted on 26-Nov-2014) 
The chart above displays, for each reaction group, the number of cases reported where the 
drug was flagged as a suspect drug causing the adverse event. All percentages (%) are the 
cases reported for a specific reaction group within the sum up of all reported cases in all 
reactions groups (percent does not represent rate related to drug utilization). 
U.S. Top 10 of Individual Cases (by reactions groups): 
1. Infections – Pathogen Unspecified (2180 cases) 
2. Bacterial Infectious (1005 cases) 
3. Skin Neoplasms Malignant and Unspecified (883 cases) 
4. Epidermal and Dermal Conditions (806 cases) 
5. Respiratory (806 cases) 
6. Mycobacterial Infectious (785 cases) 
7. Gastrointestinal Signs (775 cases) 
8. Gastrointestinal Inflammatory Conditions (764 cases) 
9. Therapeutic and Nontherapeutic Effects (666 cases) 
10. Viral Infectious (631 cases)  
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 Comparison of Adverse Events reported in EU and in the U.S. 
Following the analysis of the Adverse Events previously presented, it became clear that there 
were some differences between EU data and U.S. data. In order to have a visually enhanced 
perception of such differences, it was decided to create a cumulative chart which would 
aggregate all the data previously presented: 
 Post Marketing EU data (Blue bars in the cumulative chart) 
 Post Marketing U.S. data (Orange bars in the cumulative chart) 
 EU data as per Initial documents for MA (MedDRA SOCs highlighted in yellow in the 
cumulative chart) 
For aggregation purposes, a common classification had to be used and so MedDRA SOC was 
the selected classification for the cumulative chart below presented. 
 
Chart 6 – Individual cases sorted by reactions groups (MedDRA 17.1 SOC), submitted for INFLIXIMAB prior and 
post MA in Europe and post MA the United States 
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Comments to INFLIXIMAB cumulative chart: 
1. SOCs included in EU pre-MA reports vs SOCs included in EU post-MA reports 
Main discrepancies: There are cases of SOCs with a considerable number of AE reports (>2000) 
in post-MA and which were not foreseen by pre-MA clinical trials data. These include: Injury, 
poisoning and procedural complications & Surgical and Medical Procedures. 
 
2. SOCs included in EU post-MA reports vs. SOCs included in U.S. post-MA reports 
Although Infliximab is approved in EU and in the U.S. for the same indications, there are some 
significant discrepancies in the numbers above observed. 
Main discrepancies: Having EU data as reference, there were some U.S. bars which were 
expected to be bigger but are not. These include: General disorders and administration site 
conditions; Immune System Disorders; Injury, poisoning and procedural complications; 
Musculoskeletal and connective tissue disorders; Nervous system disorders & Vascular 
disorders. 
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1.2. GOLIMUMAB 
1.2.1. GOLIMUMAB Characterization 
Pharmacotherapeutic group: Immunosuppressants 
ATC code: L04AB06 [57] 
L — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 
L04 — IMMUNOSUPPRESSANTS 
L04A — IMMUNOSUPPRESSANTS 
L04AB — Tumour necrosis factor alpha inhibitors 
 
Golimumab (trade name SIMPONI) is a human IgG1 k, monoclonal antibody specific for human 
tumour necrosis factor alpha (TNF-a) that exhibits multiple glycoforms with molecular masses 
of approximately 150 to 151 kilodaltons [78]. 
Golimumab was created using genetically engineered mice immunized with human TNF, 
resulting in an antibody with human-derived antibody variable and constant regions. 
Golimumab is produced by recombinant cell line cultured by continuous perfusion and is 
purified by a series of steps that includes measures to inactivate and remove viruses [78]. 
 
1.2.2. GOLIMUMAB Mechanism of Action 
Golimumab is a human IgG1қ monoclonal antibody that binds to both the soluble and 
transmembrane bioactive forms of human TNFα. This interaction prevents the binding of TNFα 
to its receptors, thereby inhibiting the biological activity of TNFα (a cytokine protein). There 
was no evidence of the Golimumab antibody binding to other TNF superfamily ligands; in 
particular, the Golimumab antibody did not bind or neutralize human lymphotoxin. 
Golimumab did not lyse human monocytes expressing transmembrane TNF in the presence of 
complement or effector cells. 
 
Elevated TNFα levels in the blood, synovium, and joints have been implicated in the 
pathophysiology of several chronic inflammatory diseases such as rheumatoid arthritis, 
psoriatic arthritis, and ankylosing spondylitis. TNFα is an important mediator of the articular 
inflammation that is characteristic of these diseases. Golimumab modulated the in vitro 
biological effects mediated by TNF in several bioassays, including the expression of adhesion 
proteins responsible for leukocyte infiltration (E-selectin, ICAM-1 and VCAM-1) and the 
secretion of pro-inflammatory cytokines (IL-6, IL-8, O-CSF and GM-CSF) [78]. 
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1.2.3. GOLIMUMAB Treatment 
Table 11 – Golimumab Treatment: Method of administration and Indications 
GOLIMUMAB  |  Administration: subcutaneous injection 
 
U.S. EU Indications Population Indications Details References 
X X 
Rheumatoid 
Arthritis (RA) Adults 
 in combination with methotrexate for moderate to 
severe, active RA without adequate response to 
disease-modifying antirheumatic drugs (DMARDs)  
 in combination with methotrexate for severe, active 
and progressive RA which is has not been treated with 
MTX before 
[78, 79] 
X X 
Ankylosing 
Spondylitis 
Adults 
 severe, active ankylosing spondylitis which has not 
responded adequately to conventional therapy; 
[78, 79] 
X X 
Psoriatic 
Arthritis 
Adults 
 in combination with methotrexate, or on its own for 
active and progressive psoriatic arthritis which has not 
responded adequately to DMARDs 
[78, 79] 
X X Ulcerative Colitis Adults 
 moderately to severely active ulcerative colitis who 
have not responded adequately or are intolerant to 
conventional therapy including corticosteroids and 6-
mercaptopurine (6-MP) or azathioprine (AZA) 
[78, 79] 
 
1.1.1. GOLIMUMAB Adverse Events (as per EU Initial MA documents) 
Table 12 – Golimumab Adverse Events as per European Initial Marketing-authorisation Documents 
MedDRA 17.1 
System Organ Class (SOC) 
AEs Detailed References 
Cardiac disorders  
 Arrhythmia 
 Congestive heart failure (CHF) – it was decided the contraindication 
for patients with moderate to severe heart failure (NYHA class iii/iv) 
and a special warning for use of Golimumab in CHF 
 Ischemic coronary artery disorders 
[80] 
General disorders and 
administration site conditions 
 Deaths – among these deaths, there were infections, malignancy, 
cardiac and hepatic events which were possibly related to 
Golimumab treatment. 
[80] 
Hepatobiliary disorders 
 Acute cholecystitis 
 Hepatomegaly 
 Toxic hepatitis 
[80] 
Immune system disorders 
 Hypersensitivity 
 Rare cases of serum sickness 
[80] 
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MedDRA 17.1 
System Organ Class (SOC) 
AEs Detailed References 
Infections and Infestations  
 Abscess 
 Cellulitis 
 Infectious mononucleosis 
 Otitis media chronic 
 Pneumonia 
 Sepsis (sepsis and urosepsis) 
 Tuberculosis 
 Upper respiratory tract infection 
[80] 
Injury, poisoning and procedural 
complications 
 Injection reactions [80] 
Investigations 
 Antinuclear antibodies (ANA) increased – the proportion of subjects 
who were negative for antinuclear antibodies (ANA) at baseline, 
but who had a newly positive ANA test result during the studies, 
was increased in the majority of Golimumab groups. There were 
few cases that newly tested positive for anti-dsDNA antibodies. 
 Liver enzyme elevations – some cases of patients experiencing alt 
increase 
 Neutrophils reduced 
[80] 
Musculoskeletal and connective 
tissue disorders 
 Lupus erythematosus 
 Lupus-like syndrome 
[80] 
Neoplasms benign, malignant 
and unspecified (incl cysts and 
polyps) 
 Lymphoma 
 Nonmelanoma skin cancers 
[80] 
Nervous system disorders  Demyelination [80] 
Psychiatric disorders 
 Anxiety 
 Depression 
 Insomnia 
 Suicide attempt/ideation 
[80] 
Respiratory, thoracic and 
mediastinal disorders 
 Fibrosing alveolitis 
 Interstitial lung disease 
 Pneumonitis 
[80] 
Skin and subcutaneous tissue 
disorders 
 Erythema 
 Pustular psoriasis 
 Rash 
 Urticaria 
[80] 
Vascular disorders 
 Hypertension 
 Vasculitis 
[80] 
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1.1.1. GOLIMUMAB Adverse Events Charts (following MA) 
 European Data (EU database of suspected adverse drug reactions reports) 
The data here displayed was launched by EMA in the European database of suspected adverse 
drug reactions reports. Reports included in this database correspond to the data submitted 
electronically to EudraVigilance by national medicines regulatory authorities and by 
pharmaceutical companies that hold marketing authorisations (licences) for the medicines. 
 
Chart 7 – Individual cases sorted by reactions groups, submitted for GOLIMUMAB (up to Oct’14) 
in European database of suspected adverse drug reaction reports (www.adrreports.eu) 
(data extracted on 26-Nov-2014) 
The chart above displays the number of cases reported for each reaction group, divided by 
age. The original chart (online format) enabled to pass the mouse through each bar and reveal 
the number of cases for a specific age. Below are the values of the biggest bars. 
EU Top 10 of Individual Cases (by reactions groups): 
1. Infections and Infestations (726 cases) 
2. General disordes and administration site conditions (599 cases) 
3. Nervous system disorders (361 cases) 
4. Skin and subcutaneous tissue disorders (355 cases) 
5. Musculoskeletal and connective tissue disorders (331 cases) 
6. Gastrointestinal disorders (291 cases) 
7. Respiratory, thoracic and mediastinal disorders (269 cases) 
8. Injury, poisoning and procedural complications (239 cases) 
9. Neoplasms benign, malignant and unspecified (including cysts and polyps) (216 cases) 
10. Investigations (e.g. Chest X-ray abnormal; Electocardiogram QT prolonged) (203 cases)  
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 FDA Adverse Event Reporting System (FAERS) Data (DrugCite.com) 
The data here displayed was made available by DrugCite database. Results included in this 
database correspond to the collection and analysis of reported adverse performed by FDA 
Adverse Events Reporting System (FAERS). These reports are submitted by physicians, 
healthcare consumers, lawyers amongst others. 
 
Chart 8 – Individual cases sorted by reactions groups, submitted for GOLIMUMAB and other drugs with same 
active substance (Q1 2004 – Q3 2012) in DrugCite.com (www.drugcite.com) 
(data extracted on 26-Nov-2014) 
The chart above displays, for each reaction group, the number of cases reported where the 
drug was flagged as a suspect drug causing the adverse event. All percentages (%) are the 
cases reported for a specific reaction group within the sum up of all reported cases in all 
reactions groups (percent does not represent rate related to drug utilization). 
U.S. Top 10 of Individual Cases (by reactions groups): 
1. Infections – Pathogen Unspecified (1377 cases) 
2. Bacterial Infectious (343 cases) 
3. Viral Infectious (197 cases) 
4. Lower Respiratory Disorders (158 cases) 
5. Mycobacterial Infectious (155 cases) 
6. Respiratory and Mediastinal Neoplasms Malignant and Unspecified (131 cases) 
7. Gastrointestinal Neoplasms Malignant and Unspecified (130 cases) 
8. Joint (e.g. Arthralgia; Joint Stiffness) (115 cases) 
9. Gastrointestinal Inflammatory Conditions (107 cases) 
10. Gastrointestinal Signs (104 cases)  
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 Comparison of Adverse Events reported in EU and in the U.S. 
Following the analysis of the Adverse Events previously presented, it became clear that there 
were some differences between EU data and U.S. data. In order to have a visually enhanced 
perception of such differences, it was decided to create a cumulative chart which would 
aggregate all the data previously presented: 
 Post Marketing EU data (Blue bars in the cumulative chart) 
 Post Marketing U.S. data (Orange bars in the cumulative chart) 
 EU data as per Initial documents for MA (MedDRA SOCs highlighted in yellow in the 
cumulative chart) 
For aggregation purposes, a common classification had to be used and so MedDRA SOC was 
the selected classification for the cumulative chart below presented. 
 
Chart 9 – Individual cases sorted by reactions groups (MedDRA 17.1 SOC), submitted for GOLIMUMAB prior and 
post MA in Europe and post MA the United States 
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Comments to GOLIMUMAB cumulative chart: 
1. SOCs included in EU pre-MA reports vs SOCs included in EU post-MA reports 
Main discrepancies: There are cases of SOCs with a considerable number of AE reports (>150) 
in post-MA and which were not foreseen by pre-MA clinical trials data. These include: Eye 
disorders; Gastrointestinal disorders& Surgical and Medical Procedures. 
 
2. SOCs included in EU post-MA reports vs. SOCs included in U.S. post-MA reports 
Although Golimumab is approved in EU and in the U.S. for the same indications, there are 
some significant discrepancies in the numbers above observed. 
Main discrepancies: Having EU data as reference, there were some U.S. bars which were 
expected to be bigger but are not. These include: Cardiac disorders; General disorders and 
administration site conditions; Immune system disorders; Injury, poisoning and procedural 
complications; Musculoskeletal and connective tissue disorders; Nervous system disorders; 
Psychiatric disorders & Skin and subcutaneous tissue disorders. 
Based on EU data, there were also some U.S. bars which were expected to be smaller: 
Neoplasms benign, malignant and unspecified (including cysts and polyps). 
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1.2. CERTOLIZUMAB PEGOL 
Certolizumab pegol (trade name CIMZIA) is currently in the market with different indications 
for Europe and for the United Sates. 
Certolizumab pegol firstly applied for Market Authorisation in Europe for treatment of Crohn’s 
Disease. This application was refused on 21st May 2008 on the grounds of safety concerns and 
insignificant effectiveness [81]. 
FDA, on another hand, issued in 22nd April 2008 the approval for Certolizumab pegol for the 
treatment of Crohn’s Disease, based on safety and efficacy data from clinical trials in more 
than 1 500 patients with Crohn's disease [82]. 
Following that disapproval/approval, respectively, Certolizumab pegol applied for another 
number of indications (to be discussed further on) and it has now approvals granted both in 
Europe and U.S. Marketing Authorisation in Europe was granted on 1st October 2009, for the 
treatment of Arthritis Rheumatoid. 
 
1.2.1. CERTOLIZUMAB PEGOL Characterization 
Pharmacotherapeutic group: Immunosuppressants 
ATC code: L04AB05 [57] 
L — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 
L04 — IMMUNOSUPPRESSANTS 
L04A — IMMUNOSUPPRESSANTS 
L04AB — Tumour necrosis factor alpha inhibitors 
 
Certolizumab pegol (CIMZIA) is a recombinant, humanised antibody Fab' fragment, specific for 
human tumour necrosis factor alpha (TNFα), conjugated to an approximately 40kDa 
polyethylene glycol (PEG2MAL40K). 
The Fab' fragment is manufactured in E. coli and is then subjected to purification and 
conjugation to PEG2MAL40K, to generate Certolizumab pegol. The Fab' fragment is composed 
of a light chain with 214 amino acids and a heavy chain with 229 amino acids. 
The molecular weight of Certolizumab pegol is approximately 91 kiloDaltons [83]. 
 
1.2.2. CERTOLIZUMAB PEGOL Mechanism of Action 
Certolizumab pegol is a pegylated humanised Fab' fragment of an anti-TNF-alpha monoclonal 
antibody that binds to free and membrane-bound human TNFα with a KD of 90pM and 
neutralizes its activity. 
TNFα is a key pro-inflammatory cytokine with a central role in inflammatory processes. 
Certolizumab pegol selectively neutralizes TNFα but does not neutralize lymphotoxin α (TNFβ). 
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Certolizumab pegol cross-reacts poorly with TNF from rodents and rabbits, therefore in vivo 
efficacy was evaluated using animal models in which human TNFα was the physiologically 
active molecule.  
Certolizumab pegol was shown to neutralize membrane-associated and soluble human TNFα in 
a dose-dependent manner. Incubation of monocytes with Certolizumab pegol resulted in a 
dose-dependent inhibition of LPS-induced TNFα and IL-1β production in human monocytes. 
Certolizumab pegol does not contain a fragment crystallisable (Fc) region, which is normally 
present in a complete antibody, and therefore does not fix complement or cause antibody-
dependent cell-mediated cytotoxicity in vitro. It does not induce apoptosis in vitro in human 
peripheral blood-derived monocytes or lymphocytes, nor does Certolizumab pegol induce 
neutrophil degranulation. Certolizumab pegol clearly shows that the efficacy of anti-TNF-alpha 
antibodies does not require the apoptosis for the efficacy in response and maintenance of 
remission. 
A tissue reactivity study was carried out ex vivo to evaluate potential cross-reactivity of 
Certolizumab pegol with cryosections of normal human tissues. Certolizumab pegol showed no 
reactivity with a designated standard panel of normal human tissues [83, 84]. 
 
1.2.3. CERTOLIZUMAB PEGOL Treatment 
Table 13 – Certolizumab pegol Treatment: Method of administration and Indications 
CERTOLIZUMAB PEGOL  |  Administration: subcutaneous injection 
 
U.S. EU Indications Population Indications Details References 
X X 
Rheumatoid 
Arthritis (RA) 
Adults 
 in combination with methotrexate, or on its own for 
moderate to severe, active RA without adequate 
response to disease-modifying antirheumatic drugs 
(DMARDs)  
[83, 85] 
 X 
Axial 
spondyloarthritis 
Adults 
 severe axial spondyloarthritis without evidence in the 
X-ray of ankylosing spondylitis but with objective signs 
of inflammation, by elevated C-reactive protein (CRP) 
and /or magnetic resonance imaging (MRI), which has 
not responded adequately or are intolerant to non-
steroidal anti-inflammatory drugs (NSAIDs) 
[85] 
 X 
Ankylosing 
Spondylitis 
Adults 
 severe, active ankylosing spondylitis which has not 
responded adequately to, or are intolerant to 
nonsteroidal anti-inflammatory drugs (NSAIDs) 
[85] 
 X 
Psoriatic 
Arthritis 
Adults 
 in combination with methotrexate, or on its own for 
active and progressive psoriatic arthritis which has not 
responded adequately to DMARDs 
[85] 
X  Crohn’s Disease Adults 
 moderately to severely active Crohn’s disease which 
has not responded adequately to conventional 
therapy including corticosteroids, and/or 
immunomodulator 
[83] 
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1.1.1. CERTOLIZUMAB PEGOL Adverse Events (as per EU Initial MA documents) 
Table 14 – Certolizumab Adverse Events as per European Initial Marketing-authorisation Documents 
MedDRA 17.1 
System Organ Class (SOC) 
AEs Detailed References 
Blood and lymphatic system 
disorders 
 Anaemia 
 Eosinophilia 
[86] 
Cardiac disorders  
 Congestive heart failure –  the use of anti-TNF agents is 
contraindicated in subjects with moderate to severe heart failure 
[86] 
Gastrointestinal disorders 
 Gastrointestinal haemorrhage 
 Melaena 
 Melaena (due to epistaxis) 
 Rectal haemorrhage 
[86] 
General disorders and 
administration site conditions 
 Deaths – The majority of deaths were from cardiac and infectious 
causes, a pattern similar to that observed in other biologically-
treated RA subject populations 
 Hepatobiliary investigations – increased alanine aminotransferase, 
aspartate aminotransferase and gamma-glutamyl transferase 
[86] 
Immune system disorders 
 Hypersensitivity 
 Serum sickness 
[86] 
Infections and Infestations  
 Herpes infections 
 Lower respiratory tract infections 
 Lung infections 
 Nasopharyngitis 
 Opportunistic infections 
 Reactivation of viral infections 
 Tuberculosis (including pulmonary tuberculosis, disseminated 
tuberculosis, peritoneal tuberculosis, lymph node tuberculosis, and 
tuberculosis pleurisy) 
 Upper respiratory tract infection 
 Urinary tract infections 
[86] 
Injury, poisoning and procedural 
complications 
 Post-procedural haemorrhage [86] 
Investigations  Activated partial thromboplastin time (APTT) prolonged [86] 
Musculoskeletal and connective 
tissue disorders 
 Lupus-like events [86] 
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MedDRA 17.1 
System Organ Class (SOC) 
AEs Detailed References 
Neoplasms benign, malignant 
and unspecified (incl cysts and 
polyps) 
 B cell lymphoma 
 Basocellular carcinoma of the skin 
 Colon cancer 
 Hepatic neoplasm 
 Lung cancer 
 Metastases to CNS 
 Oesophageal carcinoma 
 Testicular cancer 
 Tongue neoplasm 
 Uterine cancer 
[86] 
Renal and urinary disorders  Haematuria [86] 
Reproductive system and breast 
disorders 
 Menorrhagia 
 Uterine haemorrhage 
[86] 
Respiratory, thoracic and 
mediastinal disorders 
 Bleeding nasal polyp 
 Lung infiltration 
[86] 
Skin and subcutaneous tissue 
disorders 
 Purpura [86] 
Vascular disorders 
 Haematoma 
 Hypertensive events 
[86] 
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1.1.1. CERTOLIZUMAB PEGOL Adverse Events Charts (following MA) 
 European Data (EU database of suspected adverse drug reactions reports) 
The data here displayed was launched by EMA in the European database of suspected adverse 
drug reactions reports. Reports included in this database correspond to the data submitted 
electronically to EudraVigilance by national medicines regulatory authorities and by 
pharmaceutical companies that hold marketing authorisations (licences) for the medicines. 
 
Chart 10 – Individual cases sorted by reactions groups, submitted for CERTOLIZUMAB (up to Oct’14) 
in European database of suspected adverse drug reaction reports (www.adrreports.eu) 
(data extracted on 26-Nov-2014) 
The chart above displays the number of cases reported for each reaction group, divided by 
age. The original chart (online format) enabled to pass the mouse through each bar and reveal 
the number of cases for a specific age. Below are the values of the biggest bars. 
EU Top 10 of Individual Cases (by reactions groups): 
1. Infections and Infestations (1475 cases) 
2. Gastrointestinal disorders (1304 cases) 
3. General disordes and administration site conditions (1237 cases) 
4. Skin and subcutaneous tissue disorders (784 cases) 
5. Musculoskeletal and connective tissue disorders (593 cases) 
6. Nervous system disorders (578 cases) 
7. Surgical and medical procedures (549 cases) 
8. Respiratory, thoracic and mediastinal disorders (474 cases) 
9. Injury, poisoning and procedural complications (470 cases) 
10. Investigations (e.g. Chest X-ray abnormal; Electocardiogram QT prolonged) (400 cases)  
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 FDA Adverse Event Reporting System (FAERS) Data (DrugCite.com) 
The data here displayed was made available by DrugCite database. Results included in this 
database correspond to the collection and analysis of reported adverse performed by FDA 
Adverse Events Reporting System (FAERS). These reports are submitted by physicians, 
healthcare consumers, lawyers amongst others. 
 
Chart 11 – Individual cases sorted by reactions groups, submitted for CERTOLIZUMAB and other drugs with same 
active substance (Q1 2004 – Q3 2012) in DrugCite.com (www.drugcite.com) 
(data extracted on 26-Nov-2014) 
The chart above displays, for each reaction group, the number of cases reported where the 
drug was flagged as a suspect drug causing the adverse event. All percentages (%) are the 
cases reported for a specific reaction group within the sum up of all reported cases in all 
reactions groups (percent does not represent rate related to drug utilization). 
U.S. Top 10 of Individual Cases (by reactions groups): 
1. Infections – Pathogen Unspecified (1496 cases) 
2. Hematology Investigations (592 cases) 
3. Bacterial Infectious (475 cases) 
4. Gastrointestinal Signs (360 cases) 
5. Joint (e.g. Arthralgia; Joint Stiffness) (354 cases) 
6. Epidermal And Dermal Conditions (268 cases) 
7. Respiratory (243 cases) 
8. Hepatobiliary (198 cases) 
9. Viral Infectious (192 cases) 
10. Central Nervous System Vascular (186 cases)  
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 Comparison of Adverse Events reported in EU and in the U.S. 
Following the analysis of the Adverse Events previously presented, it became clear that there 
were some differences between EU data and U.S. data. In order to have a visually enhanced 
perception of such differences, it was decided to create a cumulative chart which would 
aggregate all the data previously presented: 
 Post Marketing EU data (Blue bars in the cumulative chart) 
 Post Marketing U.S. data (Orange bars in the cumulative chart) 
 EU data as per Initial documents for MA (MedDRA SOCs highlighted in yellow in the 
cumulative chart) 
For aggregation purposes, a common classification had to be used and so MedDRA SOC was 
the selected classification for the cumulative chart below presented. 
 
Chart 12 – Individual cases sorted by reactions groups (MedDRA 17.1 SOC), submitted for CERTOLIZUMAB PEGOL 
prior and post MA in Europe and post MA the United States 
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Comments to CERTOLIZUMAB PEGOL cumulative chart: 
1. SOCs included in EU pre-MA reports vs SOCs included in EU post-MA reports 
Main discrepancies: There are cases of SOCs with a considerable number of AE reports (>150) 
in post-MA and which were not foreseen by pre-MA clinical trials data. These include: 
Metabolism and nutrition disorders; Nervous system disorders; Psychiatric disorders & Surgical 
and Medical Procedures. 
 
2. SOCs included in EU post-MA reports vs. SOCs included in U.S. post-MA reports 
Certolizumab pegol is approved in EU and in the U.S. for different indications (with the 
exception of Rheumatoid Arthritis which is common), which may help to explain some 
significant discrepancies in the numbers above observed. 
Main discrepancies: Having EU data as reference, there were some U.S. bars which were 
expected to be bigger but are not: these include General disorders and administration site 
conditions; Psychiatric disorder; Skin and subcutaneous tissue disorders & Surgical and Medical 
Procedures. 
Based on EU data, there were also some U.S. bars which were expected to be smaller: 
Hepatobiliary disorders; Investigations & Neoplasms benign, malignant and unspecified 
(including cysts and polyps). 
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2. Comparison of AEs reported for anti-TNFα mAbs 
In the previous analysis of the AEs reported for each anti-TNFα mAb it was visible that there 
were some discrepancies in the AEs reported pre and post MA as well as some discrepancies in 
AEs reported in Europe and the United States. 
Following those mAb-specific analysis, it becomes important to see how the AEs are being 
reported throughout anti-TNFα mAbs class.  
The table below intends to provide a global picture on the ranking of mostly reported AEs for 
anti-TNFα mAbs. For comparison purposes, there was the need to choose a common data set 
and, for that reason, the table only comprises the EU reports post-MA. 
Table 15 – Comparison of most commonly reported AEs for anti-TNFα mAbs (post-marketing EU data) 
MedDRA 17.1 
System Organ Class (SOC) 
Post-Marketing EU data – ranking of most reported AEs 
Comments 
ADALIMUMAB INFLIXIMAB GOLIMUMAB CERTOLIZUMAB 
Gastrointestinal disorders 3
rd
 3
rd
 6
th
 2
nd
 
Transversally reported AEs 
for all anti- TNFα mAbs. 
General disorders and 
administration site conditions 
2nd 2nd 2nd 3rd 
Most reported AEs for all 
anti-TNFα mAbs. 
Infections and Infestations  1st 1st 1st 1st 
Most reported AEs for all 
anti-TNFα mAbs. 
Injury, poisoning and procedural 
complications 
10th 4th 8th 9th 
Transversally reported AEs 
for all anti-TNFα mAbs. 
Investigations 9th 10th 10th 10th 
Least reported AEs for all 
anti-TNFα mAbs. 
Musculoskeletal and connective 
tissue disorders 
5th 8th 5th 5th 
Transversally reported AEs 
for all anti-TNFα mAbs. 
Neoplasms benign, malignant and 
unspecified (incl cysts and polyps) 
4th 9th 9th --   
Nervous system disorders 6th 7th 3rd 6th 
Transversally reported AEs 
for all anti-TNFα mAbs. 
Respiratory, thoracic and 
mediastinal disorders 
8th 5th 7th 8th 
Transversally reported AEs 
for all anti-TNFα mAbs. 
Skin and subcutaneous tissue 
disorders 
7th 6th 4th 4th 
Transversally reported AEs 
for all anti-TNFα mAbs. 
Surgical and medical procedures  -- -- -- 7
th
   
NOTE: The colours represent the ranking of reported AEs. GREEN represents the mostly reported AEs whereas RED 
the least reported AEs. 
According to the above table, anti-TNFα mAbs seem to have a very similar profile of AEs 
reported in EU following MA. There are only 2 out of 11 (≈18%) SOCs above listed which are 
not transversally applicable to all mAbs of this class: Neoplasms benign, malignant and 
unspecified (incl cysts and polyps) & Surgical and medical procedures. This means that 82% of 
profile is similar in terms of the AEs mostly reported. Of course each mAb may have different 
rankings of AEs reported. Still, in general, the profiles seems constant throught all anti-TNFα 
mAbs – which represents great figures for similarity through this mAbs class. 
Although the mAbs comprised in anti-TNFα class have some differences, including the type of 
mAb (2 human, 1 humanised and 1 chimeric mAb) and the configuration of mAbs (1 mAb is a 
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pegylated humanised Fab' fragment), it is interesting to observe that those differences did not 
affect significantly the general outcome of AEs reported to each mAb. 
Similar treatment indication and administration routes may have been a key factor for the 
consistency of AEs observed throughout the anti-TNFα mAbs class. These similarities are 
aligned with the concept of AEs being correlated to mAbs mechanism of action. 
For the particular case of anti-TNFα mAbs, the mostly reported AEs were i) Infections and 
Infestations, ii) General disorders and administration site conditions as well as iii) 
Gastrointestinal disorders and all these are according to the expectation. 
While General disorders and administration site conditions are antibody-related AEs which 
generally occur for every mAb; Infections and Infestations & Gastrointestinal disorders can be 
correlated to the specific Mechanism of Action of anti-TNFα. 
As immunosuppressors, it is expected that anti-TNFα mAbs decrease the immune system 
capabilities and raise the chances for Infections and Infestations to arise. 
On what regards Gastrointestinal disorders, it is interesting to observe that, similar to anti 
inflammatory drugs, these mAbs also have this kind of AEs. 
TNFα has been shown to stimulate prostaglandin E2 synthesis [62] and these prostaglandins 
E2, in turn, have been shown to have strong cytoprotective effects on the gastric mucosa [87]. 
It is expected that anti-TNFα mAbs alter the usual TNFα-mediated effects and these can 
include the usual Prostaglandin E2 gastro protective effect. It is therefore possible that 
inhibition of TNFα can lead to a greater number of Gastrointestinal disorders. 
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I. Anti-VEGF mAbs 
Most approved and experimental anticancer antibodies directly target tumour cells. 
Alternative strategies include inhibiting angiogenesis or directly targeting tumour 
neovasculature. Angiogenesis (blood vessel neoformation) is a tightly regulated process 
responsible for the development of new blood vessels from a pre-existing vascular network. 
During development and normal physiological processes such as wound healing and the 
menstrual cycle, angiogenesis is regulated by endogenous activators and inhibitors [38, 88-91]. 
In pathological settings, such as age-related macular degeneration, rheumatoid arthritis, 
diabetic retinopathy and tumour growth and metastasis, angiogenesis is critical for disease 
progression. An independent blood supply is critical for a tumour to grow beyond a certain size 
and spread (metastasise) to other parts of the body. Tumours develop their own blood supply 
by releasing vascular endothelial growth factor (VEGF) – a key driver for tumour growth. The 
neovascularisation enhanced by the release of VEGF allows the tumour cells to acquire a 
growth advantage and proliferative autonomy compared to the normal cells [38, 88-91]. 
As the vascular endothelial growth factor (VEGF) family of proteins are key regulators tumour 
angiogenesis, they provide attractive targets for anti-cancer therapies [91]. Targeting the 
tumour vasculature has several potential advantages over direct tumour targeting: the 
vasculature is more accessible to antibodies; vasculature damage has a multiplicative effect as 
many tumour cells are dependent on each capillary; and as vascular endothelial cells are not 
transformed, they seem less likely to become resistant to antibody therapy [38]. 
 
Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen and survival 
factor as well as regulator and promoter of angiogenesis during developmental, physiological, 
and pathological processes. It  encompasses a class of proteins: VEGF-A, B, C, D, and placental 
growth factor, among which VEGF-A is the most relevant for angiogenesis and vascular 
permeability [90-93]. 
Apart from VEGF physiological functions it has a decisive role in tumour-angiogenesis and in 
the pathogenesis of neovascular eye diseases, including neovascular AMD, diabetic 
retinopathy, and retinopathy of prematurity. Endothelial cells that are present in choroidal 
neovascular membrane are strongly dependent on VEGF for cell survival and interference with 
VEGF activity induces endothelial apoptosis. It is this difference between normal and choroidal 
neovascularisation (CNV)-associated vasculature with respect to VEGF dependence by 
endothelial cells for survival that support the rationale for clinical use of an anti-VEGF Fab as 
therapeutic agent to treat patients with age-related macular degeneration (AMD) [90-93]. 
 
In animal models, murine mAb VEGF A4.6.1. revealed to be a high affinity mAb capable of 
recognizing all VEGF isoforms, which would inhibit the growth of a variety of human tumour 
cell lines in nude mice and inhibit the iris neovascularisation secondary to retinal ischemia in a 
primate model following intraocular administration. Murine antibodies have, however, a major 
limitation in what regards the potential risk of an immune reaction to occur; a powerful 
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approach to overcome this limitation in the clinical use of monoclonal antibodies is 
"humanization" of the murine antibodies. In the case of murine VEGF mAb, the humanisation 
resulted in a mAb which exhibited only a slight reduction in binding compared to the parent 
murine antibody, but this modest reduction in on-rate did not result in any decreased ability to 
antagonize VEGF bioactivity and both antibodies (fully murine & humanised) had essentially 
identical activity, both in an endothelial cell proliferation assay and in an in vivo tumour model 
[90]. 
Both Ranibizumab (LUCENTIS) and Bevacizumab (AVASTIN) were derived from the murine 
monoclonal antibody A4.6.1. Ranibizumab was developed from a humanised Fab variant of 
A4.6.1, known as MB1.6. This Fab then underwent a series of modifications: Affinity selection 
using phage display technology increased the affinity of Ranibizumab for VEGF-A by several 
times. Thus, Ranibizumab cannot simply be described as a Fab of Bevacizumab because their 
complementarity-determining regions (CDR) are markedly different [92]. 
In contrast to a full-size antibody, Ranibizumab cannot bind complement because it lacks the 
Fc (Fragment crystallisable) region. The increased potency, the smaller molecular size 
compared to a full-length antibody for enhanced penetration into the retina and choroid, and 
the lack of the Fc region were considered to be advantageous for intravitreal efficacy [92]. 
When comparing both mAbs [92]: 
 ↑Bevacizumab – the systemic half-life of Ranibizumab is a few hours compared to roughly 
3 weeks for Bevacizumab. This may be a disadvantage in respect to the number of 
required re-injections; 
 ↑Ranibizumab – the affinity of Ranibizumab for VEGF-A is higher than that of 
Bevacizumab but it is unclear whether this has significant clinical implications; 
 ↑Ranibizumab – the presence of the Fc fragment in Bevacizumab might turn the patients 
receiving Bevacizumab more susceptible to the development of an immune response to 
the agent.  
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1. mAbs targeted for VEGF 
Table 16 – anti-VEGF mAbs approved indications for Europe and for the United States 
Anti-VEGF mAbs 
 
BEVACIZUMAB RANIBIZUMAB 
Indications 
U.S. EU U.S. EU 
X X   Metastatic Carcinoma of the Colon or Rectum (mCRC) 
 X   Metastatic breast cancer (mBC) 
X X   Non-Small Cell Lung Cancer 
X X   Metastatic Renal Cell Carcinoma (mRCC) 
 X   Epithelial ovarian, fallopian tube and primary peritoneal cancer 
X    Glioblastoma 
X    Cervical Cancer 
  X X Age-related macular degeneration (AMD) 
  X X Diabetic macular oedema (DME) 
  X X Macular oedema secondary to Retinal Vein Occlusion (RVO) 
   X Choroidal Neovascularisation (CNV) Secondary to Pathologic Myopia 
 
1.1. BEVACIZUMAB 
Bevacizumab (trade name AVASTIN) is currently in the market with different indications for 
Europe and for the United Sates. 
Europe and the United States share the approval of Bevacizumab treatment for colorectal 
cancer, non-small cell lung cancer and kidney cancer. However, other Bevacizumab’s 
indications remain different in Europe and the United States. 
Currently only Europe has the Bevacizumab approval granted for treatment of advanced stages 
of breast cancer and ovarian cancer. For a while Bevacizumab was also approved in the United 
States for the treatment of breast cancer (approval granted in 2008 through the US FDAs 
Accelerated Approval Program) but following 3 years in the market this indication was revoked 
(2011) after concluding that the drug has not been shown to be safe and effective for the 
treatment of breast cancer (revocation was announced in November 2011 by the US FDA 
Commissioner Margaret Hamburg) [94]. 
The United States, on another hand, have Bevacizumab also approved for treatment of 
patients with progressive Glioblastoma following prior therapy whereas Europe has not. 
Europe refused the Glioblastoma indication on the grounds that effectiveness of Bevacizumab 
in combination with radiotherapy and temozolomide had not been sufficiently demonstrated 
and that there was no benefit in terms of overall survival [88, 95, 96]. 
The US FDA and EMEA have reached different scientific conclusions on the efficacy and safety 
of drugs in the past. The reasons for different decisions are not readily apparent between the 
US FDA and EMEA [94]. 
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1.1.1. BEVACIZUMAB Characterization 
Pharmacotherapeutic group: Monoclonal antibodies 
ATC code: L01XC07 [57] 
L — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 
L01 — ANTINEOPLASTIC AGENTS 
L01X — OTHER ANTINEOPLASTIC AGENTS 
L01XC — Monoclonal antibodies 
 
Bevacizumab (AVASTIN) is a full-size recombinant humanised monoclonal IgG1 antibody 
(93% human, 7% murine sequences) that binds to and inhibits the biologic activity of 
human vascular endothelial growth factor (VEGF) in vitro and in vivo assay systems. 
Neutralisation of VEGF’s biologic activity is achieved through a steric blocking of the 
binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of 
endothelial cells. Receptors activation normally induces their tyrosine phosporylation and 
the subsequent series of signal transduction events elicit mitogenic and pro-survival 
activity signals for the vascular endothelial cells. 
Bevacizumab is produced by DNA technology in Chinese Hamster Ovary cells and it 
contains human framework regions in addition to the complementarity-determining 
regions of a murine antibody which bind to VEGF. 
The molecular weight of Bevacizumab is approximately 149 kD [92, 97-99]. 
 
1.1.2. BEVACIZUMAB Mechanism of Action 
Bevacizumab is a tumour-starving (anti-angiogenic) therapy. Bevacizumab is designed to bind 
to vascular endothelial growth factor (VEGF), the key driver of vasculogenesis and prevent 
VEGF interaction to its receptors – Flt-1 (VEGFR-1) and KDR (VEGFR-2) – on the surface of 
endothelial cells. 
The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood 
vessel formation in in vitro models of angiogenesis. Therefore, neutralising the biological 
activity of VEGF results in regression of tumours vascularisation, normalisation of the 
remaining tumour vasculature, and inhibition of the formation of new tumour vasculature, 
thereby inhibiting tumour growth[97, 98, 100]. 
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1.1.3. BEVACIZUMAB Treatment 
Table 17 – Bevacizumab Treatment: Method of administration and Indications 
BEVACIZUMAB  |  Administration: intravenous infusion 
 
U.S. EU Indications Population Indications Details References 
X X 
Metastatic 
Carcinoma of the 
Colon or Rectum 
(mCRC) 
Adults 
 in combination with fluoropyrimidine-irinotecan  or 
fluoropyrimidine-oxaliplatin-based chemotherapy is 
indicated for second-line treatment of metastatic 
colorectal cancer which has progressed on a first-line 
Bevacizumab-containing regimen 
[97, 98, 101] 
 X 
Metastatic 
breast cancer 
(mBC) 
Adults 
 in combination with paclitaxel is indicated for first-line 
treatment of metastatic breast cancer 
 in combination with capecitabine is indicated for first-
line treatment of metastatic breast cancer which has 
not responded adequately to other chemotherapy 
options, including taxanes or anthracyclines 
[98] 
X X 
Non-Small Cell 
Lung Cancer 
Adults 
 in addition to platinum-based chemotherapy, is 
indicated for first-line treatment of unresectable 
advanced, metastatic or recurrent non-small cell lung 
cancer other than predominantly squamous cell 
histology 
[97, 98, 101] 
X X 
Metastatic Renal 
Cell Carcinoma 
(mRCC) 
Adults 
 in combination with interferon alfa-2a is indicated for 
first line treatment of advanced and/or metastatic 
renal cell cancer 
[97, 98] 
 X 
Epithelial 
ovarian, 
fallopian tube 
and primary 
peritoneal 
cancer 
Adults 
 in combination with carboplatin and paclitaxel is 
indicated for the front-line treatment of advanced 
stages epithelial ovarian, fallopian tube, or primary 
peritoneal cancer 
 in combination with carboplatin and gemcitabine, is 
indicated for treatment of first recurrence of 
platinum-sensitive epithelial ovarian, fallopian tube or 
primary peritoneal cancer which has not received 
prior therapy with a VEGF inhibitor/receptor–targeted 
agent 
 in combination with paclitaxel, topotecan, or 
pegylated liposomal doxorubicin is indicated for the 
treatment of adult patients with platinum-resistant 
recurrent epithelial ovarian, fallopian tube, or primary 
peritoneal cancer which received no more than 2 prior 
chemotherapy regimens and which has not received 
prior therapy with a VEGF inhibitor/receptor–targeted 
agent 
[98] 
X  Glioblastoma Adults 
 treatment of Glioblastoma with progressive disease 
following prior therapy as a single agent 
[97] 
X  Cervical Cancer Adults 
 in combination with paclitaxel and cisplatin or 
paclitaxel and topotecan for the treatment of 
persistent, recurrent, or metastatic carcinoma of the 
cervix 
[97] 
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1.1.4. BEVACIZUMAB Adverse Events (as per EU Initial MA documents) 
Table 18 – Bevacizumab Adverse Events as per European Initial Marketing-authorisation Documents 
MedDRA 17.1 
System Organ Class (SOC) 
AEs Detailed 
Reference
s 
Cardiac disorders  
 Congestive heart failure (CHF)/cardiomyopathy – these events 
varied in severity from asymptomatic declines in left ventricular 
ejection fraction to symptomatic CHF requiring hospitalisation and 
treatment 
[99] 
Gastrointestinal disorders 
 Diarrhoea 
 Gastrointestinal perforation – Bevacizumab has been associated 
with serious cases of gastrointestinal. The common feature among 
these cases was intra-abdominal inflammation, either from gastric 
ulcer disease, tumour necrosis, diverticulitis, or chemotherapy-
associated colitis 
[99] 
Injury, poisoning and procedural 
complications 
 Wound healing – post-operative bleeding or wound healing 
complication were observed in some Bevacizumab-treated patients 
who underwent major surgery while receiving treatment 
[99] 
Investigations 
 Blood alkaline phosphatase increased 
 Blood glucose increased 
 Blood phosphorus decreased 
 Blood potassium decreased 
 Neutrophil count decreased 
 Presence of urine protein 
 White blood cell count decreased 
[99] 
Neoplasms benign, malignant 
and unspecified (incl cysts and 
polyps) 
 Tumour-associated haemorrhage – the haemorrhagic events that 
have been observed in clinical studies were predominantly tumour-
associated haemorrhage 
[99] 
Renal and urinary disorders 
 Proteinuria – it ranged in severity from clinically asymptomatic, 
transient, trace proteinuria to nephritic syndrome, with the great 
majority as grade 1 proteinuria 
[99] 
Vascular disorders 
 Deep thrombophlebitis 
 Haemorrhage – grade 3 and 4 bleeding events were reported in 
some Bevacizumab-treated patients 
 Hypertension – grade 3 hypertension (requiring oral anti-
hypertensive medication) was observed in some Bevacizumab-
treated patients 
 Thromboembolism – thromboembolic events including CVAS, MIS, 
TIAS, and other arterial thromboembolic events was higher in some 
Bevacizumab-treated patients 
[99] 
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1.1.5. BEVACIZUMAB Adverse Events Charts (following MA) 
 European Data (EU database of suspected adverse drug reactions reports) 
The data here displayed was launched by EMA in the European database of suspected adverse 
drug reactions reports. Reports included in this database correspond to the data submitted 
electronically to EudraVigilance by national medicines regulatory authorities and by 
pharmaceutical companies that hold marketing authorisations (licences) for the medicines. 
 
Chart 13 – Individual cases sorted by reactions groups, submitted for BEVACIZUMAB (up to Oct’14) 
in European database of suspected adverse drug reaction reports (www.adrreports.eu) 
(data extracted on 26-Nov-2014) 
The chart above displays the number of cases reported for each reaction group, divided by 
age. The original chart (online format) enabled to pass the mouse through each bar and reveal 
the number of cases for a specific age. Below are the values of the biggest bars. 
EU Top 10 of Individual Cases (by reactions groups): 
1. General disordes and administration site conditions (7078 cases) 
2. Gastrointestinal disorders (4874 cases) 
3. Respiratory, thoracic and mediastinal disorders (2942 cases) 
4. Nervous system disorders (2860 cases) 
5. Vascular disorders (2764 cases) 
6. Infections and Infestations (2055 cases) 
7. Blood and lymphatic system disorders (1722 cases) 
8. Investigations (e.g. Chest X-ray abnormal; Electocardiogram QT prolonged) (1634 cases) 
9. Neoplasms benign, malignant and unspecified (incl cysts and polyps) (1369 cases) 
10. Eye disorders (1280 cases)  
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 FDA Adverse Event Reporting System (FAERS) Data (DrugCite.com) 
The data here displayed was made available by DrugCite database. Results included in this 
database correspond to the collection and analysis of reported adverse performed by FDA 
Adverse Events Reporting System (FAERS). These reports are submitted by physicians, 
healthcare consumers, lawyers amongst others. 
 
Chart 14 – Individual cases sorted by reactions groups, submitted for BEVACIZUMAB and other drugs with same 
active substance (Q1 2004 – Q3 2012) in DrugCite.com (www.drugcite.com) 
(data extracted on 25-Nov-2014) 
The chart above displays, for each reaction group, the number of cases reported where the 
drug was flagged as a suspect drug causing the adverse event. All percentages (%) are the 
cases reported for a specific reaction group within the sum up of all reported cases in all 
reactions groups (percent does not represent rate related to drug utilization). 
U.S. Top 10 of Individual Cases (by reactions groups): 
1. Infections – Pathogen Unspecified (3496 cases) 
2. Gastrointestinal Signs (3064 cases) 
3. Hemathology Investigations (2129 cases) 
4. Respiratory (2036 cases) 
5. Electrolyte And Fluid Balance Conditions (1881 cases) 
6. White Blood Cell (1764 cases) 
7. Neurological (1622 cases) 
8. Gastrointestinal Motility And Defecation Conditions (1598 cases) 
9. Cardiac Arrhythmias (1102 cases) 
10. Body Temperature Conditions (1039 cases)  
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 Comparison of Adverse Events reported in EU and in the U.S. 
Following the analysis of the Adverse Events previously presented, it became clear that there 
were some differences between EU data and U.S. data. In order to have a visually enhanced 
perception of such differences, it was decided to create a cumulative chart which would 
aggregate all the data previously presented: 
 Post Marketing EU data (Blue bars in the cumulative chart) 
 Post Marketing U.S. data (Orange bars in the cumulative chart) 
 EU data as per Initial documents for MA (MedDRA SOCs highlighted in yellow in the 
cumulative chart) 
For aggregation purposes, a common classification had to be used and so MedDRA SOC was 
the selected classification for the cumulative chart below presented. 
 
Chart 15 – Individual cases sorted by reactions groups (MedDRA 17.1 SOC), submitted for BEVACIZUMAB prior 
and post MA in Europe and post MA the United States 
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Comments to BEVACIZUMAB cumulative chart: 
1. SOCs included in EU pre-MA reports vs SOCs included in EU post-MA reports 
Main discrepancies: There are cases of SOCs with a considerable number of AE reports (>1000) 
in post-MA and which were not foreseen by pre-MA clinical trials data. These include: Blood 
and lymphatic system disorders; Eye disorders; Infections and infestations; Nervous system 
disorders; Respiratory, thoracic and mediastinal disorders & Skin and subcutaneous tissue 
disorders. 
 
2. SOCs included in EU post-MA reports vs. SOCs included in U.S. post-MA reports 
Although there are some discrepancies in the main SOCs referred on EU post-MA reports and 
U.S. post-MA reports and these are not very relevant in the global outcome of the chart. 
Small discrepancies: Having EU data as reference, there were some U.S. bars which were 
expected to be bigger but are not: these include Eye disorders; General disorders and 
administration site conditions. 
In general, it was observed that Bevacizumab had a similar profile of AEs reported post-MA in 
EU and in the U.S. 
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1.2. RANIBIZUMAB 
Ranibizumab (trade name LUCENTIS) is currently in the market with slightly different 
indications for Europe and for the United Sates. 
Ranibizumab was jointly developed by Genentech and Novartis. Genentech has the 
commercial rights in the US, while Novartis has exclusive rights in the rest of the world. 
Lucentis is a registered trademark of Genentech Inc [102, 103]. 
Europe and the United States share the approval of Ranibizumab treatment for wet age-
related macular degeneration (wet AMD), diabetic macular oedema (DME) and macular 
oedema following retinal vein occlusion (RVO) [104]. Additionally, in Europe, Novartis has been 
granted approval by the European Commission for Ranibizumab to treat patients with visual 
impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia 
(myopic CNV) [102-105]. 
 
1.2.1. RANIBIZUMAB Characterization 
Pharmacotherapeutic group: Ophthalmologicals 
ATC code: S01LA04 [57] 
S — SENSORY ORGANS 
S01 — OPHTHALMOLOGICALS 
S01L — OCULAR VASCULAR DISORDER AGENTS 
S01LA — Antineovascularisation agents 
 
Ranibizumab (LUCENTIS) is a recombinant humanised monoclonal antibody fragment (Fab) 
produced in Escherichia coli cells, by standard recombinant DNA technology, and is targeted 
against all biologically active forms of human vascular endothelial cell growth factor-A (VEGF-
A) [92, 103, 106, 107]. 
Increased levels of VEGF-A are seen in wet AMD and other ocular diseases such as diabetic 
macular oedema (DME) and retinal vein occlusion (RVO). Ranibizumab was specifically 
designed for the eye, minimizing systemic exposure [103]. 
Ranibizumab, which lacks an Fc region, is produced by an E. coli expression system by 
recombinant DNA technology. It has a molecular weight of approximately 48 kDa [106, 108, 
109].  
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1.2.2. RANIBIZUMAB Mechanism of Action 
Ranibizumab binds with high affinity to the VEGF-A isoforms (e.g. VEGF110, VEGF121 and 
VEGF165), thereby preventing binding of VEGF-A to its receptors VEGFR-1 and VEGFR-2, on the 
surface of endothelial cells. 
Usually VEGF-A binding to its receptors leads to endothelial cell proliferation and 
neovascularisation, as well as vascular leakage, all of which are thought to contribute to the 
progression of the neovascular form of age-related macular degeneration (AMD), pathologic 
myopia or to visual impairment caused by either diabetic macular oedema (DME) or macular 
oedema secondary to retinal vein occlusion (RVO). Ranibizumab binding to VEGF-A prevents 
the interaction with the receptors; therefore reducing endothelial cell proliferation, vascular 
leakage, and new blood vessel formation [93, 105, 106, 108, 109]. 
 
1.2.3. RANIBIZUMAB Treatment 
Table 19 – Bevacizumab Treatment: Method of administration and Indications 
BEVACIZUMAB  |  Administration: intravitreal injections 
 
U.S. EU Indications Population Indications Details References 
X X 
Age-related 
macular 
degeneration 
(AMD) 
Adults 
 treatment of neovascular (wet) age-related macular 
degeneration (AMD), until maximum visual acuity is 
achieved (i.e. the patient’s visual acuity is stable for 3 
consecutive monthly assessments) 
[97, 108] 
X X 
Diabetic macular 
oedema (DME) 
Adults 
 treatment of visual impairment due to diabetic 
macular oedema (DME), until maximum visual acuity 
is achieved (i.e. the patient’s visual acuity is stable for 
3 consecutive monthly assessments) 
[97, 108] 
X X 
Macular oedema 
secondary to 
Retinal Vein 
Occlusion (RVO) 
Adults 
 treatment of visual impairment due to macular 
oedema secondary to retinal vein occlusion (branch 
RVO or central RVO), until maximum visual acuity is 
achieved (i.e. the patient’s visual acuity is stable for 3 
consecutive monthly assessments) 
[97, 108] 
 X 
Choroidal 
Neovascularisati
on (CNV) 
Secondary to 
Pathologic 
Myopia 
Adults 
 treatment of visual impairment due to choroidal 
neovascularisation (CNV) secondary to pathologic 
myopia (PM) 
[108] 
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1.1.1. RANIBIZUMAB Adverse Events (as per EU Initial MA documents) 
Table 20 – Ranibizumab Adverse Events as per European Initial Marketing-authorisation Documents 
MedDRA 17.1 
System Organ Class (SOC) 
AEs Detailed References 
Eye disorders 
 Conjunctival haemorrhage 
 Eye pain 
 Foreign body sensation in eyes 
 Macular degeneration 
 Retinal detachment 
 Retinal haemorrhage 
 Retinal tear 
 Uveitis 
 Vitreous detachment 
 Vitreous floaters 
 Vitreous haemorrhage 
[107] 
Infections and Infestations  
 Bronchitis 
 Endophthalmitis 
 Nasopharygitis 
 Upper respiratory tract infection 
[107] 
Investigations  Intraocular pressure increased [107] 
Nervous system disorders  Headache [107] 
Respiratory, thoracic and 
mediastinal disorders 
 Cough [107] 
Vascular disorders 
 Arterial thromboembolic events 
 Hypertension 
[107] 
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1.1.1. RANIBIZUMAB Adverse Events Charts (following MA) 
 European Data (EU database of suspected adverse drug reactions reports) 
The data here displayed was launched by EMA in the European database of suspected adverse 
drug reactions reports. Reports included in this database correspond to the data submitted 
electronically to EudraVigilance by national medicines regulatory authorities and by 
pharmaceutical companies that hold marketing authorisations (licences) for the medicines. 
 
Chart 16 – Individual cases sorted by reactions groups, submitted for RANIBIZUMAB (up to Oct’14) 
in European database of suspected adverse drug reaction reports (www.adrreports.eu) 
(data extracted on 26-Nov-2014) 
The chart above displays the number of cases reported for each reaction group, divided by 
age. The original chart (online format) enabled to pass the mouse through each bar and reveal 
the number of cases for a specific age. Below are the values of the biggest bars. 
EU Top 10 of Individual Cases (by reactions groups): 
1. Eye disorders (3732 cases) 
2. General disordes and administration site conditions (2163 cases) 
3. Infections and Infestations (1512 cases) 
4. Nervous system disorders (1397 cases) 
5. Cardiac disorders (795 cases) 
6. Investigations (e.g. Chest X-ray abnormal; Electocardiogram QT prolonged) (644 cases) 
7. Injury, poisoning and procedural complications (636 cases) 
8. Vascular disorders (442 cases) 
9. Respiratory, thoracic and mediastinal disorders (428 cases) 
10. Neoplasms benign, maligant and unspecified (incl cysts and polyps) (339 cases)  
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 FDA Adverse Event Reporting System (FAERS) Data (DrugCite.com) 
The data here displayed was made available by DrugCite database. Results included in this 
database correspond to the collection and analysis of reported adverse performed by FDA 
Adverse Events Reporting System (FAERS). These reports are submitted by physicians, 
healthcare consumers, lawyers amongst others. 
 
Chart 17 – Individual cases sorted by reactions groups, submitted for RANIBIZUMAB and other drugs with same 
active substance (Q1 2004 – Q3 2012) in DrugCite.com (www.drugcite.com) 
(data extracted on 26-Nov-2014) 
The chart above displays, for each reaction group, the number of cases reported where the 
drug was flagged as a suspect drug causing the adverse event. All percentages (%) are the 
cases reported for a specific reaction group within the sum up of all reported cases in all 
reactions groups (percent does not represent rate related to drug utilization). 
U.S. Top 10 of Individual Cases (by reactions groups): 
1. Vision (610 cases) 
2. Ocular Structural Change, Deposit and Degeneration (529 cases) 
3. Retina, Choroid And Vitrous Hemorrhages and Vascular (525 cases) 
4. Central Nervous System Vascular (413 cases) 
5. Fatal Outcomes (331 cases) 
6. Coronary Artery (283 cases) 
7. Ocular Infections, Irritations And Inflammations (247 cases) 
8. Infections – Pathogen Unspecified (162 cases) 
9. Injuries (146 cases) 
10. Neurological (135 cases)  
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 Comparison of Adverse Events reported in EU and in the U.S. 
Following the analysis of the Adverse Events previously presented, it became clear that there 
were some differences between EU data and U.S. data. In order to have a visually enhanced 
perception of such differences, it was decided to create a cumulative chart which would 
aggregate all the data previously presented: 
 Post Marketing EU data (Blue bars in the cumulative chart) 
 Post Marketing U.S. data (Orange bars in the cumulative chart) 
 EU data as per Initial documents for MA (MedDRA SOCs highlighted in yellow in the 
cumulative chart) 
For aggregation purposes, a common classification had to be used and so MedDRA SOC was 
the selected classification for the cumulative chart below presented. 
 
Chart 18 – Individual cases sorted by reactions groups (MedDRA 17.1 SOC), submitted for RANIBIZUMAB prior 
and post MA in Europe and post MA the United States 
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Comments to RANIBIZUMAB cumulative chart: 
1. SOCs included in EU pre-MA reports vs SOCs included in EU post-MA reports 
Main discrepancies: There are cases of SOCs with a considerable number of AE reports (>600) 
in post-MA and which were not foreseen by pre-MA clinical trials data. These include: Cardiac 
disorders & Injury, poisoning and procedural complications. 
 
2. SOCs included in EU post-MA reports vs. SOCs included in U.S. post-MA reports 
Although Ranibizumab is approved in EU and in the U.S. almost for the same indications, there 
are some significant discrepancies in the numbers above observed. 
Main discrepancies: Having EU data as reference, there were some U.S. bars which were 
expected to be bigger but are not. These include: General disorders and administration site 
conditions; Infections and infestations; Investigations; & Psychiatric disorders. 
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2. Comparison of AEs reported for anti-VEGF mAbs 
In the previous analysis of the AEs reported for each anti-VEGF mAb it was visible that there 
were some discrepancies in the AEs reported pre and post MA as well as some discrepancies in 
AEs reported in Europe and the United States. 
Following those mAb-specific analysis, it becomes important to see how the AEs are being 
reported throught anti-VEGF mAbs class.  
The table below intends to provide a global picture on the ranking of mostly reported AEs for 
anti-VEGF mAbs. For comparison purposes, there was the need to chose a common data set 
and, for that reason, the table only comprises the EU reports post-MA. 
Table 21 – Comparison of most commonly reported AEs for anti-VEGF mAbs (post-marketing EU data) 
MedDRA 17.1 
System Organ Class (SOC) 
Post-Marketing EU data – ranking of most reported AEs 
Comments 
BEVACIZUMAB RANIBIZUMAB 
Blood and lymphatic system 
disorders 
7
th
 --   
Cardiac disorders  -- 5th   
Gastrointestinal disorders 2nd --   
General disorders and 
administration site conditions 
1st 2nd 
Most reported AEs for all 
anti-VEGF mAbs. 
Eye disorders  10th 1st 
Opposite profiles in these 
two anti-VEGF mAbs. 
Infections and Infestations  6th 3rd 
Transversally reported AEs 
for all anti-VEGF mAbs. 
Injury, poisoning and procedural 
complications 
-- 7th   
Investigations 8th 6th 
Transversally reported AEs 
for all anti-VEGF mAbs. 
Neoplasms benign, malignant and 
unspecified (incl cysts and polyps) 
9th 10th 
Least reported AEs for all 
anti-VEGF mAbs. 
Nervous system disorders 4th 4th 
Transversally reported AEs 
for all anti-VEGF mAbs. 
Reproductive system and breast 
disorders 
3rd --   
Respiratory, thoracic and 
mediastinal disorders 
-- 9th   
Vascular disorders 5th 8th 
Transversally reported AEs 
for all anti-VEGF mAbs. 
NOTE: The colours represent the ranking of reported AEs. GREEN represents the mostly reported AEs whereas RED 
the least reported AEs. 
According to the above table, anti-VEGF mAbs seem to have a quite different profile of AEs 
reported in EU following MA. There are 6 out of 13 (≈46%) SOCs above listed which are not 
transversally applicable to all this class mAbs. This means that only 54% of profile is similar in 
terms of AEs mostly reported. 
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Although the mAbs comprised in anti-VEGF class have the same mechanism of action, it is clear 
in this class that there are other key features that can significantly impact the outcome of AEs 
reported. Mechanism of Action continues to play a major role in the AEs reported but, for the 
particular case of anti-VEGF, there are significant differences among the mAbs of this class: 
 Bevacizumab and Ranibizumab are used for different treatment indications (refer to 
ANNEX 1 – Underlying diseases of anti-VEGF mAbs) 
 Bevacizumab and Ranibizumab administration route is completely different 
(intravenous infusion vs. intravitreal injection, respectively) 
 Bevacizumab and Ranibizumab structure is very different (compete mAb vs. Fab 
fragment, respectively). 
 
Similar to other mAbs, it is observed that anti-VEGF mAbs also have a significant number of 
General disorders and administration site conditions reported. As mentioned before, these are 
antibody-related AEs which generally occur for every mAb and are not class-specific AEs. 
 
On what regards class-specific AEs, it would be expected that anti-VEGF mAbs would have 
effects at a vascular-level and Vascular disorders are in fact reported for both mAbs here 
comprised. The numbers of reports are different and numbers are higher for Bevacizumab, but 
this can be explained by the mAb structure – when compared to Ranibizumab (Fab fragment 
administered by intravitreal injection), Bevacizumab (complete mAb administered 
intravenously) has more potential for systemic reactions, including Vascular disorders. 
The reports above observed for Nervous system disorders & Cardiac disorders may also 
comprise the disorders related to nervous system vasculature and cardiac vasculature and, in 
that case, the numbers are also predictable. Also here, the characteristics of anti-VEGF mAbs 
have a crucial impact on the number of reports. While Nervous system disorders appear for 
both mAbs with similar numbers, Cardiac disorders are very different.  
This differences in Cardiac disorders reports may be related to the differences of these mAbs 
treatment indications. While Bevacizumab is used for tumours vasculature suppression, 
Ranibizumab is used for ocular complications. In the presence of a tumour, anti-VEGF 
Bevacizumab is preferably targeted to the tumour and may not have a significant cardiac 
impact. Ranibizumab, on another hand, is administered by intravitreal injection in patients 
without tumours and after administration it may have more potential to promote Cardiac 
disorders.  
 
Gastrointestinal disorders & Reproductive system and breast disorders are also differently 
reported for the above anti-VEGF mAbs. These differences may be related to the 
administration route: while Bevacizumab is administered intravenously and has more potential 
for systemic complications; Ranibizumab is administered in the eye and the systemic exposure 
is reduced.  
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Other significant difference between the two anti-VEGF mAbs are the reports of Eye disorders 
& Infections and Infestations. Once again, these can be explained by the differences of the 
mAbs. While Bevacizumab systemic distribution does seem to have major impact at eye-level 
nor on arising infections, Ranibizumab is administered directly in the Eye – administration in 
such site can not only potentiate Eye disorders but can also enhance the possibility of 
Infections and Infestations at eye-level. 
 
Although many discrepancies were observed in the two mAbs of anti-VEGF class, these 
differences were highly related to the characteristics of each mAb and do not contradict the 
concept of main AEs reported being highly correlated to mAbs mechanism of action. 
Nevertheless, it was interesting to see that there some key factors that cannot be excluded 
when analysing the safety profiles of mAbs – amdnistration routes, mAbs structural 
configurations and profile of patients receiving those mAbs may have a significant impact and 
this was observed for anti-VEGF mAbs. 
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I. Anti-CD20 mAbs 
Many therapeutic strategies have been explored that use mAb or their derivatives in the 
treatment of cancer, and some promising therapeutic possibilities have already emerged. 
Rituximab (Mabthera) is the first mAb approved for the treatment of cancer [32]. 
Antibodies to CD20 have confirmed the hypothesis that monoclonal reagents can be given in 
vivo to alleviate human diseases. The targeting of CD20 on normal, malignant and auto-
immune B-lymphocytes by rituximab has demonstrated substantial benefits for patients with a 
variety of B-cell lymphomas, as well as some with autoimmune disorders. There has been a 
notable increase in the survival rates from B-cell lymphoma in the decade since anti-CD20 
therapy was introduced. 
CD20 mAbs can be classified into type I and type II based on their ability to induce the 
reorganization of CD20 molecules into lipid rafts upon binding. Type I CD20 mAbs induce the 
reorganization of CD20 molecules into lipid rafts and efficiently activate the classical pathway 
of the complement system. In contrast, type II CD20 mAbs poorly activate complement, but 
are capable to directly induce cell death upon binding to CD20 without cross-linking by 
secondary Abs. Both types are capable of inducing antibody dependent cell-mediated 
cytotoxicity (ADCC) in the presence of effector cells [110]. 
 
Anti-CD20 mAbs appear to eliminate their targets by engaging in a range of effector pathways. 
These include mAb Fc-FcγR interactions, including antibody-dependent cellular cytotoxicity 
(ADCC) and phagocytosis, complement-dependent cytotoxicity (CDC), and the direct induction 
of programmed cell death (PCD).14 More recently, evidence has emerged to suggest a 
potential role for passive antibody induced immunization [111, 112]. 
 
Rituximab was originally shown to be capable of binding C1q and inducing complement-
mediated cell lysis. Subsequent work confirmed this and it is clear that CD20 is an excellent 
target for Complement-Dependent Toxicity (CDC) against numerous cell types in vitro 
probably, at least in part, because of its high expression and the proximity of the mAb-binding-
epitope to the plasma membrane.  
Nevertheless, it should be noted that C1q has numerous other effects in vivo including a 
critical role in the phagocytosis of apoptotic bodies and effects on APC maturation and 
function. Also, recent data suggests that complement is not an important component for 
clearance of tumour and may indeed even be detrimental to therapeutic efficacy. 
There is no doubt that Rituximab does effectively engage C1q and induces CDC in lymphoma 
cell lines and primary tumour cells in vitro because of its ability to rapidly redistribute CD20 
into membrane lipid rafts. The importance of this mechanism in the elimination of B cells in 
vivo does, however, remain controversial [111, 112]. 
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It has also been proposed that mAb binding of CD20 can directly transmit intracellular signals 
that lead to Programmed Cell Death (PCD). However it has never been formally shown what 
molecular process in vivo might mimic the high affinity cross linking achieved with mAb 
reagents in vitro, although it is postulated that this could be performed by FcgR-bearing 
effector cells. As for CDC, the support for rituximab promoting cell death is apparent, but 
whether this mechanism is critical for the depletion of CD20 positive target cells in vivo 
remains to be proven [111]. 
 
Although the evidence regarding the involvement of CDC and PCD remains inconclusive, it is 
clear that Fc:FcgR interactions are perhaps the most critical for the efficacy of anti- CD20 
immunotherapy. FcgR are expressed on immune cells such as monocytes, macrophages, 
natural killer cells and neutrophils. FcgR-dependent activation of these immune effectors 
potentially leads to the release of inflammatory mediators and/or killing/direct phagocytosis of 
the opsonised target cells. However, the outcome of these mAb: effector cell interactions 
varies markedly, dependent on both the cell type and balance of activatory and inhibitory FcgR 
signalling induced. 
In syngeneic mouse model systems, using either mouse anti-mouse CD20 mAb in wild-type 
mice or anti-human CD20 mAb in human CD20 transgenic mice, a complete absence of normal 
B-cell depletion has been observed in mice lacking the common g chain, indicating an absolute 
requirement in vivo for activatory FcgR interactions. However, it still remains to be determined 
which of the FcgR-expressing immune effector cells are critical [111, 112]. 
 
Mechanisms such as CDC, ADCC and PCD are considered to be immediate and comparatively 
short-acting, but the clinical response to a single course of mAb can be late acting and 
prolonged. This has led to the suggestion that anti-CD20 mAb could also have an immunization 
effect. Rituximab-induced cell death, by the three main pathways described, will result in 
release of tumour antigens and changes in localized inflammation. Such an environment 
promotes the uptake of tumour-associated antigens by dendritic cells and cross-presentation 
to T lymphocytes, providing the potential for cell mediated immunity. It is yet to be concluded 
whether this immunization effect correlates with clinical outcome [111]. 
 
As detailed earlier, the main success of anti-CD20 mAb has been in combination with chemo- 
or radiotherapy. Addition of Rituximab to standard front-line chemotherapy regimens 
significantly improves ORR, CR and OS in low-grade non-Hodgkin’s lymphoma and newly 
diagnosed patients with diffuse large B-cell lymphoma. The mechanism of this synergistic 
activity is not clear [111]. 
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1. mAbs targeted for CD20 
Table 22 – anti-CD20 mAbs approved indications for Europe and for the United States 
Anti-CD20 mAbs 
 
RITUXIMAB OFATUMUMAB 
IBRITUMOMAB 
TIUXETAN Indications 
U.S. EU U.S. EU U.S. EU 
X X   X X Follicular Lymphoma NHL 
X X     Diffuse Large B cell NHL 
X X X X   Chronic lymphocytic leukaemia (CLL) 
X X     Rheumatoid arthritis 
X X     Granulomatosis with polyangiitis and microscopic polyangiitis 
 
1.1. RITUXIMAB 
Rituximab (trade name MabThera/RITUXAN in Europe and United States, respectively) is 
currently in the market with the following indications: 
 Two forms of non-Hodgkin’s Lymphoma 
o follicular lymphoma 
o diffuse large B cell non-Hodgkin’s lymphoma 
 Chronic Lymphocytic Leukaemia (CLL) 
 Rheumatoid Arthritis (RA) 
 Two forms of severe vasculitis 
o Granulomatosis with Polyangiitis (GPA) (also called, Wegener’s 
granulomatosis) 
o Microscopic Polyangiitis (MPA) 
 
Rituximab, discovered by Biogen Idec, first received FDA approval for the treatment of 
relapsed indolent non-Hodgkin Lymphoma (NHL) in 1997 and was the first targeted cancer 
medicine approved by the U.S. Food and Drug Administration [1]. Rituximab was approved 
under the trade name MabThera in the EU in June 1998. 
 
Rituximab is known as RITUXAN in the United States, Japan and Canada. 
Genentech, a member of the Roche Group, and Biogen Idec collaborate on Rituximab in the 
United States. Roche markets Rituximab in the rest of the world, except Japan, where 
Rituximab is co-marketed by Chugai and Zenyaku Kogyo Co. Ltd [113]. 
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1.1.1. RITUXIMAB Characterization 
Pharmacotherapeutic group: Antineoplastic agents 
ATC code: L01XC02 [57] 
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 
L01 ANTINEOPLASTIC AGENTS 
L01X OTHER ANTINEOPLASTIC AGENTS 
L01XC Monoclonal antibodies 
 
Rituximab is a genetically engineered chimeric murine/human monoclonal antibody 
representing a glycosylated immunoglobulin with human IgG1 constant regions (Fc domain) 
and murine light-chain and heavy chain variable region sequences (Fab domain). 
Rituximab is directed against the CD20 antigen and it has a binding affinity for the CD20 
antigen of approximately 8.0 nM. 
Rituximab has an approximate molecular weight of 145 kD. The antibody is produced by 
mammalian (Chinese hamster ovary) cell suspension culture and purified by affinity 
chromatography and ion exchange, including specific viral inactivation and removal procedures 
[114, 115]. 
 
1.1.2. RITUXIMAB Mechanism of Action 
Rituximab is a monoclonal antibody that targets the CD20, a non-glycosylated phosphoprotein, 
located on pre-B and mature B-lymphocytes. The antigen is expressed on >95 % of all B cell 
non-Hodgkin’s lymphomas. 
CD20 is found on both normal and malignant B cells, but not on haematopoietic stem cells, 
pro-B cells, normal plasma cells or other normal tissue. The CD20 antigen has characteristics 
that render it a suitable target for treatment: 
 CD20 does not circulate freely in the plasma, 
 CD20 does not shed from the surface of B-cells after binding of anti-CD20 antibodies, 
 CD20 does not internalise upon antibody binding. 
The potential therapeutic advantage of chimeric antibodies as compared with pure murine 
mAbs is the reduction of immunogenicity thereby permitting repeated administration. Other 
important features of chimeric mAbs are their ability of binding human complement (C1q), and 
the mediation of human effector functions such as complement fixation and antibody-
dependent cellular cytotoxicity resulting in a potentially more effective destruction of tumour 
cells. 
The Fab domain of rituximab binds to the CD20 antigen on B lymphocytes and the Fc domain 
can recruit immune effector functions to mediate B cell lysis. Possible mechanisms of cell lysis 
include complement dependent cytotoxicity (CDC) resulting from C1q binding, and antibody-
dependent cellular cytotoxicity (ADCC) mediated by one or more of the Fcγ receptors on the 
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surface of granulocytes, macrophages and NK cells. Rituximab binding to CD 20 antigen on B 
lymphocytes has also been demonstrated to induce cell death via apoptosis. 
B cells are believed to play a role in the pathogenesis of rheumatoid arthritis (RA) and 
associated chronic synovitis. In this setting, B cells may be acting at multiple sites in the 
autoimmune/inflammatory process, including through production of rheumatoid factor (RF) 
and other autoantibodies, antigen presentation, T-cell activation, and/or pro-inflammatory 
cytokine production [114-116]. 
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1.1.3. RITUXIMAB Treatment 
Table 23 – Rituximab Treatment: Method of administration and Indications 
RITUXIMAB  |  Administration: intravenous infusion 
 
U.S. EU Indications Population Indications Details References 
X X 
Follicular 
Lymphoma NHL 
Adults 
 in combination with chemotherapy for previously 
untreated patients with stage III-IV follicular 
lymphoma 
 maintenance therapy for follicular lymphoma patients 
responding to induction therapy 
 monotherapy for stage III-IV follicular lymphoma who 
are chemoresistant or are in their second or 
subsequent relapse after chemotherapy 
[114, 115] 
X X 
Diffuse Large B 
cell NHL 
Adults 
 in combination with CHOP (cyclophosphamide, 
doxorubicin, vincristine, prednisolone) chemotherapy 
for CD20 positive diffuse large B cell NHL 
[114, 115] 
X X 
Chronic 
lymphocytic 
leukaemia (CLL) 
Adults 
 in combination with chemotherapy for patients with 
previously untreated and relapsed/refractory chronic 
lymphocytic leukaemia 
[114, 115] 
X X 
Rheumatoid 
arthritis 
Adults 
 in combination with methotrexate for severeactive 
rheumatoid arthritis which has had an inadequate 
response or intolerance to other diseasemodifying 
anti-rheumatic drugs (DMARD), including one or more 
tumour necrosis factor (TNF) inhibitor therapies. 
[114, 115] 
X X 
Granulomatosis 
with polyangiitis 
and microscopic 
polyangiitis 
Adults 
 in combination with glucocorticoids for the induction 
of remission of severe, active granulomatosis with 
polyangiitis (Wegener’s) (GPA) and microscopic 
polyangiitis (MPA). 
[114, 115] 
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1.1.1. RITUXIMAB Adverse Events (as per EU Initial MA documents) 
Table 24 – Rituximab Adverse Events as per European Initial Marketing-authorisation Documents 
MedDRA 17.1 
System Organ Class (SOC) 
AEs Detailed References 
General disorders and 
administration site conditions 
 Chills 
 Fever 
[116] 
Immune system disorders  Cytokine release syndrome [116] 
Infections and Infestations  
 Bacterial infections 
 Viral infection 
[116] 
Metabolism and nutrition 
disorders 
 Rapid tumour lysis and features of tumour lysis syndrome [116] 
Neoplasms benign, malignant 
and unspecified (incl cysts and 
polyps) 
 Paraneoplastic pemphigus [116] 
Respiratory, thoracic and 
mediastinal disorders 
 Bronchospasm 
 Dyspnoea 
 Hypoxaemia (in those patients who had oxygen saturation and/or 
oxygen tension assessed) 
 Pulmonary infiltrates (in those patients who had chest x-ray 
performed) 
[116] 
Skin and subcutaneous tissue 
disorders 
 Angioedema 
 Lichen planus 
 Lichenoid dermatitis 
 Toxic epidermal necrolysis 
[116] 
Vascular disorders 
 Flushing 
 Hypotension 
[116] 
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1.1.1. RITUXIMAB Adverse Events Charts (following MA) 
 European Data (EU database of suspected adverse drug reactions reports) 
The data here displayed was launched by EMA in the European database of suspected adverse 
drug reactions reports. Reports included in this database correspond to the data submitted 
electronically to EudraVigilance by national medicines regulatory authorities and by 
pharmaceutical companies that hold marketing authorisations (licences) for the medicines. 
 
Chart 19 – Individual cases sorted by reactions groups, submitted for RITUXIMAB (up to Oct’14) 
in European database of suspected adverse drug reaction reports (www.adrreports.eu) 
(data extracted on 25-Nov-2014) 
The chart above displays the number of cases reported for each reaction group, divided by 
age. The original chart (online format) enabled to pass the mouse through each bar and reveal 
the number of cases for a specific age. Below are the values of the biggest bars. 
EU Top 10 of Individual Cases (by reactions groups): 
1. Infections and Infestations (5406 cases) 
2. General disorders and administration site conditions (5183 cases) 
3. Blood ans lymphatic system disorders (3909 cases) 
4. Respiratory, thoracic and mediastinal disorders (3817 cases) 
5. Nervous system disorders (2190 cases) 
6. Skin and subcutaneous tissue disorders (2150 cases) 
7. Investigations (e.g. Chest X-ray abnormal; Electocardiogram QT prolonged) (2084 cases) 
8. Gastrointestinal disorders (1954 cases) 
9. Immune system disorders (1672 cases) 
10. Cardiac disorders (1648 cases)  
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 FDA Adverse Event Reporting System (FAERS) Data (DrugCite.com) 
The data here displayed was made available by DrugCite database. Results included in this 
database correspond to the collection and analysis of reported adverse performed by FDA 
Adverse Events Reporting System (FAERS). These reports are submitted by physicians, 
healthcare consumers, lawyers amongst others. 
 
Chart 20 – Individual cases sorted by reactions groups, submitted for RITUXIMAB and other drugs with same 
active substance (Q1 2004 – Q3 2012) in DrugCite.com (www.drugcite.com) 
(data extracted on 25-Nov-2014) 
The chart above displays, for each reaction group, the number of cases reported where the 
drug was flagged as a suspect drug causing the adverse event. All percentages (%) are the 
cases reported for a specific reaction group within the sum up of all reported cases in all 
reactions groups (percent does not represent rate related to drug utilization). 
U.S. Top 10 of Individual Cases (by reactions groups): 
1. Infections – Pathogen Unspecified (4474 cases) 
2. White Blood Cell (e.g. Febril Neutropenia; Leukopenia) (3517 cases) 
3. Respiratory (e.g. Cough; Hypoxia; Lung Disorder) (2063 cases) 
4. Hematology Investigations (e.g. Haemoglobin/White Blood Cell Count) (2054 cases) 
5. Viral Infections (1715 cases) 
6. Gastrointestinal Signs (1705 cases) 
7. Neurological (e.g. Syncope; Dizziness; Somnolence) (1556 cases) 
8. Anemias Nonhemolytic And Marrow Depression (1345 cases) 
9. Epidermal And Dermal Conditions (1329 cases) 
10. Bacterial Infections (1178 cases)  
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 Comparison of Adverse Events reported in EU and in the U.S. 
Following the analysis of the Adverse Events previously presented, it became clear that there 
were some differences between EU data and U.S. data. In order to have a visually enhanced 
perception of such differences, it was decided to create a cumulative chart which would 
aggregate all the data previously presented: 
 Post Marketing EU data (Blue bars in the cumulative chart) 
 Post Marketing U.S. data (Orange bars in the cumulative chart) 
 EU data as per Initial documents for MA (MedDRA SOCs highlighted in yellow in the 
cumulative chart) 
For aggregation purposes, a common classification had to be used and so MedDRA SOC was 
the selected classification for the cumulative chart below presented. 
 
Chart 21 – Individual cases sorted by reactions groups (MedDRA 17.1 SOC), submitted for RITUXIMAB prior and 
post MA in Europe and post MA the United States 
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Comments to RITUXIMAB cumulative chart: 
1. SOCs included in EU pre-MA reports vs SOCs included in EU post-MA reports 
Main discrepancies: There are cases of SOCs with a considerable number of AE reports (>1600) 
in post-MA and which were not foreseen by pre-MA clinical trials data. These include: Blood 
and lymphatic system disorders; Cardiac disorders; Gastrointestinal disorders; Investigations & 
Nervous system disorders. 
 
2. SOCs included in EU post-MA reports vs. SOCs included in U.S. post-MA reports 
Although Rituximab is approved in EU and in the U.S. for the same indications, there are some 
significant discrepancies in the numbers above observed. 
Main discrepancies: Having EU data as reference, there were some U.S. bars which were 
expected to be bigger but are not. These include: General disorders and administration site 
conditions; Immune system disorder; Injury, poisoning and procedural complications & 
Neoplasms benign, malignant and unspecified (including cysts and polyps). 
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1.2. OFATUMUMAB 
Europe and the United States share the approval of Ofatumumab (trade name ARZERRA) for 
the treatment of chronic lymphocytic leukaemia (CLL), a cancer of a type of white blood cells 
called lymphocytes.  
Ofatumumab is manufactured by Glaxo Group Ltd and has been approved in the U.S and 
Europe since 2009 and 2010, respectively [117, 118]. 
Ofatumumab is designated as an orphan medicinal product in the EU for the indication: 
“treatment of chronic lymphocytic leukaemia” (EU/3/08/581). The Committee for Orphan 
Medicinal Products (COMP) concluded that chronic lymphocytic leukaemia was estimated to 
be affecting approximately 3.5 in 10,000 persons in the Community, at the time the application 
was made (June 2008). This is equivalent to a total of around 176,000 people, and is below the 
threshold for orphan designation, which is 5 people in 10,000. Also, Chronic Lymphocytic 
Leukaemia is a condition chronically debilitating and life-threatening, in particular due to poor 
long-term survival in high-risk patients [119, 120]. 
 
Criteria for Orphan designation (as per Regulation (EC) No 141/2000, article 3): 
A medicinal product shall be designated as an orphan medicinal product if its sponsor can 
establish: 
I. that it is intended for the diagnosis, prevention or treatment of a life-threatening or 
chronically debilitating condition affecting not more than five in 10 thousand persons in the 
Community when the application is made, 
or 
that it is intended for the diagnosis, prevention or treatment of a life-threatening, seriously 
debilitating or serious and chronic condition in the Community and that without incentives 
it is unlikely that the marketing of the medicinal product in the Community would generate 
sufficient return to justify the necessary investment; 
and 
II.  that there exists no satisfactory method of diagnosis, prevention or treatment of the 
condition in question that has been authorised in the Community or, if such method exists, 
that the medicinal product will be of significant benefit to those affected by that condition 
[121]. 
 
Sponsors who obtain orphan designation benefit from a number of incentives, including 
protocol assistance, a type of scientific advice specific for designated orphan medicines, and 
market exclusivity once the medicine is on the market. Fee reductions are also available 
depending on the status of the sponsor and the type of service required [121, 122]. 
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1.2.1. OFATUMUMAB Characterization 
Pharmacotherapeutic group: Monoclonal antibodies 
ATC code: L01XC10 [57] 
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 
L01 ANTINEOPLASTIC AGENTS 
L01X OTHER ANTINEOPLASTIC AGENTS 
L01XC Monoclonal antibodies 
 
Ofatumumab is an IgG1κ human monoclonal antibody with a molecular weight of 
approximately 149 kDa. The antibody was generated via transgenic mouse and hybridoma 
technology and is produced in a recombinant murine cell line (NS0) using standard mammalian 
cell cultivation and purification technologies [117]. 
 
1.2.2. OFATUMUMAB Mechanism of Action 
Ofatumumab is a human monoclonal antibody (IgG1) that binds specifically to a distinct 
epitope encompassing both the small and large extracellular loops of the CD20 molecule. 
The CD20 molecule is a transmembrane phosphoprotein expressed on B lymphocytes from the 
pre-B to mature B lymphocyte stage and on B cell tumours. The B cell tumours include CLL 
(generally associated with lower levels of CD20 expression) and non-Hodgkin's lymphomas 
(where > 90% tumours have high levels of CD20 expression). The CD20 molecule is not shed 
from the cell surface and is not internalised following antibody binding.  
Ofatumumab induces cross linking of CD20 molecules and relocation of these CD20 molecules 
to so-called lipid rafts considered important for induction of cell signalling and effective 
complement activation. The binding of Ofatumumab to the membrane-proximal epitope of the 
CD20 molecule induces recruitment and activation of the complement pathway at the cell 
surface, leading to complement-dependent cytotoxicity (CDC) and resultant lysis of tumour 
cells. 
Ofatumumab has been shown to induce appreciable lysis of cells with high expression levels of 
complement defence molecules. Ofatumumab has also been shown to induce cell lysis in both 
high and low CD20 expressing cells and in rituximab-resistant cells. In addition, the binding of 
Ofatumumab allows the recruitment of natural killer cells allowing the induction of cell death 
through antibody-dependent cell-mediated cytotoxicity (ADCC). The resulting depletion of 
malignant B cells carrying the CD20 epitope by Ofatumumab treatment is considered the main 
mechanism of action leading to clinical benefit to subjects with CD20-expressing cell tumours. 
[118, 119]. 
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1.2.3. OFATUMUMAB Treatment 
Table 25 – Ofatumumab Treatment: Method of administration and Indications 
OFATUMUMAB  |  Administration: intravenous infusion 
 
U.S. EU Indications Population Indications Details References 
X X 
Previously 
untreated 
Chronic 
Lymphocytic 
Leukaemia (CLL) 
Adults 
 in combination with chlorambucil or bendamustine for 
patients with CLL who have not received prior therapy 
and who are not eligible for fludarabine-based therapy 
[117, 118] 
X X Refractory CLL Adults 
 treatment of CLL in patients who are refractory to 
fludarabine and alemtuzumab 
[117, 118] 
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1.1.1. OFATUMUMAB Adverse Events (as per EU Initial MA documents) 
Table 26 – Ofatumumab Adverse Events as per European Initial Marketing-authorisation Documents 
MedDRA 17.1 
System Organ Class (SOC) 
AEs Detailed References 
Blood and lymphatic system 
disorders 
 Anaemia 
 Febrile neutropenia 
 Leukopenia 
 Neutropenia 
  thrombocytopenia 
[119] 
Cardiac disorders  Tachycardia [119] 
Gastrointestinal disorders 
 Diarrhoea 
 Nausea 
 Small bowel obstruction 
[119] 
General disorders and 
administration site conditions 
 Chest discomfort 
 Chills 
 Fatigue 
 Pyrexia 
 Rigors 
[119] 
Immune system disorders 
 Anaphylactoid reactions 
 Cytokine release syndrome 
 Hypersensitivity 
[119] 
Infections and Infestations  
 Herpes virus infection 
 Lower respiratory tract infection, including pneumonia 
 Sepsis, including neutropenic sepsis and septic shock 
 Upper respiratory tract infection 
 Urinary tract infection 
[119] 
Musculoskeletal and connective 
tissue disorders 
 Back pain [119] 
Respiratory, thoracic and 
mediastinal disorders 
 Bronchospasm 
 Cough 
 Dyspnoea 
 Hypoxia 
 Nasal congestion 
 Pharyngolaryngeal pain 
[119] 
Skin and subcutaneous tissue 
disorders 
 Hyperhidrosis 
 Pruritus 
 Rash 
 Urticaria 
[119] 
Vascular disorders 
 Flushing 
 Hypertension 
 Hypotension 
[119] 
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1.1.1. OFATUMUMAB Adverse Events Charts (following MA) 
 European Data (EU database of suspected adverse drug reactions reports) 
The data here displayed was launched by EMA in the European database of suspected adverse 
drug reactions reports. Reports included in this database correspond to the data submitted 
electronically to EudraVigilance by national medicines regulatory authorities and by 
pharmaceutical companies that hold marketing authorisations (licences) for the medicines. 
 
Chart 22 – Individual cases sorted by reactions groups, submitted for OFATUMUMAB (up to Oct’14) 
in European database of suspected adverse drug reaction reports (www.adrreports.eu) 
(data extracted on 25-Nov-2014) 
The chart above displays the number of cases reported for each reaction group, divided by 
age. The original chart (online format) enabled to pass the mouse through each bar and reveal 
the number of cases for a specific age. Below are the values of the biggest bars. 
EU Top 10 of Individual Cases (by reactions groups): 
1. General disorders and administration site conditions (120 cases) 
2. Infections and Infestations (89 cases) 
3. Blood ans lymphatic system disorders (83 cases) 
4. Respiratory, thoracic and mediastinal disorders (77 cases) 
5. Investigations (e.g. Chest X-ray abnormal; Electocardiogram QT prolonged) (62 cases) 
6. Skin and subcutaneous tissue disorders (49 cases) 
7. Nervous system disorders (42 cases) 
8. Gastrointestinal disorders (38 cases) 
9. Vascular disorders (32 cases) 
10. Injury, poisoning and procedual complications (32 cases)  
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 FDA Adverse Event Reporting System (FAERS) Data (DrugCite.com) 
The data here displayed was made available by DrugCite database. Results included in this 
database correspond to the collection and analysis of reported adverse performed by FDA 
Adverse Events Reporting System (FAERS). These reports are submitted by physicians, 
healthcare consumers, lawyers amongst others. 
 
Chart 23 – Individual cases sorted by reactions groups, submitted for OFATUMUMAB and other drugs with same 
active substance (Q1 2004 – Q3 2012) in DrugCite.com (www.drugcite.com) 
(data extracted on 25-Nov-2014) 
The chart above displays, for each reaction group, the number of cases reported where the 
drug was flagged as a suspect drug causing the adverse event. All percentages (%) are the 
cases reported for a specific reaction group within the sum up of all reported cases in all 
reactions groups (percent does not represent rate related to drug utilization). 
U.S. Top 10 of Individual Cases (by reactions groups): 
1. Infections – Pathogen Unspecified (207 cases) 
2. White Blood Cell (e.g. Febril Neutropenia; Leukopenia) (197 cases) 
3. Respiratory (e.g. Cough; Hypoxia; Lung Disorder) (92 cases) 
4. Gastrointestinal Signs (69 cases) 
5. Neurological (e.g. Syncope; Dizziness; Somnolence) (56 cases) 
6. Hematology Investigations (e.g. Haemoglobin/White Blood Cell Count) (53 cases) 
7. Electrolyte And Fluid Balance Conditions (52 cases) 
8. Body Temperature Conditions (51 cases) 
9. Viral Infections (50 cases) 
10. Renal Disorders (43 cases)  
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 Comparison of Adverse Events reported in EU and in the U.S. 
Following the analysis of the Adverse Events previously presented, it became clear that there 
were some differences between EU data and U.S. data. In order to have a visually enhanced 
perception of such differences, it was decided to create a cumulative chart which would 
aggregate all the data previously presented: 
 Post Marketing EU data (Blue bars in the cumulative chart) 
 Post Marketing U.S. data (Orange bars in the cumulative chart) 
 EU data as per Initial documents for MA (MedDRA SOCs highlighted in yellow in the 
cumulative chart) 
For aggregation purposes, a common classification had to be used and so MedDRA SOC was 
the selected classification for the cumulative chart below presented. 
 
Chart 24 – Individual cases sorted by reactions groups (MedDRA 17.1 SOC), submitted for OFATUMUMAB prior 
and post MA in Europe and post MA the United States 
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Comments to OFATUMUMAB cumulative chart: 
1. SOCs included in EU pre-MA reports vs SOCs included in EU post-MA reports 
Main discrepancies: There are cases of SOCs with a considerable number of AE reports (>30) in 
post-MA and which were not foreseen by pre-MA clinical trials data. These include: Injury, 
poisoning and procedural complications; Investigations; Neoplasms benign, malignant and 
unspecified (including cysts and polyps); Nervous system disorders & Respiratory, thoracic and 
mediastinal disorders. 
 
2. SOCs included in EU post-MA reports vs. SOCs included in U.S. post-MA reports 
Although Ofatumumab is approved in EU and in the U.S. for the same indications, there are 
some significant discrepancies in the numbers above observed. 
Main discrepancies: Having EU data as reference, there were some U.S. bars which were 
expected to be bigger but are not. These include: General disorders and administration site 
conditions; Injury, poisoning and procedural complications; & Psychiatric disorders. 
Based on EU data, there were also some U.S. bars which were expected to be smaller: 
Hepatobiliary disorders & Metabolism and nutrition disorders. 
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1.2. IBRITUMOMAB TIUXETAN 
Ibritumomab Tiuxetan (trade name ZEVALIN) is currently in the market with slightly different 
indications for Europe and for the United Sates. 
 
While in Europe Ibritumomab Tiuxetan is used in the following groups of patients: 
 patients who have gone into remission (reduction in the number of cancerous cells) 
after their first ‘induction treatment’ (initial chemotherapy treatment) for lymphoma. 
Zevalin is given as ‘consolidation therapy’ to improve the remission; 
 patients in whom Rituximab (another treatment for non-Hodgkin’s lymphoma) is no 
longer effective or whose disease has come back after rituximab treatment. 
 
In the United States, Ibritumomab Tiuxetan is used for: 
 relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL) 
 previously untreated follicular NHL who achieve a partial or complete response to first-
line chemotherapy 
Zevalin is marketed by Spectrum Pharmaceuticals in the United States and by Bayer Schering 
Pharma in Europe.  
 
1.2.1. IBRITUMOMAB TIUXETAN Characterization 
Pharmacotherapeutic group: Therapeutic radiopharmaceuticals 
ATC code: V10XX02[57] 
V VARIOUS 
V10 THERAPEUTIC RADIOPHARMACEUTICALS 
V10X OTHER THERAPEUTIC RADIOPHARMACEUTICALS 
V10XX Various therapeutic radiopharmaceuticals 
 
Zevalin contains ibritumomab, an IgG1 kappa immunoglobulin produced in Chinese hamster 
ovary (CHO) cells which reacts specifically with the CD20 antigen found on the surface of 
normal and malignant B lymphocytes (inc. mature B cells, activated proliferating B cells and 
differentiating B cells), targets of its cytotoxicity. 
Ibritumomab Tiuxetan, IDEC-2B8-MX-DTPA is defined as the active substance in Zevalin. It is 
obtained by chemically linking the monoclonal antibody ibritumomab to the amino directed 
bifunctional chelate MX-DTPA (Tiuxetan), via a covalent, urea type bond. This linker-chelator 
provides a high affinity, conformationally restricted chelation site for Yttrium-90. 
The approximate molecular weight of ibritumomab Tiuxetan is 148 kD. 
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Ibritumomab Tiuxetan achieves selective targeting CD20+ cells, which are inherently sensitive 
to radiation. The radionucleide yttrium-90 (half-life of 64 hours) emits pure high-energy beta 
radiation with a local tissue penetration (5 to 10 mm) and effect. 
The proposed Zevalin regimen combines the antibody-based tumour cell killing Rituximab with 
an antibody based radioimmuno-therapy and thus further tumour-cell killing, but with a 
different mechanism of action (radiation) [123, 124]. 
 
1.2.2. IBRITUMOMAB TIUXETAN Mechanism of Action 
Ibritumomab Tiuxetan binds specifically to the CD20 antigen. The apparent affinity (KD) of 
ibritumomab Tiuxetan for the CD20 antigen ranges between approximately 14 to 18 nM. 
The CD20 antigen is expressed on pre-B and mature B lymphocytes and on > 90% of B-cell non-
Hodgkin’s lymphomas (NHL). The CD20 antigen is not shed from the cell surface and does not 
internalize upon antibody binding.  
The chelate Tiuxetan, which tightly binds Y-90, is covalently linked to ibritumomab. The beta 
emission from Y-90 induces cellular damage by the formation of free radicals in the target and 
neighboring cells [124]. 
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1.2.3. IBRITUMOMAB TIUXETAN Treatment 
Table 27 – Ibritumomab Tiuxetan Treatment: Method of administration and Indications 
IBRITUMOMAB TIUXETAN  |  Administration: intravenous infusion (radiopharmaceutical preparation) 
 
U.S. EU Indications Population Indications Details References 
X X 
Relapsed or 
refractory 
follicular B-cell 
NHL 
Adults 
 (EU) patients in whom Rituximab (another treatment 
for non-Hodgkin’s lymphoma) is no longer effective or 
whose disease has come back after rituximab 
treatment. 
 (U.S.) relapsed or refractory, low-grade or follicular B-
cell NHL 
[123-125] 
X X 
Previously 
untreated 
Follicular NHL 
Adults 
 (EU) patients who have gone into remission (reduction 
in the number of cancerous cells) after their first 
‘induction treatment’ (initial chemotherapy 
treatment) for lymphoma. Ibritumomab Tiuxetan is 
given as ‘consolidation therapy’ to improve the 
remission; 
 (U.S.) previously untreated follicular NHL who achieve 
a partial or complete response to first-line 
chemotherapy 
[123-125] 
 
Ibritumomab Tiuxetan is supplied as kit for radiopharmaceutical preparation for intravenous 
use. It contains four components, including all the non-radioactive ingredients necessary to 
produce a single dose of [90Y] Ibritumomab Tiuxetan: 
 1 vial of ibritumomab Tiuxetan 1.6 mg/ml 
 1 vial of 50 mM sodium acetate 
 1 vial of formulation buffer 
 1 empty reaction vial 
Yttrium-90 [90Y] is not part of the kit and should be provided by the end-user. 
The container is the same for all components; a colourless Type I glass vial, teflon-faced gray 
bromobutyl rubber stopper, alu-cap, different coloured flip-off seal [123, 124]. 
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1.1.1. IBRITUMOMAB TIUXETAN Adverse Events (as per EU Initial MA 
documents) 
Table 28 – Ibritumomab Tiuxetan Adverse Events as per European Initial Marketing-authorisation Documents 
MedDRA 17.1 
System Organ Class (SOC) 
AEs Detailed References 
Blood and lymphatic system 
disorders 
 Anaemia 
 Neutropenia 
 Thrombocytopenia 
[123] 
Gastrointestinal disorders 
 Abdominal pain 
 Diarrhoea 
 Nausea 
 Vomiting 
[123] 
General disorders and 
administration site conditions 
 Chest pain 
 Chills 
 Fever 
 Pain 
 Peripheral oedema 
[123] 
Infections and Infestations  
 Bacterial infection 
 Cold syndrome 
 Fungal infection 
 Rhinitis 
 Sepsis 
 Sinusitis 
 Urinary tract infection 
[123] 
Musculoskeletal and connective 
tissue disorders 
 Arthralgia 
 Asthenia 
 Back pain 
 Myalgia 
[123] 
Nervous system disorders 
 Dizziness 
 Headache 
[123] 
Psychiatric disorders  Anorexia [123] 
Respiratory, thoracic and 
mediastinal disorders 
 Bronchospasm 
 Increased cough 
 Throat irritation 
[123] 
Skin and subcutaneous tissue 
disorders 
 Angioedema 
 Ecchymosis 
 Pruritus 
 Rash 
[123] 
Vascular disorders 
 Flushing 
 Hypotension 
[123] 
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1.1.1. IBRITUMOMAB TIUXETAN Adverse Events Charts (following MA) 
 European Data (EU database of suspected adverse drug reactions reports) 
The data here displayed was launched by EMA in the European database of suspected adverse 
drug reactions reports. Reports included in this database correspond to the data submitted 
electronically to EudraVigilance by national medicines regulatory authorities and by 
pharmaceutical companies that hold marketing authorisations (licences) for the medicines. 
 
Chart 25 – Individual cases sorted by reactions groups, submitted for IBRITUMOMAB TIUXETAN (up to Oct’14) 
in European database of suspected adverse drug reaction reports (www.adrreports.eu) 
(data extracted on 25-Nov-2014) 
The chart above displays the number of cases reported for each reaction group, divided by 
age. The original chart (online format) enabled to pass the mouse through each bar and reveal 
the number of cases for a specific age. Below are the values of the biggest bars. 
EU Top 10 of Individual Cases (by reactions groups): 
1. Blood ans lymphatic system disorders (197 cases) 
2. Infections and Infestations (79 cases) 
3. General disorders and administration site conditions (77 cases) 
4. Neoplasms benign, malignant and unspecified (including cysts and polyps) (63 cases) 
5. Investigations (e.g. Chest X-ray abnormal; Electocardiogram QT prolonged) (54 cases) 
6. Respiratory, thoracic and mediastinal disorders (27 cases) 
7. Gastrointestinal disorders (27 cases) 
8. Nervous system disorders (25 cases) 
9. Skin and subcutaneous tissue disorders (20 cases) 
10. Cardiac disorders (16 cases)  
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 FDA Adverse Event Reporting System (FAERS) Data (DrugCite.com) 
The data here displayed was made available by DrugCite database. Results included in this 
database correspond to the collection and analysis of reported adverse performed by FDA 
Adverse Events Reporting System (FAERS). These reports are submitted by physicians, 
healthcare consumers, lawyers amongst others. 
 
Chart 26 – Individual cases sorted by reactions groups, submitted for Ibritumomab Tiuxetan and other drugs with 
same active substance (Q1 2004 – Q3 2012) in DrugCite.com (www.drugcite.com) 
(data extracted on 25-Nov-2014) 
The chart above displays, for each reaction group, the number of cases reported where the 
drug was flagged as a suspect drug causing the adverse event. All percentages (%) are the 
cases reported for a specific reaction group within the sum up of all reported cases in all 
reactions groups (percent does not represent rate related to drug utilization). 
U.S. Top 10 of Individual Cases (by reactions groups): 
1. Hematology Investigations (e.g. Haemoglobin/White Blood Cell Count) (40 cases) 
2. Leukemias (33 cases) 
3. White Blood Cell (e.g. Febril Neutropenia; Leukopenia) (29 cases) 
4. Infections – Pathogen Unspecified (20 cases) 
5. Anemias Nonhemolytic And Marrow Depression (14 cases) 
6. Platelet (e.g. Thrombocytopenia) (11 cases) 
7. Viral Infections (11 cases) 
8. Gastrointestinal Signs (10 cases) 
9. Neurological (e.g. Syncope; Dizziness; Somnolence) (8 cases) 
10. Body Temperature Conditions (6 cases)  
Master’s degree in Biopharmaceutical Sciences: Adverse Events/Mode of Action Relationship 
of Monoclonal Antibodies-Based Therapies: Overview of Marketed Products in the European Union 
Francisca Mendes Lemos 109 
 
 Comparison of Adverse Events reported in EU and in the U.S. 
Following the analysis of the Adverse Events previously presented, it became clear that there 
were some differences between EU data and U.S. data. In order to have a visually enhanced 
perception of such differences, it was decided to create a cumulative chart which would 
aggregate all the data previously presented: 
 Post Marketing EU data (Blue bars in the cumulative chart) 
 Post Marketing U.S. data (Orange bars in the cumulative chart) 
 EU data as per Initial documents for MA (MedDRA SOCs highlighted in yellow in the 
cumulative chart) 
For aggregation purposes, a common classification had to be used and so MedDRA SOC was 
the selected classification for the cumulative chart below presented. 
 
Chart 27 – Individual cases sorted by reactions groups (MedDRA 17.1 SOC), submitted for IBRITUMOMAB 
TIUXETAN prior and post MA in Europe and post MA the United States 
 
Vascular disorders 
Surgical and medical 
procedures 
Social circumstances 
Skin and subcutaneous 
tissue disorders 
Respiratory, thoracic & 
mediastinal disorders 
Reproductive system and 
breast disorders 
Renal and urinary disorders 
Psychiatric disorders 
Pregnancy, puerperium & 
perinatal conditions 
Nervous system disorders 
Neoplasms benign, 
malignant & unspecified 
Musculoskeletal & connect. 
tissue disorders  
Metabolism and nutrition 
disorders 
Investigations 
Injury, poisoning & 
procedural complications 
Infections and infestations 
Immune system disorders 
Hepatobiliary disorders 
General disorders & adm. 
site conditions 
Gastrointestinal disorders 
Eye disorders 
Endocrine disorders 
Ear and labyrinth disorders 
Congenital, familial & 
genetic disorders 
Cardiac disorders 
Blood and lymphatic system 
disorders 
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25 
63 
12 
15 
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4 
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7 
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1 
0 
16 
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Adverse Events reported in EU and in the U.S. for IBRITUMOMAB 
TIUXETAN 
AEs already part of EU Initial docs for MA 
Post Markting U.S. data until Q3'2012 
Post Markting EU data until Oct'14 
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Comments to IBRITUMOMAB TIUXETAN cumulative chart: 
1. SOCs included in EU pre-MA reports vs SOCs included in EU post-MA reports 
Main discrepancies: There are cases of SOCs with a considerable number of AE reports (>15) in 
post-MA and which were not foreseen by pre-MA clinical trials data. These include: Cardiac 
disorders; Investigations & Neoplasms benign, malignant and unspecified (including cysts and 
polyps). 
 
2. SOCs included in EU post-MA reports vs. SOCs included in U.S. post-MA reports 
Although there are some discrepancies in the main SOCs referred on EU post-MA reports and 
U.S. post-MA reports and these are not very relevant in the global outcome of the chart. 
Small discrepancies: Having EU data as reference, there were some U.S. bars which were 
expected to be bigger but are not: these include General disorders and administration site 
conditions. 
In general, it was observed that Ibritumomab Tiuxetan had a similar profile of AEs reported 
post-MA in EU and in the U.S. 
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2. Comparison of AEs reported for anti-CD20 mAbs 
In the previous analysis of the AEs reported for each anti-CD20 mAb it was visible that there 
were some discrepancies in the AEs reported pre and post MA as well as some discrepancies in 
AEs reported in Europe and the United States. 
Following those mAb-specific analysis, it becomes important to see how the AEs are being 
reported throught anti-CD20 mAbs class.  
The table below intends to provide a global picture on the ranking of mostly reported AEs for 
anti-CD20 mAbs. For comparison purposes, there was the need to chose a common data set 
and, for that reason, the table only comprises the EU reports post-MA. 
Table 29 – Comparison of most commonly reported AEs for anti-CD20 mAbs (post-marketing EU data) 
MedDRA 17.1 
System Organ Class (SOC) 
Post-Marketing EU data – ranking of most reported AEs 
Comments 
RITUXIMAB OFATUMUMAB 
IBRITUMOMAB 
TIUXETAN 
Blood and lymphatic system 
disorders 
3rd 3rd 1st 
Most reported AEs for all 
anti-CD20 mAbs. 
Cardiac disorders  10th -- 10th   
Gastrointestinal disorders 8th 8th 7th 
Least reported AEs for all 
anti-CD20 mAbs. 
General disorders and 
administration site conditions 
2nd 1st 3rd 
Most reported AEs for all 
anti-CD20 mAbs. 
Immune system disorders 9th -- --   
Infections and Infestations  1st 2nd 2nd 
Most reported AEs for all 
anti-CD20 mAbs. 
Injury, poisoning and procedural 
complications 
-- 10th --   
Investigations 7th 5th 5th 
Transversally reported AEs 
for all anti-CD20 mAbs. 
Neoplasms benign, malignant and 
unspecified (incl cysts and polyps) 
-- -- 4th   
Nervous system disorders 5th 7th 8th 
Transversally reported AEs 
for all anti-CD20 mAbs. 
Respiratory, thoracic and 
mediastinal disorders 
4
th
 4
th
 6
th
 
Transversally reported AEs 
for all anti-CD20 mAbs. 
Skin and subcutaneous tissue 
disorders 
6
th
 6
th
 9
th
 
Transversally reported AEs 
for all anti-CD20 mAbs. 
Vascular disorders -- 9
th
 --   
NOTE: The colours represent the ranking of reported AEs. GREEN represents the mostly reported AEs whereas RED 
the least reported AEs. 
According to the above table, anti-CD20 mAbs seem to have a quite similar profile of AEs 
reported in EU following MA. There are 5 out of 13 (≈38%) SOCs above listed which are not 
transversally applicable to all this class mAbs. This means that at least 62% of profile is similar 
in terms of AEs mostly reported.  
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There were some differences in anti-CD20 mAbs, including the type of mAb (chimeric and 
human) and the configuration of mAbs (1 mAb is linked the monoclonal antibody to the amino 
directed bifunctional chelate MX-DTPA), but those differences did not had a major impact on 
the general outcome of AEs mostly reported to each mAb. 
The similar profile seen throught the anti-CD20 mAbs class may be due to a number of factors, 
including similar treatment indications and equal administration route: intravenous infusion. 
The similarities within anti-CD20 mAbs class seem to be aligned with the concept of AEs being 
correlated to mAbs mechanism of action. 
For the particular case of anti-CD20 mAbs, the mostly reported AEs were i) Infections and 
Infestations, ii) General disorders and administration site conditions as well as iii) Blood and 
lymphatic system disorders and all these are according to the expectation. 
While General disorders and administration site conditions are antibody-related AEs which 
generally occur for every mAb; Infections and Infestations & Blood and lymphatic system 
disorders can be correlated to the specific Mechanism of Action of anti-CD20. 
Similar to anti-TNFα, anti-CD20 have immunosuppressive-like reactions because they reduce B 
cells and affect the immunity. Their impact on the immune system can result in greater 
chances for Infections and Infestations to arise. 
On what regards Blood and lymphatic system disorders, these disorders are closely related to 
the mechanism of action of this restricted class of mAbs. 
CD20 is found on both normal and malignant B cells [116]. B cells, in turn, circulate 
continuously between the blood and lymph [36]. It is predictable that the reduction of B cells, 
mediated by anti-CD20 mAbs, can contribute to a greater number of Blood and lymphatic 
system disorders. 
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I. Comparison of AEs reported through all mAbs classes– anti-
TNFα, VEGF and CD20 
Following the previous analysis which comprised the investigation of AEs reported for a 
specific mAb and the comparison of AEs reported through each mAb class, it becomes clear 
that although some discrepancies are found, most mAbs classes have at least half similar AEs 
profile within the class. 
Based on those findings, it was interesting to see if the AEs profiles which were observed to be 
similar within the class, were also similar at a higher level: through different mAbs class. The 
table below intends to provide a macro global picture on the ranking of mostly reported AEs 
for all mAbs class– anti-TNFα, VEGF and CD20. 
Once again, for comparison purposes, a common data set had to be chosen and, for that 
reason, the table only comprises the EU reports post-MA. 
 
 
  
Table 30 – Comparison of most commonly reported AEs in the 3 mAbs classes (post-marketing EU data) 
MedDRA 17.1 
System Organ Class (SOC) 
Post-Marketing EU data – rating of AEs mostly reported 
anti-TNFα mAbs anti-CD20 mAbs anti-VEGF mAbs 
ADALIMUMAB INFLIXIMAB GOLIMUMAB CERTOLIZUMAB RITUXIMAB OFATUMUMAB 
IBRITUMOMAB 
TIUXETAN 
BEVACIZUMAB RANIBIZUMAB 
Blood and lymphatic system disorders -- -- -- -- 3rd 3rd 1st 7th -- 
Cardiac disorders  -- -- -- -- 10
th
 -- 10
th
 -- 5
th
 
Gastrointestinal disorders 3rd 3rd 6th 2nd 8th 8th 7th 2nd -- 
General disorders and administration site 
conditions 
2
nd
 2
nd
 2
nd
 3
rd
 2
nd
 1
st
 3
rd
 1
st
 2
nd
 
Eye disorders  -- -- -- -- -- -- -- 10
th
 1
st
 
Immune system disorders -- -- -- -- 9
th
 -- -- -- -- 
Infections and Infestations  1st 1st 1st 1st 1st 2nd 2nd 6th 3rd 
Injury, poisoning and procedural 
complications 
10th 4th 8th 9th -- 10th -- -- 7th 
Investigations 9th 10th 10th 10th 7th 5th 5th 8th 6th 
Musculoskeletal and connective tissue 
disorders 
5th 8th 5th 5th -- -- -- -- -- 
Neoplasms benign, malignant and 
unspecified (incl cysts and polyps) 
4th 9th 9th -- -- -- 4th 9th 10th 
Nervous system disorders 6th 7th 3rd 6th 5th 7th 8th 4th 4th 
Renal and urinary disorders -- -- -- -- -- -- -- -- -- 
Reproductive system and breast disorders -- -- -- -- -- -- -- 3
rd
 -- 
Respiratory, thoracic and mediastinal 
disorders 
8
th
 5
th
 7
th
 8
th
 4
th
 4
th
 6
th
 -- 9
th
 
Skin and subcutaneous tissue disorders 7th 6th 4th 4th 6th 6th 9th -- -- 
Surgical and medical procedures  -- -- -- 7th -- -- -- -- -- 
Vascular disorders -- -- -- -- -- 9th -- 5th 8th 
NOTE: The colours represent the ranking of reported AEs. GREEN represents the mostly reported AEs whereas RED the least reported AEs. 
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General comments on the global AEs comparison: Some interesting findings can be observed 
in the global table comprising all mAbs classes – anti-TNFα, anti-CD20 and anti-VEGF. 
At a macro level, the profiles have similarities and some differences and it is interesting to see 
that the AEs here reported can be divided in three main types: 
1. antibody-related AEs: General disorders and administration site conditions are 
transversally reported throughout all mAbs classes. These occur for every mAb, regardless 
of the target involved. 
2. class-related AEs: Infections and Infestations are observed for all immunosuppressor 
agents: anti-TNFα and anti-CD20 mAbs. 
3. restricted class-related AEs: Blood and lymphatic system disorders observed for anti-CD20 
mAbs; Vascular disorders for anti-VEGF and Gastrointestinal disorders for anti-TNF-α 
mAbs. 
 
As per above table, there are not many reports of AEs classified as Neoplasms benign, 
malignant and unspecified (incl cysts and polyps). It is yet to discover if these low numbers will 
be maintained or if they will change alongside with the long-term exposure to these mAbs. 
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FINAL REMARKS 
Although mAbs were, at first, thought to be the closest thing to “ideal drugs” due to their 
specificity and efficacy, latter in usage it became clear that mAbs can have adverse events too. 
Furthermore, it was understood that many of those adverse events could not be expected by 
the results obtained in non-clinical studies. If from one point of view, mAbs have in their 
favour higher specificity, which gives them great efficacy results and prevents adverse events 
due to action in non-intended targets; this same characteristic can also have some cons [4, 
126]. It is well known that many mAbs operate through the immunosuppressive effect [127], 
which is useful for the treatment of various conditions, such as the prevention of graft 
rejection, cancer and auto-immune diseases including rheumatoid arthritis, Crohn disease or 
multiple sclerosis. The problem is that mAbs’ targets have many times critical roles for the well 
function of the body and their suppression can compromise vital functions. A classic reported 
example are the anti-TNFα mAbs that by suppressing the target to reduce clinical signs and 
symptoms of chronic inflammatory diseases, also revealed to compromise host infections’ 
defence [126]. These occurrences brought new concerns and, more than proving that 
mechanism of action plays an important role for adverse events occurrences, it is important to 
understand how this happens and what can be predicted upfront. 
The goal of this project was to correlate mAbs’ adverse events with their specific mechanism of 
action. For that purpose, and considering the extensive number of mAbs available in Europe, it 
was decided to study only 3 classes of mAbs well-established in the market: anti-TNFα, anti-
VEGF and anti-CD20. The adverse events collected and analysed included European and United 
States data as well as data available pre and post marketing authorisations. 
Although with some exceptions, it was observed that the adverse events anticipated prior 
marketing authorisation were similar to the ones observed in post marketing and it was also 
observed that the European data was similar to the United States data. 
On what regards adverse events correlation with the mechanism of action, it was confirmed 
that one influences the other. There were reports of antibody-related adverse events 
occurring for all mAbs (e.g. General disorders and administration site conditions); class-related 
adverse events occurring for specific classes of mAbs (e.g. Infections and Infestations) as well 
as restricted class-related adverse events (e.g. Blood and lymphatic system disorders observed 
for anti-CD20 mAbs & Vascular disorders for anti-VEGF mAbs).  
For restricted class-related adverse events, it was also observed that there are additional key 
factors that cannot be excluded when analysing the safety profiles of mAbs – administration 
routes, mAbs structural configurations and profile of patients receiving those mAbs can also 
impact significantly the adverse events reported in clinic. This was the case for anti-VEGF 
mAbs.  
All the class-related and restricted-class related adverse events confirmed that mAbs’ 
mechanism of action plays a crucial role in the adverse events later reported in clinic. The 
characterisation of each mAb specificities together with a precise understanding of the mAbs 
mechanism of action can be the basis for mAbs safety profile characterisation. 
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APPENDIX 1 – mAbs UNDERLYING DISEASES 
 
I. Underlying diseases of anti-TNFα mAbs 
Table 31 – Underlying diseases of mAbs targeted to TNFα 
anti-TNFα mAbs 
with that indication 
Indications Diseases Characterization References 
 Adalimumab 
 Infliximab 
 Golimumab 
 Certolizumab peg. 
Rheumatoid 
Arthritis (RA) 
 chronic multisystemic inflammatory disease with prominent 
autoimmune features 
 characterised by chronic inflammation of several joints and 
is often complicated by the involvement of internal organs 
 principal characteristic is persistent inflammatory synovitis, 
but it displays also a variety of clinical manifestations as 
defined by the American College of Rheumatology: 
 Morning stiffness (≥ 1 hr) 
 Swelling of joints (≥ 3) 
 Swelling of soft tissue of hand joints (PIP*, MCP*, wrist) 
 Symmetrical soft tissue swelling 
 Subcutaneous nodules 
 Serum rheumatoid factor 
 Radiographic evidence of erosion or periarticular 
osteopenia in hand or wrist joints 
*PIP = proximal interphalangeal; 
  MCP = metacarpophalangeal 
Criteria 1 to 4 must be continuous for 6 weeks. 
A diagnosis of rheumatoid arthritis requires that 4 of the 7 
criteria be fulfilled.  
[69, 77] 
 Adalimumab 
 Infliximab 
 Golimumab 
 Certolizumab peg. 
Polyarticular 
Juvenile 
Idiopathic 
Arthritis 
(Poly-JIA) 
 autoimmune disease with a complex genetic predisposition 
 onset occurring in children under the age of 16 years 
 most common rheumatic disease of childhood and an 
important cause of disability in children 
 The onset of JIA is characterized by three primary modes: 
1. pauciarticular (<5 joints) – the most frequent mode, 
observed in 50% of patients; 
2. polyarticular (≥5 joints) – observed in 30% of patients; 
3. systemic arthritis (≥1 joint with fever and rash) – observed 
in 10% to 20% of patients 
[128] 
Master’s degree in Biopharmaceutical Sciences: Adverse Events/Mode of Action Relationship 
of Monoclonal Antibodies-Based Therapies: Overview of Marketed Products in the European Union 
120 Francisca Mendes Lemos 
 
anti-TNFα mAbs 
with that indication 
Indications Diseases Characterization References 
 Adalimumab 
 Infliximab 
 Golimumab 
 Certolizumab peg. 
Axial 
spondyloarth
ritis (AxSpA) 
 refers to spondyloarthropathy with predominantly axial 
involvement and comprises: 
 sub-group of ankylosing Spondylitis 
 sub-group with little or no changes on plain 
radiographs, referred to as non-radiographic Axial 
Spondylitis (nr-AxSpA) 
 Assessments in Spondyloarthritis International Society 
(ASAS) criteria for classification of AxSpA, are: 
 Back pain of ≥3 month duration at age of onset <45 
 and either of the three is true for the subject: 
1. active (acute) inflammation on MRI highly suggestive of 
sacroiliitis associated with SpA and at least 1 clinical 
features* 
2. definitive sacroiliitis (grade ≥2 bilaterally or ≥3 unilaterally) 
on x-ray and at least 1 clinical features* 
3. HLA B27 positive and has at least 2 clinical features* 
* Clinical features e.gs.: inflammatory back pain; arthritis; 
enthesitis; uveitis; dactylitis; psoriasis; elevated CRP; family 
history for SpA 
[129, 130] 
 Adalimumab 
 Infliximab 
 Golimumab 
 Certolizumab peg. 
Ankylosing 
Spondylitis 
(AS) 
 If definite radiographic sacroiliitis on plain X-rays is present, 
the disease can most likely be classified as Ankylosing 
Spondylitis (AS) 
 modified New York criteria for AS (mNY) requires: 
  x-ray findings of sacroiliitis grade ≥2 bilaterally or 
grade 3-4 unilaterally 
 and at least 1 of the following clinical criteria: 
1. Low back pain and stiffness for more than 3 months that 
improves with exercise but is not relieved by rest. 
2. Limitation of motion of the lumbar spine in the sagittal and 
frontal planes. 
3. Limitation of chest expansion relative to normal values 
correlated for age and sex 
 chronic inflammatory disease of unknown etiology, which 
involves the spine and tendons 
 characterised by progressive, stiffening of the sacroiliac, 
intervertebral and costovertebral joints and leading to bony 
ankylosis 
 systemic rheumatic disease and may also effect enthesis 
(tendon insertions) and peripheral joints, as well as other 
organs such as the eyes, heart, and lungs 
 may also have nonskeletal manifestations, including uveitis, 
carditis, pulmonary fibrosis, and cardiac conduction 
abnormalities 
 is associated with the presence of the HLA-B27 allele 
[72, 77, 80, 
129] 
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anti-TNFα mAbs 
with that indication 
Indications Diseases Characterization References 
 Adalimumab 
 Infliximab 
 Golimumab 
 Certolizumab peg. 
Psoriatic 
Arthritis 
(PsA) 
 chronic, inflammatory, usually rheumatoid factor (RF)-
negative arthritis associated with psoriasis, which is 
classified within the group of the spondyloarthritis 
 the combination of joint and skin manifestations of PsA can 
have a profound impact on patient function, well-being, and 
health-related quality of life 
 usually involves multiple peripheral joints, the axial 
skeleton, sacroiliac joints, fingernails, and enthuses 
 presentation of PsA has been categorised into 5 overlapping 
clinical patterns: 
1. oligoarthritis 
2. polyarthritis 
3. arthritis of distal interphalangeal (DIP) joints 
4. Spondylitis 
5. arthritis mutilans 
 More than one-half of the patients with PsA may have 
evidence of erosions on X-rays, and up to 40% of the 
patients may develop severe, erosive arthropathy 
[77, 131-135] 
 Adalimumab 
 Infliximab 
 Golimumab 
 Certolizumab peg. 
Psoriasis (Ps) 
 common, chronic immunologic disease 
 characterised by marked inflammation and thickening of the 
epidermis resulting in thick, scaly plaques involving the skin 
 life-long disease often diagnosed early in life  
 not a life-threatening disease, but in relation to the extent 
and location of the plaques can lead to serious social and 
psychological impairment 
 Psoriasis may be classified as plaque psoriasis, guttate 
psoriasis, erythrodermic psoriasis, generalised pustular and 
localised pustular psoriasis, and inverse or intertriginous 
psoriasis (plaque psoriasis is the most common form seen in 
75 to 80% of psoriasis patients). 
 Approximately 6% up to 40% of Psoriasis patients may have 
PsA associated 
[136, 137] 
 Adalimumab 
 Infliximab 
 Golimumab 
 Certolizumab peg. 
Crohn’s 
Disease (CD) 
 chronic inflammatory disease of the bowel, which appears 
periodically with a varying course 
 characterized by segmental transmural inflammation and 
granulomatous changes. 
 affects primarily the distal small intestine and the colon, but 
it may affect also any part of the gut 
[72, 76, 77] 
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anti-TNFα mAbs 
with that indication 
Indications Diseases Characterization References 
 Adalimumab 
 Infliximab 
 Golimumab 
 Certolizumab peg. 
Ulcerative 
Colitis (UC) 
 first of the 2 primary forms of idiopathic inflammatory 
bowel disease 
 chronic, relapsing inflammatory disease of the rectum 
and/or large intestine 
 characterized by inflammation and ulceration of the 
mucosal and submucosal intestinal layers 
 about 40 to 50% of patients have disease limited to the 
rectum and rectosigmoid, 30 to 40% have disease extending 
beyond the sigmoid but not involving the whole colon, and 
20% have a total colitis 
 diagnosis is established after colonoscopy and histology of 
colonic mucosa 
 can be considered an autoimmune disease, harbouring in 
genetically susceptible individuals 
[72, 138-140] 
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II. Underlying diseases of anti-VEGF mAbs 
Table 32 – Underlying diseases of mAbs targeted to VEGF 
anti-VEGF mAbs 
with that indication 
Indications Diseases Characterization References 
 Bevacizumab 
 Ranibizumab  
Metastatic 
Carcinoma of 
the Colon or 
Rectum (mCRC) 
 major public health problem 
 second most common malignancies in both men and 
women 
 Approximately 30% of all patients with CRC have 
metastatic disease at diagnosis, and 50% of early-stage 
patients will eventually develop metastatic or advanced 
disease 
[99] 
 Bevacizumab 
 Ranibizumab 
Metastatic 
breast cancer 
(mBC) 
 Most common cancer in women worldwide. The 
median survival for patients with metastases at 
diagnosis is around 2-3 years with <20% still alive at 5 
years 
[141] 
 Bevacizumab 
 Ranibizumab 
Non-Small Cell 
Lung Cancer 
(NSCLC) 
 NSCLC represents about 80% of lung cancer 
 The most common histologies are epidermoid or 
squamous cell carcinoma (30-35%), adenocarcinoma 
(40-45%), and large cell carcinoma (<10%). 
 These histologies are often classified together 
because approaches to diagnosis, staging, 
prognosis, and treatment are similar. 
 many patients are diagnosed an advanced stage of the 
disease (approximately 30% locally advanced and 40% 
metastatic disease) with the remainder (25-30%) 
presenting with early stage 
 the 5-year survival rate is only about 15% 
[142] 
 Bevacizumab 
 Ranibizumab 
Metastatic Renal 
Cell Carcinoma 
(mRCC) 
 adenocarcinoma originating in the renal cortex 
 accounts for about 2% of all solid tumours, and 90-95% 
of tumours arising from the kidney 
 the four main histological subtypes of RCC are, 
according to their degree of increasing aggressiveness: 
1. oncocytic 
2. chromophobic 
3. chromophilic 
4. clear-cell 
 Commonly, RCC presents as a mixture of these different 
histological subtypes. 
 the 5-year survival rate is only about 5 -15% 
[143] 
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anti-VEGF mAbs 
with that indication 
Indications Diseases Characterization References 
 Bevacizumab 
 Ranibizumab 
Epithelial 
ovarian, 
fallopian tube 
and primary 
peritoneal 
cancer 
 one of the most common gynaecological 
 affects globally nearly a quarter of a million women 
each year and it is the 8
th
 leading cause of cancer death 
in women and the 7th leading cause of cancer death 
among women 
 The most common group of ovarian cancers that arise 
in the epithelium are: 
 epithelial ovarian cancer (EOC) 
 fallopian tube cancer (FTC) 
 primary peritoneal cancer (PPC). 
 Because the disease tends to be asymptomatic in early 
stages, or associated with vague, non-specific 
symptoms, the majority of patients are diagnosed with 
advanced stage disease 
[144, 145] 
 Bevacizumab 
 Ranibizumab 
Glioblastoma 
 rapidly progressing cancer that invades brain tissue and 
can impact physical activities and mental abilities 
[146] 
 Bevacizumab 
 Ranibizumab 
Cervical Cancer 
 grows in the tissues of the lower part of the uterus 
known as the cervix 
 commonly occurs when human papillomaviruses (HPV), 
a virus that spreads through sexual contact, cause cells 
to become cancerous 
[147] 
 Bevacizumab 
 Ranibizumab 
Age-related 
macular 
degeneration 
(AMD) 
 progressive degenerative macular disease attacking the 
region of highest visual acuity (VA), the macula 
 major cause of vision loss in the elderly population 
 although the disease rarely results in complete 
blindness and peripheral vision may remain unaffected, 
central vision is gradually blurred, severely affecting 
ordinary daily activities 
 AMD is classified into two different types: 
 non-exudative (or dry) form (most prevalent ≈ 
90% cases) 
 exudative (wet or neovascular) form 
 angiographic classification of AMD lesions includes the 
determination of 
 lesion size 
 proportion of the entire AMD lesion that consists 
of ‘classic’ and ‘occult’ choroidal 
neovascularisation (CNV) 
[107] 
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anti-VEGF mAbs 
with that indication 
Indications Diseases Characterization References 
 Bevacizumab 
 Ranibizumab 
Diabetic macular 
oedema (DME) 
 characterised by swelling of the central part of the 
retina, the macula, which mediates high-resolution 
visual acuity (VA) 
 one of the most sight-threatening complications in 
diabetes mellitus 
 estimated to occur in around 10% of the diabetic 
population, with a high prevalence of 30% in 
patients with more than 25-year history of 
diabetes. 
 DME arises from breakdown of the blood retinal barrier 
(BRB), leading to leakage of fluid and plasma 
constituents in the surrounding retina, resulting in 
retinal oedema 
 The natural progression of DME leads to vision loss of 
two or more lines (≥ 10 letters) of VA within 2 years in 
approximately 50% of patients 
[148] 
 Bevacizumab 
 Ranibizumab 
Macular oedema 
secondary to 
Retinal Vein 
Occlusion (RVO) 
 second leading cause of blindness for patients with 
retinal vascular disease, following diabetic retinopathy 
 There are two main types of RVO, depending on the site 
of the vein occlusion: 
 branch retinal vein occlusion (BRVO) 
 central retinal vein occlusion (CRVO) 
 In addition, when the occlusion is located in one of the 
2 branches after the division of the central vein the 
occlusion is classified as a hemiretinal vein occlusion 
(HRVO). 
 most common presenting symptom of RVO is an abrupt, 
painless decrease of central visual acuity (VA) which 
varies in severity in BRVO and CRVO. 
 Untreated eyes with CRVO generally have poor VA (less 
than 20/40) which declines further over time 
[149] 
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anti-VEGF mAbs 
with that indication 
Indications Diseases Characterization References 
 Bevacizumab 
 Ranibizumab 
Choroidal 
Neovascularisati
on (CNV) 
Secondary to 
Pathologic 
Myopia 
 CNV secondary to Pathologic Myopia is considered one 
of the major causes of legal blindness in several 
countries and the leading cause of visual impairment in 
young patients worldwide. 
 In Pathologic Myopia the axial length of the eyeball is 
abnormally elongated (> 26 mm), which is associated 
with high myopia refractive errors and changes of the 
posterior pole of the eye such as posterior staphyloma, 
atrophy of the retinal pigment epithelium, Bruch’s 
membrane cracks, subretinal haemorrhage, retinal 
detachment, and CNV. 
 CNV is considered the most vision threatening 
complication in patients with Pathologic Myopia. 
 During the natural course of CNV secondary to 
Pathologic Myopia, patients progressively lose VA at a 
rate of approximately 10 to 15 letters (2 to 3 lines) over 
2 years.  
 The prevalence of CNV in patients with Pathologic 
Myopia is high in patients under the age of 50 years; 
which contributes for a profound impact on the 
productivity of this working age group. 
[150] 
 
III. Underlying diseases of anti-CD20 mAbs 
Table 33 – Underlying diseases of mAbs targeted to CD20 
anti-CD20 mAbs 
with that indication 
Indications Diseases Characterization References 
 Rituximab 
 Ofatumumab 
 Ibritumomab 
Tiuxetan 
Follicular 
Lymphoma 
NHL(Non-
Hodgkin's 
Lymphoma*) 
 Follicular lymphomas account for 20-25% of all 
lymphomas and are the second most common subtype 
of NHL 
 mostly occur on middle-aged and older people, with a 
median age at diagnosis of approximately 60 years. 
 Most of the time, this lymphoma occurs in many lymph 
node sites in the body, as well as in the bone marrow 
 often slow-growing and respond well to treatment, but 
they are hard to cure 
 these lymphomas may not require treatment when they 
are first diagnosed and treatment may be delayed until 
the lymphoma is causing problems 
 Over time, about 1 in 3 follicular lymphomas turns into 
a fast-growing diffuse B-cell lymphoma. 
[116, 151-153] 
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anti-CD20 mAbs 
with that indication 
Indications Diseases Characterization References 
 Rituximab 
 Ofatumumab 
 Ibritumomab 
Tiuxetan 
Diffuse Large B 
cell NHL 
 mostly occurs in older people (the average age is mid-
60s) 
 usually starts as a quickly growing mass in a lymph node 
deep inside the body, such as in the chest or abdomen, 
or in a lymph node, such as in the neck or armpit 
 It can also start in other areas such as the 
intestines, bone, or even the brain or spinal cord 
 Some of these lymphomas are localized, which makes it 
easier to treat 
[153] 
 Rituximab 
 Ofatumumab 
 Ibritumomab 
Tiuxetan 
Chronic 
lymphocytic 
leukaemia (CLL) 
 most common form of adult leukaemia comprising 30% 
of all adult leukaemias 
 The median age at first diagnosis is in the range of 65-70 
years and men are affected more often than women. 
Over the years, the incidence has increased in younger 
patients and now about one-third of CLL patients are 
younger than 55 years at diagnosis. 
 characterized by an extremely variable clinical course 
and prognosis depending on disease stage and 
presence. The two clinical staging systems developed by 
Rai and Binet are widely used and are an accepted 
prognostic tool 
[154] 
 Rituximab 
 Ofatumumab 
 Ibritumomab 
Tiuxetan 
Rheumatoid 
arthritis (RA) 
 B cells both responds to, and produce, chemokines and 
cytokines that promote leukocyte infiltration into the 
joints, formation of ectopic lymphoid structures, 
angiogenesis, and synovial hyperplasia that characterize 
the pathophysiological changes observed in the 
rheumatoid joint 
 In some patients, rheumatoid synovitis is associated 
with the formation of complex lymphoid 
microstructures, to the extent that the rheumatoid 
process induces the formation of T cell-B cell follicles 
with germinal centre reactions in the synovium of 
affected joints. Thus, B-cell targeted therapy can play a 
variety of roles in RA through reduction in B-cell 
effector cells, as well as downstream effects on other 
cells that participate in the inflammatory response 
[155] 
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anti-CD20 mAbs 
with that indication 
Indications Diseases Characterization References 
 Rituximab 
 Ofatumumab 
 Ibritumomab 
Tiuxetan 
Granulomatosis 
with polyangiitis 
(GPA) and 
microscopic 
polyangiitis 
(MPA) 
 GPA and MPA are both associated with anti-neutrophil 
cytoplasmic antibodies (ANCAs) and are therefore 
referred to collectively as ANCA-associated vasculitis 
(AAV). 
 Two types of ANCA have been identified in GPA and 
MPA, defined by the antigenicity against two different 
self-antigens which are the endogenous enzymes; MPO 
(myeloperoxidase) and PR3 (proteinase-3) that are 
present in neutrophilic lymphocytes. 
 ANCA-serology has a different distribution between 
GPA and MPA. GPA is mainly associated with PR3-ANCA 
(95% of the cases), whereas MPA is more frequently 
associated with MPO-ANCA (75% of MPA patients) 
 GPA prominent features: crusting granulomata in the 
ear, nose and throat area and alveolar bleeding. 
Segmental, necrotizing glomerulonephritis may occur in 
about 50% of the cases. 
 MPA prominent features: glomerulonephritis 
 In both GPA and MPA, vasculitis may be extended to 
other organs like the skin, nervous system (specifically 
vaso nervorum of peripheral nerves), heart and 
gastrointestinal tract (mesenterium). 
 CNS involvement is relatively rare for both disorders. 
 Systemic features (fever, arthritis) are more common in 
MPA 
[156] 
* Non-Hodgkin's Lymphoma (NHL): 
Non-Hodgkin's Lymphoma (NHL) is t he most common of the malignant lymphoid neoplasms. 
NHL is the common name for a cluster of related but individual diseases, which have neoplastic 
transformation of a lymphoid cell as the common denominator. 85% of the NHLs are derived 
from a B-lymphocyte and 15% from a T-lymphocyte. Follicular Lymphoma and Diffuse Large B 
cell Non-Hodgkin’s Lymphoma are included in B- cell lymphomas. 
There have been some improvements and changes in the system broadly used for NHL’s 
classification. Currently the main system used is the WHO classification. Translation of 
diagnoses within the systems is possible for most but not all classes. The WHO system groups 
lymphomas based on how they look under a microscope, the chromosome features of the 
lymphoma cells, and the presence of certain proteins on the surface of the cells. 
The WHO classification recognizes 13 individual B-cell lymphomas (with several further 
subdivisions), which form a clinical spectrum from the low-grade lymphocytic and follicular 
lymphomas with a medium survival of 10-15 years at one end, and the high grade 
lymphoblastic lymphomas with a medium survival of months at the other end of the spectrum 
[116, 153]. 
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The course of disease often contains several relapses that are manageable but ultimately most 
patients will develop chemoresistant lymphoma often with a transformation to a large cell 
more malignant NHL [116]. 
The disease generally manifests with hypertrophy of peripheral and deep lymph nodes and 
splenomegaly, together with bone marrow infiltration. Histological transformation to more 
aggressive non-Hodgkin’s lymphoma (NHL) with poor prognosis has been documented to occur 
in 20-80% of patients over time. Also, the likelihood of resistant lymphoma or occurrence of 
secondary malignancies such as myelodysplastic syndrome/acute myeloid leukaemia 
(MDS/AML) increases with time and with the number, choice and intensity of previous 
treatments [151, 152]. 
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